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The first practical application of a radioisotope was made by George de Hevesy in 1911.  At the time de 
Hevesy was a young Hungarian student working in Manchester with naturally radioactive materials. 
 Not having much money he lived in modest accommodation and took his meals with his landlady.  He 
began to suspect that some of the meals that appeared regularly might be made from leftovers from the 
preceding days or even weeks, but he could never be sure.  To try and confirm his suspicions de Hevesy put 
a small amount of radioactive material into the remains of a meal.  Several days later when the same dish 
was served again he used a simple radiation detection instrument - a gold leaf electroscope - to check if the 
food was radioactive.  It was, and de Hevesy's suspicions were confirmed. 
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 3 
THESIS OUTLINE 
 
Neuroimaging has provided the means to elucidate healthy physiological 
processes in human beings along with the causes and consequences of 
neurological and psychiatric disorders. The use of suitable radiopharmaceuticals 
assists clinicians in the diagnosis and care of patients with brain disorders. The 
human brain consists of millions of inter-communicating neurons. Mental 
processes are driven by the complex interplay of neurotransmitter systems and 
their disruption underlies many diseases of the central nervous system. A 
prerequisite of efficient drug treatment of diseases of the central nervous system 
is that sufficient amounts of the drug enter the brain. An important factor 
determining this bioavailability is the capability to accumulate in the brain. Active 
transport by P-glycoprotein (P-gp) from the brain back into the bloodstream has 
a major impact on drug resistance to psychotropic drugs.  
 
In this thesis we aimed to develop radiotracers for targets of the dopamine and 
norepinephrine system that causes neurotransmitter inactivation being the 
norepinephrine transporter, the dopamine transporter and monoamine oxidase. 
By the discovery that one of the designed radiotracers is modulated by P-gp, the 
focus of this thesis was redirected towards imaging of P-gp function and 
expression.  
 
Chapter 1 gives a short overview of the medical imaging techniques and 
describes the requirements of a valuable radiopharmaceutical for SPECT or PET 
imaging.  
Chapter 2 discusses the blood-brain barrier and the transport of compounds 
across this barrier. One of the most important transport mechanisms limiting 
brain uptake of drugs, P-gp, is detailed in this chapter.  
Thesis Outline 
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The dopamine and norepinephrine system and more specifically the dopamine 
transporter, the norepinephrine transporter and monoamine oxidase, are 
discussed in Chapter 3.  
In Chapter 4 the general material and methods are described.  
The lack of a valuable radiotracer for the norepinephrine transporter, leads us to 
the development of an iodinated reboxetine analogue, [123I]-(S,S)-IPBM, to 
visualize this transporter. Chapter 5 reports the synthesis, radiosynthesis and 
preliminary evaluation of [123I]-(S,S)-IPBM.  
In Chapter 6 the radiolabelling as well as the in vivo characterization of two [11C]-
labelled pyrrole-2-carboxamide derivatives, [11C]-RS 2315 and [11C]-RS 2360, are 
described. In vitro, RS 2315 and RS 2360 were both potent inhibitors of 
monoamine oxidase-A. The search for new ligands for MAO-A with optimal  
kinetic properties is justified by the lack of an ideal ligand and the observation 
that fluctuations in MAO-A functionality are associated with human diseases and 
tobacco addiction.  
The synthesis along with the radiolabelling and in vivo evaluation of [123I]-FMIP as 
a selective radiotracer for the dopamine transporter is reported in Chapter 7. 
FMIP has nanomolar affinity for the dopamine transporter and better selectivity 
over the other monoamine transporters compared to the already existing ligands 
for dopamine transporter imaging with SPECT.  
The contribution of P-gp to the low brain uptake of [123I]-FMIP along with its 
potential as P-gp imaging agent are investigated in Chapter 8. To date, no 
iodinated SPECT ligands for P-gp imaging have been published.  
Finally, Chapter 9 describes the radiolabelling of an in vitro characterized 
substrate (MC80) of the P-gp pump with 11C and the evaluation of this tracer in 
vivo for its potential to image P-gp function or expression.  
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Chapter 1 
 
General Introduction 
 
1.1. Medical imaging 
 
1.1.1. HISTORICAL BACKGROUND 
 
The first known method for medical imaging made use of X-rays and has been 
discovered in 1895 by Wilhelm Röntgen. Nowadays there exist different imaging 
techniques that can be divided into two categories: structural and functional 
imaging.  
Structural imaging is primarily aimed at anatomical localisation of pathological 
processes. Besides X-rays, computed tomography (CT) and magnetic resonance 
imaging (MRI) are the most important ones. Due to their short wavelength, X-
rays penetrate through most tissues depending on the density of the tissue. The 
detection of X-rays on a photographic plate, providing an image that is in 
accordance with the density of the tissues. This makes them especially useful in 
the detection of pathology of the skeletal system. To a lesser extent, they are also 
used for identifying some disease processes in soft tissue. Imaging alternatives for 
soft tissues are CT and MRI. CT has been developed in 1967 and is still the gold 
standard in the diagnosis of a large number of different disease entities. CT also 
uses X-rays but here, the X-ray source rotates around the patient, resulting in a 
high quality three dimensional image (resolution of 1 mm). MRI has been 
discovered a few years later than CT and is not only used for structural but also 
for functional imaging. MRI technology is based on nuclear magnetic resonance 
(NMR). The advantaged of MRI is that it provides high contrast images between 
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the different types of soft tissues within the body without exposing subjects to 
ionizing radiation.  
Functional imaging is, rather than anatomical imaging, focussed on physiological 
processes like metabolism, blood flow, receptor binding, etc. The pivotal 
functional imaging techniques, Positron Emission Tomography (PET) and Single 
Photon Emission Computed Tomography (SPECT), belong to the domain of 
nuclear medicine. Widespread clinical use of nuclear medicine began in the early 
1950’s. Unlike the use of X-rays and CT where radiation is passed through the 
body, nuclear imaging modalities detect the radiation emitted by the human body 
after administration of radiopharmaceuticals. This provides very accurate images 
of the area of the body being investigated. Depending on the radiopharmaceutical 
used, information about certain biological changes or processes is gathered, 
leading to knowledge or diagnosis of diseases (For review see Guy, 1996; 
Wolbarst and Hendee, 2006). 
 
1.1.2. PET 
 
PET is a non-invasive imaging method used to study physiological, biochemical 
and pharmacological processes in the human body. PET utilizes positron (β+) 
emitting isotopes. Positrons are particles with an equal mass as electrons, but with 
a positive charge. The positron travels a short distance in tissue until it interacts 
with an electron, in a process called annihilation. The total mass of positron and 
electron is converted into electromagnetic energy, producing two photons of 511 
keV emitted under an angle of 180°C (Wong and Brasic, 2001; Lewellen, 2008). A 
PET scanner contains a set of detectors arranged in a ring surrounding the object 
to be imaged (Figure 1.1). The pair of photons produced from a single 
annihilation will be detected almost simultaneously on opposing pairs of 
scintillation detectors as a coincidence event. The rings of scintillation detectors 
register thousand of coincidence events emitted from the subject and convert 
them into an electrical signal that can be registered. The acquired emission data 
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are then converted into a tomographic image via computerised reconstruction 
algorithms. Theoretically, PET has a resolution of 2 - 4 mm (Wong and Brasic, 
2001; Lewellen, 2008; Ganguly et al., 2009).  
 
 
Figure 1.1 Principle of PET camera 
 
Radionuclides commonly used in PET are 18F (T1/2 ≈ 110 min), 11C (T1/2 ≈ 20.4 
min), and 15O (T1/2 ≈ 2 min). The stable counterparts of 11C and 15O are the 
building blocks of all living matter which makes it possible to incorporate them 
into the molecules of interest without changing their pharmacological or 
physiological properties. On the other hand, the presence of an on-site cyclotron 
is required to produce the radionuclides with relative short half-lives, immediately 
prior to use (Wong and Brasic, 2001).  
 
1.1.3. SPECT 
 
The origin of SPECT can be found in the groundbreaking experiments on 
emission tomography performed approximately 50 years ago (Kuhl and Edwards, 
1963). SPECT is used to gain information on physiological parameters or certain 
biological processes based on the in vivo distribution of the radioactivity, 
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measured by external mapping of the location and density of the emitted 
photons.  
SPECT cameras detect single photons and consist of a collimator, one or more 
scintillation crystals and photomultiplier tubes (Figure 1.2). The properties of 
these three parts determine the sensitivity and spatial resolution of the SPECT 
camera. The use of a collimator restricts the flow of photons to only those that 
reach the detector in a ninety degree angle, allowing localisation of the 
radionuclide. Thereafter, the scintillation crystal absorbs the energy from the 
photons and converts it to visible light which can be detected by the 
photomultiplier tubes. A sodium iodide crystal, doped with thallium (NaI(Tl)) is 
commonly used as the scintillator in SPECT imaging. Subsequently, the 
photomultiplier tubes convert these light photons into an electrical charge which 
is then amplified to a detectable level. Three dimensional tomographic images in 
the coronal, horizontal and sagittal planes are reconstructed by computer 
software programs from the data collected (Ruth, 2009). 
 
Figure 1.2 Schematic view of a SPECT camera 
 
Two- and triple-head rotating cameras have been developed resulting in 
improved sensitivity and higher spatial resolution. Workable resolution is about 6 
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mm, which is low compared to PET cameras. Because a PET camera only detects 
the coincidence events, there is no need for a collimator, improving the sensitivity 
and resolution of the PET camera. 
The ideal radionuclide for SPECT imaging possesses a relative short half-life and 
emits photons in high abundance and with sufficient energy to penetrate the body 
without undesirable scatter or attenuation. 99mTc (T1/2 ≈ 6 h, 140.5 keV) is the 
best and least expensive radionuclide but its metallic characteristics make it 
difficult to work with. Another commonly used isotope is 123I (T1/2 ≈ 13.2 h, 159 
keV). SPECT radionuclides are not commonly found in nature which makes it 
difficult to incorporate them into biological active molecules without changing 
the physiological properties of the molecule (Kung, 1991).  
 
1.1.4. SMALL ANIMAL IMAGING 
 
Small animal imaging requires, due to the size of the subjects involved, higher 
spatial resolution than most clinical systems can provide. This has led to the 
development of µSPECT and µPET (Peremans et al., 2005). To achieve a higher 
spatial resolution, scanners must use higher-resolution detectors and obtain finer 
spatial sampling while maintaining the sensitivity as high as possible (Sossi and 
Ruth, 2004; Rowland et al., 2008). 
Preclinical µSPECT mainly use pinhole collimation achieving spatial resolution of 
0.5 to 2 mm. The major limitation of pinhole µSPECT is the reduced field of 
view and subsequently the reduced sensitivity. By setting up additional pinholes 
and focusing them on different regions, it is possible to increase the field of view, 
improve the sensitivity, and obtain high spatial resolution when using sufficiently 
small pinhole diameters (Beekman et al., 2005; Rowland et al., 2008; Vanhove et 
al., 2008).  
Enhancement of preclinical PET is mainly focussed on improved photon 
detection material. Compared to the commonly used detection material NaI(Tl), 
Lutetium Orthosilicate has a high density and high light yield. This allows 
General Introduction – Chapter 1 
 
 12 
reduction in the size of individual crystals and thus leads to higher spatial 
resolutions while maintaining the same sensitivity (Ruth, 2009). As well as the 
hardware improvement, development of software that provides more accurate 
data quantification and image reconstruction contributes to the successful 
application of preclinical PET and SPECT (Sossi and Ruth, 2004; Rowland et al., 
2008).  
 
1.2. Neuroimaging 
 
The human brain is a complex organ, consisting of millions of inter-
communicating neurons. Due to the complexity of the central nervous system 
(CNS) our knowledge about CNS disorders is still limited. The understanding of 
biochemical abnormalities relating to disease and disease processes is pivotal to 
the future development of effective diagnosis, treatment and management of 
neurological and psychiatric illness. Since the development of suitable 
radioligands in the late 1970’s, the use of non-invasive imaging modalities (PET 
and SPECT) is a valuable tool for in vivo brain mapping and drug development in 
the future (Wong and Brasic, 2001; Gee, 2003).  
 
1.2.1. RADIOPHARMACEUTICALS 
 
Radiopharmaceuticals can be divided into two categories being: diagnostic and 
therapeutic radiopharmaceuticals. For the preparation of radiopharmaceuticals, a 
radionuclide is coupled to a drug with a certain target in the human body. In this 
thesis, only radiopharmaceuticals for brain imaging will be discussed. The 
development of new and improved radiopharmaceuticals is a research field that is 
actively explored. To obtain a new, valuable radiopharmaceutical, some critical 
points have to be considered during the radiotracer development (Kung, 1991). 
First, a possible interesting radiotracer must be selected out of the thousand 
molecules designed by chemists; preferentially, a molecule with high in vitro 
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affinity (Kd in nanomolar range) and selectivity (at least more than 10) for its 
target. Subsequently, radiolabelling opportunities that do not alter the affinity and 
selectivity are required. Lipophilicity is another important parameter since it 
determines the ability of the molecule to cross the blood-brain barrier (BBB). The 
lipophilicity is often expressed by the log D7.4, which is the logarithm of the 
partition coefficient between n-octanol and water at physiological pH. An ideal 
log D7.4 should be between 1.5 and 3 (Waterhouse, 2003). A molecule that is too 
hydrophilic (log D7.4 < 1.5) will not pass the BBB by passive diffusion. Elevated 
values of log D7.4 on the other hand, result in high nonspecific binding. The 
ability of the molecule to penetrate the BBB is not only determined by the 
partition coefficient. The molecular weight has to be lower than 650 g/mol, the 
molecule may not be charged and binding to plasma proteins must be reversible. 
The presence of multispecific xenobiotics transporters at the BBB can cause 
efflux of the molecule out of the brain. Consequently, a lower brain uptake than 
expected from its lipophilicity is observed. P-glycoprotein is an example of such a 
transporter (For review see Stöcklin, 1992; Elsinga, 2002).    
When preparing radiopharmaceuticals, the chemical, radiochemical and 
radionuclidic purity are of great importance. This implies that the tracer solution 
has to be free of unlabelled and labelled impurities and undesirable radionuclides. 
Further is the specific activity, expressed as the amount of radioactive molecules 
over the total mass of those molecules present in the tracer solution, also of 
critical importance. Specific activity is usually formulated as GBq/µmol or 
Ci/µmol. As most radiotracers for brain imaging are injected intravenously, 
special requirements including pH, isotonicity, sterility and apyrogenicity are 
necessary.  
When all the mentioned requirements are fulfilled, the radiopharmaceutical can 
be evaluated in vivo. It is important that the administrated radiotracer is highly 
distributed to the organ of interest resulting in a high target to non-target ratio. 
The radiotracer must interact with the system in a known and reproducible 
fashion. Rapid metabolism of the radiopharmaceutical is undesirable when the 
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specific binding of the radiopharmaceutical to its target must be detected. 
Radiolabelled metabolites can bind to other molecules or take part in unknown 
biochemical processes and result in nonspecific accumulation of radioactivity. 
The presence of radiometabolites in plasma that cannot cross the BBB does not 
disturb the signal to noise ratio (Elsinga, 2002; Stöcklin, 1992).  
 
1.2.2. NEUROIMAGING WITH PET AND SPECT 
 
The ability of SPECT and PET to image specific biomolecules in the living brain 
provides a unique tool for clinical researchers. Given this, it is not surprising that 
over the last decade a large number of radiotracers have been developed to image 
and quantify the various neurotransmitter systems. As mentioned before, 
development of a suitable radioligand is fraught with problems and there are 
many compounds reported in the development phase that never reached the end 
point of in vivo use in man.  
Some radiopharmaceuticals successful in clinical SPECT studies are [99mTc]ECD 
(tracer for cerebral blood flow), [123I]IBZM (dopamine D2 receptor tracer), 
[123I]ADAM (serotonin transporter tracer) and the dopamine transporter tracer 
[123I]FP-CIT (for review see Camargo, 2001; Zipursky et al., 2007; Sharma and 
Ebadi, 2008). 
The most important clinically used PET brain tracers are [18F]DOPA, 
[11C]raclopride (dopamine D2 receptor tracer), [11C]DASB (serotonin transporter 
tracer), and the serotonin 5-HT1A receptor tracer [11C]WAY100635 (For Review 
see Fowler et al., 2003; Shiue and Welch, 2004; Zipursky et al., 2007).  
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Chapter 2 
 
Blood-brain barrier transport 
 
2.1. The blood-brain barrier 
 
2.1.1. GENERAL 
 
The brain is a very delicate organ and homeostasis in the neural 
microenvironment is essential for the perfect functioning of the brain. Therefore, 
the brain must be protected against metabolic fluctuations in blood composition. 
However, at the same time contact with blood must be maintained for nutrient 
supply and waste disposal. This complex task is accomplished by the blood-brain 
barrier (BBB) (Aigner et al., 1997). The existence of such a barrier between blood 
and brain was first demonstrated by Ehrlich (1885). At the end of the 1960’s, the 
tight junctions and the fine structural localization of the BBB were discovered 
(Reese and Karnovsky 1967; Brightman and Reese 1969).  
The BBB is not the only barrier that limits drug transport to the brain 
parenchyma. There are two more barriers described: 1) blood-cerebrospinal-fluid 
barrier (presented by the choroid plexus epithelium in the ventricles) and 2) the 
ependyma (epithelial layer of cells covering the brain tissue in the ventricles and 
limiting the transport of compounds from the cerebrospinal-fluid to the brain 
tissue). Based on total blood flow and its wide vascular bed, the BBB is 
functionally the most important global influx barrier. The human BBB has a total 
blood vessel length of approximately 600 km with an estimated surface of 20 m2 
(Pardridge 2002; de Boer and Gaillard 2007). 
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Figure 2.1 Schematic brain capillary (Löscher, 2007) 
 
Brain capillary endothelial cells, pericytes, astrocytes and neuronal cells (Figure 
2.1) compose the BBB (Rubin and Staddon 1999; Ballabh et al., 2004; de Boer 
and Gaillard 2007). Brain capillary endothelial cells are distinguished from 
peripheral endothelial cells. Their specific characteristics such as tight junctions 
prevent paracellular transport of compounds from blood to the brain. 
Furthermore, low vesicular transport, high metabolic activity and lack of 
fenestrations prevent transcellular transport of xenobiotics to the brain. These 
specific features are induced and maintained by the astrocytes as well as by the 
neuronal endings. This barrier is very efficient and makes the brain practically 
inaccessible for lipid-insoluble compounds and large molecules. As a 
consequence, the therapeutic value of many promising drugs is diminished and 
cerebral diseases proved to be most refractory to therapeutic interventions. Given 
the prevalence of brain diseases, this is a considerable problem (Oldendorf 1977; 
Brightman 1977; Aigner 1997; Bodor and Buchwald 1999). 
 
2.1.2. INFLUX IN THE BRAIN 
 
Invasive drug delivery and drug delivery based on BBB transport are the two 
strategies used to bring molecules into the brain. The invasive strategy is rarely 
applied and will therefore not be discussed in this thesis (For review see 
Pardridge 1997; 2002; 2007). The non-invasive strategy can be divided into two 
Blood-brain barrier transport – Chapter 2 
 
 21 
 
main drug transport possibilities across the BBB: passive diffusion and active 
transport systems.  
 
Passive diffusion of substances through the BBB depends on molecular weight, 
lipophilicity and intermolecular forces (Levin 1980; Pardridge 1998; Bodor and 
Buchwald 1999; Habgood et al., 2000). There is a molecular weight threshold of 
approximately 650 g/mol with respect to drug penetration through the BBB. The 
more lipid-soluble a drug, the more easily it will move from the polar 
environment of the blood across the nonpolar BBB. Lipophilicity can be 
measured by the partition coefficient between octanol and water. The 
intermolecular forces are determined by the functional groups of the molecule. 
Measurement of the surface activity, which takes into account the hydrogen 
binding capabilities and the hydrophobic properties, can predict the ability of 
substances to passively diffuse through the BBB (Pardridge 1998).  
 
Active transport systems can be divided into absorptive-, carrier- or receptor-
mediated transport. Absorptive-mediated transcytosis is initiated by the binding 
of cationic substances to negative charges on the plasma membrane. This process 
does not involve specific plasma membrane receptors. Upon binding of the 
cationic compound to the plasma membrane, endocytosis occurs (de Boer et al., 
2003). The carrier-mediated transport is used for blood-to-brain transport of 
nutrients and vitamins. At least eight different nutrient transport systems have 
been identified, with each transporting a group of nutrients of the same chemical 
structure. A tool for enhancing BBB transport of drugs is to modify the drugs 
structurally to mimic the endogenous nutrients (For review see Pardridge 2002; 
2007). Receptor-mediated transport enables larger endogenous molecules, such as 
peptides, proteins and genes to specifically enter the brain. Conjugation of 
exogenous molecules such as recombinant proteins and antisense agents to brain 
transport vectors makes it possible to deliver them to the brain. The brain 
transport vector is comprised of endogenous peptides or peptidomimetic 
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monoclonal antibodies that undergo receptor-mediated transport (For Review see 
Pardridge 1999; 2002; 2007; de Boer and Gaillard 2007). 
 
2.1.3. EFFLUX OUT OF THE BRAIN 
 
To maintain homeostasis of the brain, the BBB combines restricted entering of 
endogenous and exogenous compounds to the brain with specialized transport 
mechanisms for efflux of these compounds out of the brain. These multispecific 
xenobiotic transporters are conventionally grouped into families based on 
molecular and functional similarities. Several different drug transporter families 
have been identified, including the organic anion transporter, multidrug 
resistance-associated protein, multidrug resistance protein, organic anion 
transporting polypeptide, organic cation transporter, concentrative nucleoside 
transporter and equilibrative nucleoside transporter subfamilies (Zhang et al., 
2004; Huai-Yun et al., 1998; Bauer et al., 2005; Kim, 2005). The first described 
drug efflux transporter was P-glycoprotein (P-gp), followed by several members 
of the multidrug resistance-associated protein family and more recently breast 
cancer related protein (For review see Taylor 2002; de Boer 2003; Bauer et al., 
2005; Löscher and Potschka 2005; Dallas et al., 2006). To date, P-gp is the best 
known and most important drug efflux pump. 
 
2.2. P-glycoprotein 
 
2.2.1. HISTORICAL BACKGROUND 
 
The ATP-binding cassette (ABC) family of transport proteins represents one of 
the largest families of proteins in living organisms. Its members have been found 
in each kind of organism examined so far. These transporters mediate drug 
absorption, distribution and excretion and therefore play a central role in cellular 
physiology (Ayrton and Morgan 2001). It is difficult to characterize a 
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physiological system in dept without identifying a role for an ABC transporter. 
Over the last 15 years, there has been a significant increase in the molecular 
characterization of transport proteins in animals and man. There are seven 
known distinct subfamilies of ABC transporters, designated A - G. P-gp, the 
most important transporter, belongs to the ABCB subfamily (For review see 
Klein et al., 1999; Dean et al., 2001; Schinkel and Jonker 2003; Sun et al., 2003). 
P-gp is the most extensively studied mammalian ABC transporter and is often 
regarded as the prototype for understanding the biochemical mechanisms. In 
1976, Juliano and Ling identified this efflux pump. Because the glycoprotein they 
found appeared to be unique to mutant cells that displayed altered drug 
permeability, they named it permeability-glycoprotein (P-glycoprotein or P-gp). 
The discovery of P-gp was groundbreaking because it explained multidrug 
resistance, a frequently observed phenomenon in tumours (Juliano and Ling, 
1976). In 1989, two independent research groups found expression of P-gp at the 
human BBB (Cordon-Cardo et al., 1989; Thiebaut et al., 1989). P-gp is highly 
expressed at the luminal membrane of endothelial cells which is a perfect 
localization to protect the brain from xenobiotics (Biegel et al., 1995; Beaulieu et 
al., 1997). Therefore, P-gp is generally recognized to be the most important 
element of the selective, active BBB for efflux of xenobiotics and has been the 
main focus of BBB research over the last decade.  
 
2.2.2. EXPRESSION, STRUCTURE AND FUNCTION 
 
In humans, P-gp is encoded by two genes, MDR1 and MDR2. Only the MDR1 
gene, located on chromosome 7q21, is responsible for the multidrug resistance. 
The closely related MDR2 gene, also called MDR3, is involved in intrahepatic 
cholestasis (Klein et al., 1999). In contrast to humans, mice have three genes 
encoding P-gp: mdr1a (also called mdr3), mdr1b (also called mdr1) and mdr2. As 
in humans, the mdr2 gene does not contribute to multidrug resistance. The tissue 
distribution of mdr1a and mdr1b differ from each other, but together these 
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proteins cover the same areas as the single MDR1 P-gp in humans. This suggests 
that mouse mdr1a and mdr1b together fulfil the same physiological role(s) as 
MDR1 in human (Croop et al., 1989; Chen et al., 1986; van der Bliek et al., 1988; 
Hsu et al., 1989; Gros et al., 1986; Devault and Gros 1990).  
 
Glycosylation sites
TMD
 
Figure 2.2 Predicted Secondary structure of P-gp (Schinkel et al., 1999) 
TMB = transmembrane domain; NBD = nucleotide binding domain 
 
The MDR1 gene product (Figure 2.2) is a 170 kDa transmembrane protein that 
consists of 1280 amino acids. It is organized as a single polypeptide consisting of 
two similar halves; a carboxy and an amino halve (Dey et al., 1997). Each part 
consists of a transmembrane domain containing six helices and an intracellular 
ATP-binding site also known as nucleotide binding domain (NBD). Intracellular 
and extracellular loops connect the transmembrane segments with the first 
extracellular loop being highly N-glycosylated. The NBD contains three 
conserved domains among the ABC transporters: walker A and B domains and a 
signature motif (C). The NBD binds and hydrolyzes ATP which provides the 
energy for active drug export that can occur against a large concentration 
gradient. Binding of substrates occur at the transmembrane domains (Gottesman 
et al., 1996; Sauna and Ambudkar, 2001; Higgins and Linton 2004; For review see 
Endicott and Ling 1989; Gottesman and Pastan, 1993; Bosch and Croop 1998; 
Gottesman and Ambudkar 2001; Ambudkar et al., 2005). 
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Table 2.1 mRNA expression of P-gp (adapted from Croop et al., 1989; Schinkel 
et al., 1999) 
Tissue MDR1 (human) mdr1a (mouse) 3 mdr1b (mouse) 1 
Stomach  + - + 
Intestines + + + + + + + 
Liver + + + + + 
Adrenal gland + + + + + + + + + + + + 
Ovary + + ++ 
Testis + + - 
Kidney + + + + + + 
Uterus + (+) + 
Pregnant uterus + + (+) + + + + 
Brain + + + - 
Skeletal muscle + + + 
Heart Data not available + + 
Lung + + + + 
Spleen + + + 
The relative expression is indicated by +, and very low or undetectable levels with - 
 
Apart from expression in the BBB, drug-transporting P-gp pumps are expressed 
in a range of other tissues (Table 2.1). The most prominent sites are the 
endometrium of the pregnant uterus, the apical surface of mucosal cells in the 
small and large intestines, the biliary canalicular membrane of hepatocytes and the 
luminal membrane of proximal tubular epithelial cells in the kidney. High levels 
are also located in the adrenal glands of mice and humans. This tissue distribution 
suggests that P-gp plays a role in excreting toxic xenobiotics and metabolites into 
intestinal lumen, bile and urine, respectively (Figure 2.3). In addition, moderate 
levels were found in a range of other tissues (Thiebaut et al., 1987; Croop et al., 
1988; Cordon-Cardo et al., 1989). 
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Figure 2.3 Schematic drawing of the organ distribution of P-gp in the mouse 
(modified from Schinkel, 1997) 
 
2.2.3. PHYSIOLOGICAL ROLE OF P-GP 
 
Firm evidence for the purpose of P-gp came from studies in which mdr1 genes 
were inactivated by insertional mutagenesis (For review see Borst and Ambudkar, 
1996; Ambudkar et al., 1999; Schinkel, 1999). The physiological function of P-gp 
at the BBB is to protect the brain from potentially harmful substances by 
exporting these substances out of the brain. Intestinal P-gp is an important factor 
in limiting the entry of substrate drugs from the intestinal lumen to the 
bloodstream. Therefore it can have a major negative effect on the oral 
bioavailability of drugs. Intestinal P-gp can further contribute to the direct 
excretion of drugs from the bloodstream into the intestinal lumen. The bile 
canalicular P-gp contributes to the hepatobiliary excretion of drugs. Together 
these effects can result in a markedly slower elimination of drugs from the 
bloodstream and in a clear shift from primarily fecal to primarily urinary excretion 
of some drugs. Expression of P-gp in the placenta suggests a role for P-gp in 
protecting the foetus from toxic xenobiotics. Because of its localization in 
steroid-secreting glands, P-gp might be involved in secretion of steroids, or in 
protecting the plasma membranes of steroid-secreting cells from the toxic effects 
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of high steroid concentration (Schinkel 1997; Ambudkar et al., 1999; Schinkel 
1999; Tanigawara 2000). Taking together, the physiological function of P-gp is 
the protection of the cells and organism against toxic compounds.  
 
Since the finding that resistance to anticancer drugs in human cancers is due to 
the expression of the P-gp transporter (Chen et al., 1986) it has become clear that 
P-gp also has a major impact on drug resistance to psychotropic drugs like anti-
epileptics (Löscher and Potschka, 2001; Luna-Tortós et al., 2008), anti-HIV drugs 
(Kim et al., 1998; Huisman et al., 2000), antidepressants and others (Schinkel et 
al., 1996; Wang et al 2003; Linnet and Ejsing, 2008; Schinkel and Jonker 2003).  
 
The degree of expression and the functionality of the MDR1 gene product can 
directly affect the distribution, absorption and elimination of P-gp substrates. 
Consequently, variations in the expression levels and activity of P-gp have a 
major impact on the therapeutic efficacy of many drugs. This implicates that 
absorption of drugs is variable among individuals (Kim et al., 2001; Ambudkar et 
al., 2003; Ebinger et al., 2006; Brinkmann et al., 2001). Currently, more than 100 
mutations in the human P-gp gene have been identified (Maeda et al., 2008). 
Some of these polymorphisms are directly related to human diseases such as 
epilepsy (Löscher 2007; Kwan and Brodie 2005; Siddiqui et al., 2003), Parkinson 
disease (Kortekaas et al., 2005), Alzheimer disease (Lam et al., 2001; Vogelgesang 
et al., 2002) and others (Turgut el al., 2008; Langford et al., 2004; Löscher and 
Potschka 2005). 
 
2.3. Modulation of P-gp 
 
2.3.1. SUBSTRATES 
 
P-gp recognizes and transports a structurally, chemically and pharmacologically 
diverse range of compounds with molecular weights between 200 Da and 1900 
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Da. Drugs that are found to be substrate for P-gp include anthracyclines 
(daunorubicin), vinca alkaloids (vincristine), calcium channel blockers (verapamil), 
anti-emetics (domperidone), the immunosuppressivum Cyclosporin A (CsA) and 
so on (Table 2.2) (Bauer et al., 2005; Linnet and Ejsing, 2007).  
 
Table 2.2 Examples of drugs transported by P-gp 
Cardiovascular medication Cytotoxic agents 
Verapamil Doxorubicin 
Diltiazem Daunorubicin 
Digoxin Paclitaxel 
Carvedilol Opioids 
Lovastatin Morphine-6-glucuronide 
Anti-emetics Phentanyl 
Domperidone Loperamide 
Ondansetron Antibiotics 
HIV protease inhibitors Erythromycin 
AZT Rifampicin 
Ritonavir Others 
Saquinavir Dexamethason (glucocorticoid) 
Immunosuppressive drugs Doxorubicin (antineoplastic) 
Cyclosporin A Midazolam (benzodiazepine) 
Tacrolimus Ivermectin (antihelmintic) 
 
The mechanism by which P-gp recognizes this wide range of substrates is less 
clear at the moment (Schinkel et al., 1996; Tanigawara, 2000; Bart et al., 2000; 
Linnet and Ejsing, 2008). Given the potential of P-gp to affect bioavailability and 
tissue distribution, particularly CNS drug distribution, it would be very useful to 
understand the structural features that make a compound a substrate or inhibitor 
of P-gp. However, specific structure-activity models of a P-gp pharmacophore 
have proven to be difficult to develop. A general pharmacophore with two or 
three electron donor groups in a fixed spatial separation has been suggested by 
Seelig et al. (1998). It has also been proposed that a planar aromatic domain and 
the presence of a basic nitrogen atom are features of substrates but drugs lacking 
these features could also be transported (Sun et al., 2003). The only common 
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denominator for all P-gp substrates is their amphipatic nature (Schinkel et al., 
2003). Partitioning into the lipid membrane is the rate-limiting step for the 
interaction of a substrate with P-gp. Dissociation of the P-gp-substrate complex 
is determined by the number and strength of the hydrogen bonds formed 
between the substrate and the transporter. If two substrates are applied 
simultaneously to P-gp, the compound with the highest potential to form 
hydrogen bonds, generally act as an inhibitor (Seelig et al., 2000).  
 
2.3.2. INHIBITORS 
 
In view of the potential contribution of P-gp to the drug resistance observed 
during chemotherapy in a number of clinical tumors, there is a widespread 
interest in the use of so-called P-gp reversal or modulating agents. Co-
administration of such blockers with conventional chemotherapy in cancer 
patients might reverse the P-gp-mediated multidrug resistance of the tumor, and 
thus enhance the response to therapy. Another therapeutic implication of these 
reversal agents is the enhancement of brain uptake of some drugs. This is 
favourable for therapy when the intended pharmacological target is positioned 
behind the BBB. Keeping in mind the protective role of P-gp at the BBB, P-gp 
modulators should be used carefully.  
Because of the potentially important therapeutic implications of reversal agents, 
several P-gp blockers with high efficacy and low toxicity have been developed. 
Reversal agents are as diverse in structure as the previously identified transported 
drugs. In fact, many compounds initially identified as reversal agents turned out 
to be themselves transported by P-gp, which suggests that they inhibit transport 
of other compounds in a competitive manner (Schinkel 1997; Huisman et al., 
2000; Varma et al., 2003). 
Based on the specificity and affinity, P-gp inhibitors are classified into three 
generations. First-generation inhibitors are pharmacological actives, which are in 
clinical use for other indications but have shown to inhibit P-gp. These include 
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verapamil, CsA, reserpine and tamoxifen. The use of these compounds is limited 
by their side effects when administrated with a dose that is required to inhibit P-
gp. Valspodar, biricodar and GF120918 are examples of second-generation 
modulators. They are analogues of the first-generation compounds but lack the 
pharmacological activity of the original molecule and possess usually a higher P-
gp affinity. Despite their better pharmacological profile, these agents display lack 
of absolute selectivity thereby limiting their clinical use. Most of them are often 
inhibitors of other ABC transporters or cytochrome P4503A. Third-generation 
inhibitors are the most potent, highly selective P-gp modulators, having only little 
influence on cytochrome P4503A drug metabolism and showing only little 
interaction with chemotherapeutic agents. Members of this class are zosuquidar, 
tariquidar, laniquidar and ONT-093 (Tan et al., 2000; Varma et al., 2003; Fricker 
and Miller 2004; Nobili et al., 2006). 
 
2.3.3. IMAGING OF P-GP 
 
Non-invasive imaging of P-gp functionality or expression with PET or SPECT 
could have several applications. PET or SPECT could be applied to evaluate the 
efficacy of candidate modulators that have passed initial in vitro screening assays. 
It might also allow selection of the proper modulator and dosing schedule for the 
individual patient. Information on the dynamic transport of P-gp will avoid 
unnecessary treatment with modulators in those patients who will not benefit. 
Another interesting application could be the monitoring of P-gp functionality in 
psychiatric and neurological disorders which could implicate the efflux pump as a 
possible cause in these diseases. So far, several radioligands for PET and SPECT 
have been proposed among which [11C]verapamil, [11C]N-desmethyl-loperamide 
(Lazarova et al., 2008), [11C]loperamide (Zoghbi et al., 2007), [11C]colchicine 
(Levchenko et al., 2000), [11C]carvedilol (Elsinga et al., 2005) and [18F]MPPF 
(Lacan et al., 2008; Passchier et al., 2000) for PET and [99mTc]sestamibi and 
[99mTc]tetrofosmin (Ballinger et al., 1996) for SPECT (For review see Elsinga et 
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al., 2004; Elsinga et al., 2005; Vaidyanathan and Zalutsky, 2004) (Figure 2.4). Two 
of them, [11C]verapamil and [99mTc]sestamibi, have been used in clinical trials and 
will be discussed briefly.  
 
Figure 2.4 Tracers evaluated for imaging P-gp 
 
[99mTc]sestamibi is a radiopharmaceutical used clinically to study myocardial 
perfusion (Mandalapu et al., 1999). It was demonstrated that [99mTc]sestamibi, a 
substrate for P-gp as well as for multidrug resistance protein 1, is especially useful 
for imaging P-gp expression in tumors rather than brain (Kostakoglu et al., 1996; 
Barbarics et al., 1998 for review see Hendrikse et al., 1999). 
Differences in tissue concentrations of [11C]verapamil was demonstrated between 
mdr1a knock-out mice and wild type mice. The brain uptake of [11C]verapamil is 
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remarkably higher in mdr1a knock-out mice (9.5 fold) as well as after 
pretreatment with CsA (10.6 fold) indicating that [11C]verapamil is effectively 
transported by P-gp at the BBB (Hendrikse et al., 1998). Evaluation of 
[11C]verapamil for in vivo imaging of P-gp functionality in non-human primates 
proved its usefulness as a tool for evaluating P-gp function (Lee et al., 2006). 
Nevertheless, metabolization of [11C]verapamil makes the determination of a 
pharmacokinetic model, and so absolute quantification, more complex (Syvanen 
et al., 2008; Luurtsema et al., 2004). 
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Chapter 3 
 
Catecholamine system in the brain 
 
3.1. Catecholamine pathways in the brain 
 
3.1.1. GENERAL INTRODUCTION 
 
Catecholamines (dopamine, norepinephrine and epinephrine) are 
neurotransmitters named after their chemical structure. They contain a benzene 
ring with two hydroxyl groups (catechol) and a side chain of ethylamine or one of 
its derivatives. All catecholamines are synthesized starting from tyrosine, an 
amino acid synthesized out of phenylalanine or derived from food proteins.  
Tyrosine accumulates in neurons by an active transport mechanism. There, it is 
converted to dihydroxyphenyl-alanine (DOPA) by the enzyme tyrosine 
hydroxylase. L-DOPA is then decarboxylated to dopamine which is stored in 
vesicles in the nerve terminals (Weiner, 1970) where it can be further oxidized to 
norepinephrine using dopamine-β-hydroxylase (Figure 3.1) (Goodall and 
Kirshner, 1958).  
Both neurotransmitters are released in the synaps through a calcium-dependent 
process initiated by nerve impulse activity (Figure 3.1). The released 
neurotransmitters can now interact with dopamine and adrenoreceptors, 
respectively. Termination of the signal occurs by reuptake in the presynaptic 
neuron using the dopamine and norepinephrine transporter or by enzymatic 
degradation of the neurotransmitter using the enzymes monoamine oxidase 
(MAO) and catecholamine-O-methyltransferase (COMT). Reuptake is the main 
mechanism responsible for inactivation (Kanner and Schuldiner, 1987; Schmitz et 
al., 2003). The recycled neurotransmitter can be restored in vesicles by vesicular 
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monoamine transporters or further metabolized by MAO or COMT. 
Extravesicular dopamine is metabolized to dihydroyphenylacetic acid whereas 
extracellular dopamine is degraded to homovanillic acid. 3-Methoxy-4-hydroxyl-
phenethylenglycol is the major metabolite formed by degradation of 
norepinephrine (Maas and Landis, 1968; Peyrin and Dalmaz, 1975; Eisenhofer 
and Fineberg, 1993; Kopin, 1994). 
 
Figure 3.1 Schematic representation of noradrenergic synaptic signalling 
(Klabunde, 2008) 
DA = Dopamine; DD = DOPA decarboxylase; DOPA = dihydroxyphenyl-alanine; 
DBH = dopamine-β-hydroxylase; NE = Norepinephrine; TH = tyrosine hydroxylase;  
Tyr = tyrosine 
 
The transporters responsible for inactivation of dopamine and norepinephrine as 
well as the enzyme MAO, will be further discussed. 
 
3.1.2. NORADRENERGIC SYSTEM IN THE BRAIN 
 
The major noradrenergic nucleus in the brain is the locus coeruleus. The locus 
coeruleus is the main source of the noradrenergic innervation in the 
hippocampus, thalamus, cerebellum as well as most cortical areas (Figure 3.2). 
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The lateral tegmental system, another group of noradrenergic cells, has its cells of 
origin located in discrete regions of the pons and medulla. These norepinephrine-
containing cells innervates the hypothalamus and parts of the amygdale, but has 
also descending projections to the spinal cord (Nicholas et al., 1996; Aston-Jones, 
2002).  
 
Figure 3.2 Noradrenergic pathways in the human brain (CNSforum.com) 
 
Norepinephrine is involved in mood regulation, sleep regulation, memory, 
expression of behaviour and the general degree of alertness and arousal (Aston-
Jones, 2002; Murchison et al., 2004). The actions of norepinephrine are carried 
out via the binding to the adrenoreceptors, a class of G-protein coupled 
receptors. There are two main groups of adrenergic receptors, α and β, which are 
further divided into α1A, α1B, α1D, α2A, α2B, α2C and β1, β2, β3. All receptors are G-
protein coupled receptors and are localized post- or presynaptic (Nicholas et al., 
1996; Docherty, 1998). 
 
3.1.3. DOPAMINERGIC SYSTEM IN THE BRAIN 
 
The dopaminergic neurons are classified into four main pathways (Figure 3.3) 
(For review see Reid, 1977; Moore and Bloom, 1978; Marsden, 2006). The 
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nigrostriatal pathway projects from the substantia nigra to the dorsal striatum. 
This pathway contains about 80 % of all dopaminergic innervations and is 
involved in the regulation of movements (Cousins and Salamone, 1996). The 
dopaminergic neurons involved in the mesolimbic and mesocortical pathways 
both originates in the ventral tegmental area. The mesolimbic pathway projects 
towards limbic areas such as nucleus accumbens and amygdale whereas the 
mesocortical pathway most densely projects to the prefrontal cortex. The 
mesolimbic system plays a role in emotional expression and motivation (Cabib et 
al., 1996). Memory, organization, attention and social behaviour are affected by 
the mesocortical pathway (Floresco and Magyar, 2006). Finally, the 
tuberoinfundibular pathway exists of a group of small neurons, signalling from 
the hypothalamus towards the pituitary gland. In this last pathway, dopamine 
inhibits prolactin release (Andrews and Grattan, 2004). 
 
 
Figure 3.3 Dopaminergic pathways in the human brain (Rang et al., 1999) 
Ac = nucleus accumbens; Am = amygdaloid nucleus; C = cerebellum; Hip = 
hippocampus; Hyp = hypothalamus; P = pituitary gland; Sep = septum; Str = corpus 
striatum; Th = thalamus; N = substantia nigra 
 
The actions of dopamine are mediated by binding to specific membrane 
receptors, which belongs to the family of seven transmembrane domain G-
protein coupled receptors. Two types of dopamine receptors, termed D1 and D2 
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were originally distinguished based on their biochemical and pharmacological 
properties. The D1-like family includes the D1 and D5 receptors while the D2-like 
receptors are further divided into D2, D3 and D4. The most common receptors, D1 
and D2, are involved in regulation of behaviour and are localized in striatum (D1 
and D2), cortical regions (D1 and D2), amygdale (D2), hippocampus (D2) and 
thalamus (D2). Presynaptically localized D2 receptors are involved in the 
regulation of the biosynthesis and the release of dopamine (Jackson and 
Westlind-Danielsson, 1994, Marsden, 2006).  
 
3.2.      Catecholamine transporters 
 
3.2.1. GENERAL INTRODUCTION 
 
Synaptic signalling is primarily terminated by active transport of the 
neurotransmitter in neuronal cells by neurotransmitter transporters. Once inside 
the neuronal cell, neurotransmitters can be further transported into synaptic 
vesicles by vesicular carriers. These processes are responsible for the homeostasis 
of neurotransmitter pools within nerve endings. Both at the plasma and vesicular 
membranes, neurotransmitter influxes are directly coupled to transmembrane ion 
gradients which provide the energy for the retrotransport (Kanner and 
Schuldiner, 1987).  
Neurotransmitter transporters can be classified in superfamilies, families, and 
subfamilies according to their primary structure and site of action. In particular, 
the latter criterion allows the distinction of two superfamilies: the plasma 
membrane transporters and the vesicular membrane transporters. The 
superfamily of plasma membrane transporters can be further divided into two 
families depending on their ionic dependence: the Na+/Cl--dependent 
transporters and the Na+/K+-dependent transporters. Based on their substrate 
preferences, the Na+/Cl--dependent transporters are classified into subfamilies 
among which the amino acid transporters and monoamine transporters (Masson 
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et al., 1999; Zahniser and Doolen, 2001). This thesis focuses on the dopamine 
transporter (DAT) and norepinephrine transporter (NET), both members of the 
monoamine transporter subfamily. The serotonin transporter (SERT) is the third 
transporter belonging to the monoamine transporters.  
 
3.2.2. HISTORICAL BACKGROUND  
 
The presence of an active transport system for the cellular uptake of 
norepinephrine at sympathetic nerve endings was suggested by studies on the 
tissue uptake and retention of [3H]-labelled norepinephrine administrated to 
animals (Whitby et al., 1961; Hertting et al., 1961). Regional differences within the 
brain for the uptake of dopamine and norepinephrine indicated the existence of a 
separate mechanism for the neuronal reuptake of dopamine. Striatal 
synaptosomes showed a much higher affinity for uptake of dopamine than 
norepinephrine, whereas in other brain regions, the difference was less 
pronounced. There were no stereoselective preferences for uptake of D- and L-
isomers of norepinephrine in the striatum, whereas in other regions, the L-isomer 
was the preferred substrate. This observation suggested that norepinephrine 
uptake in the striatum is mediated by DAT whereas in other regions, NET was 
abundant (Snyder and Coyle, 1969; Coyle and Snyder, 1969).  
 
3.2.3. STRUCTURE, FUNCTION AND MECHANISM  
 
Up to date, no X-ray crystallographic or high-resolution structural information is 
available for the topological assignments of the transporters. The identification of 
the cDNAs for the catecholamine transporters has contributed greatly to our 
understanding of the molecular structure and function of these important 
proteins (Amara and Kuhar, 1993).  
The polytopic membrane proteins, DAT and NET show high homology (66 %) 
and share several structural features (Figure 3.4). They are both composed of 12 
Catecholamine system in the brain - Chapter 3 
 47 
transmembrane domains (TMD), several similarly configured intracellular and 
extracellular loops with phosphorylation and glycosylation sites, and intracellular 
located amino- and carboxy-terminal residue. One large extracellular loop is 
positioned between TMD 3 and TMD 4 and contains a variable number of N-
glycosylation sites (Giros and Caron., 1993). The presence of several intracellular 
sites for phosphorylation, suggests that second messengers may regulate 
transporter function and/or subcellular redistribution. Phosphorylation can occur 
by several enzymes with protein kinase A and C and calcium-modulin kinase II as 
the most important ones. TMD 1, 2 and 4 - 8 show the highest degree of 
sequence identity between DAT and NET. The conservation of sequence in 
these membrane-spanning domains argues for their functional importance in 
transport activity. The carboxy-terminal region, spanning from TMD 9 through 
the carboxy-terminal tail, seems to be responsible for the observed 
stereoselectivity and high affinity for their respective substrates (Giros et al., 
1994; Buck and Amara, 1994 and 1995; Brüss et al., 1995; Hersch et al., 1997; 
Zahniser and Doolen, 2001). 
 
Figure 3.4 Topology of catecholamine transporters (Torres et al., 2003) 
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The observation that extracellular Na+ ions were a necessary requirement for 
substrate uptake provided one of the first insights into the transport mechanism. 
It is now well established that the mechanism by which transporter proteins 
mediate catecholamine uptake involves sequential binding and co-transport of 
Na+ and Cl- ions. The driven force for transporter-mediated catecholamine 
uptake is the ion concentration gradient that is created and maintained by the 
plasma membrane Na+/K+ ATPase. In the case of DAT, two Na+ ions and one 
Cl- ion are transported with the substrate, whereas NET co-transport its substrate 
with one Na+ ion and one Cl- ion (Kanner and Schuldiner, 1987; Torres et al., 
2003). A detailed description of the mechanism and regulation of transport is 
beyond the scope of this thesis but has extensively been discussed and reviewed 
by others (Rudnick and Clark, 1993; Sonders and Amara, 1996; Kavanaugh, 1998; 
Beckman and Quick, 1998; Torres, 2003; Meliaken, 2004; Blakely et al., 2005). 
 
3.2.4. NOREPINEPHRINE TRANSPORTER 
 
3.2.4.1. Structure and localization 
 
Pacholzyk et al. (1991) identified the cDNA encoding for the human NET using 
an expression cloning strategy in COS cells. The NET cDNA was isolated from 
the SK-N-SH human neuroblastoma cell line on the basis of its ability to direct 
the transport of 125I-labelled meta-iodobenzylguanidine, a norepinephrine 
analogue. The sequence of the NET cDNA predicts a protein of 617 amino acids 
weighing approximately 69 kDa. The human NET gene (SLC6A2) is located on 
chromosome 16q12.2, spans about 45 kb and consists of 14 exons (Gelernter et 
al., 1993; Porzgen et al., 1995). NET has 3 glycosylation sites on the second 
extracellular loop and also a few phosphorylation sites (Figure 3.5). A high 
affinity of NET for both dopamine and norepinephrine has been demonstrated 
whereas the affinity for epinephrine and the effectiveness of its transport is much 
lower (Moron et al., 2002; Bönisch and Bruss, 1994). As mentioned before, the 
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highest NET density is found in the locus coeruleus whereas striatum has 
negligible amounts of NET. Peripherally, NET is mainly localized in heart, lungs 
and smooth muscles (Raisman et al., 1982; Ressler and Nemeroff, 1999; Smith et 
al., 2006).  
 
Figure 3.5 Topology of the rat norepinephrine transporter (Brüss et al., 1997) 
Solid dots represent the 26 amino acid residues that are divergent in rat NET but are 
conserved in the human and bovine NETs. 
 
3.2.4.2. NET and human diseases  
 
Depression and anxiety disorders are common recurring disorders with a 
prevalence of 7 - 11 % (Ressler et al., 2007). The estimated annual cost of 
depression in the US alone was approximately 44 billion dollar in 1990 
(Greenberg et al., 1993). More than 40 years of research through experimental 
models and in the clinical setting, have clearly indicated the importance of 
norepinephrine neurotransmission in the pathophysiology and subsequent 
treatment of affective and mood disorders such as major depression (For review 
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see Ressler and Nemeroff, 1999; Brunello et al., 2002). Given the importance of 
NET to noradrenergic transmission it is conceivable that regulation of the level 
of expression of NET gene in noradrenergic neurons may be a natural 
mechanism by which noradrenergic neurotransmission can be adjusted in vivo in 
response to physiological demands placed on this system. Evidence for such a 
mechanism was first provide by Lee et al. (1983), who demonstrated that NET is 
upregulated and downregulated in response to enhanced availability or depletion 
of norepinephrine, respectively. Thus, levels of NET appear to be regulated in 
order to maintain ‘normal’ concentrations of norepinephrine in the noradrenergic 
synaps (Lee et al., 1983). Klimek et al. (1997) demonstrated a reduced NET 
density in the locus coeruleus measured by a lower [3H]nisoxetine binding to 
NET in brain tissues collected post-mortem from subjects diagnosed with major 
depression (Klimek et al., 1997). Variations in the genes encoding for NET could 
be involved in predisposing individuals to psychiatric disorders. Linkage analysis 
for depression and other psychiatric disorders and the genetic variations of the 
NET gene displayed contradictory findings (For review see Hahn and Blakely, 
2007). A few studies demonstrate positive association between the NET gene and 
psychiatric disorders (Urwin et al., 2002; Inoue et al., 2004; Ryu et al., 2004; Sun 
et al., 2008) while others show no association at all (Hadley et al., 1995; Owen et 
al., 1999; Sand et al., 2002; Zill et al., 2002).  
The basis for the treatment of depression is to moderate the levels of 
neurotransmitters. Several classes of drugs have been identified and used as 
antidepressants (for Review see Leonard, 1999). Reboxetine (Figure 3.6) is the 
first potent, selective and specific norepinephrine reuptake inhibitor. Two chiral 
centres are present in reboxetine. However, due to the regio- and stereo-
specificity of the key reactions used for its synthesis, only two diastereomers are 
present in reboxetine; it is a racemic mixture of RR- and SS-2-[α-(2-
ethoxyphenoxy)benzyl]morpholine methanesulphonate (Melloni et al., 1984). 
Extensive research indicated that reboxetine is a clinically active, efficacious and 
well-tolerated antidepressant. Since 1997, reboxetine is on the market with 
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different trade names including Edronax®, Norebox® and Vestra® and so on 
(Dostert et al., 1997; Holm and Spencer, 199; Wong et al., 2000). 
 
 
Figure 3.6 Chemical structures of Reboxetine mesylate and Atomoxetine 
 
Atomoxetine (Figure 3.6), also known as (-)-N-methyl-γ-(2-methylphenoxy) 
benzenepropanamine, is another selective and potent inhibitor of norepinephrine 
reuptake (Wong et al., 1982). It is currently on the market as Strattera® for the 
treatment of attention deficit hyperactivity disorder (ADHD). ADHD is the most 
common neurobehavioural disorder of childhood and affects about 5 - 10 % of 
school-aged children. ADHD is characterized by inattention, hyperactivity and 
impulsivity. Until a few years ago, only stimulants have been approved for the 
treatment for ADHD. Although these agents have shown efficacy, they also have 
some limitations including a 10 - 30 % failure rate, intolerance, abuse liability and 
adverse effects such as insomnia and anxiety. Atomoxetine is the first non 
stimulant indicated for the management of ADHD. Over the last 7 years its 
pharmacokinetics, pharmacodynamics and clinical efficacy has well been 
established (Bymaster et al., 2002; Mattiuz et al., 2003; Corman et al., 2004; Sauer 
et al., 2005). 
               
3.2.4.3. Imaging of  NET 
 
Because of the low density of NET in brain, radioligands should be highly 
selective and specific. Imaging of the NET has lagged behind due to the lack of 
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selective NET radioligands that give a high signal to noise ratio. Some potent 
NET reuptake inhibitors that have been labelled for in vitro or in vivo mapping of 
brain NET are discussed briefly. 
Desipramine, a well-known tricyclic antidepressant, is a highly potent and 
selective inhibitor of NET. Tritium-labelled desipramine has been used for in vitro 
autoradiographic studies of NET in the human brain post mortem (Gross-
Isseroff et al., 1988; Bäckström and Marcusson, 1990). Van Dort et al. (1997) 
reported the radiosynthesis of desipramine and its 2-hydroxy metabolite with 11C 
but the in vivo evaluation was not included. [11C]desipramine has been evaluated in 
vivo by Schou et al. (2005). An almost complete homogenous brain uptake was 
displayed, indicating that [11C]desipramine has a high non-specific binding and is 
subsequently not suitable for imaging NET (Schou et al., 2005).  
Although nisoxetine is very selective for NET in vitro, [11C]nisoxetine exhibits 
very high levels of nonspecific binding in vivo, making it practically unsuitable for 
PET (Haka et al., 1989; Ding et al., 2005). An iodinated analogue of nisoxetine 
with promising in vitro properties has been developed (Chumpradit et al., 1992; 
Kiyono et al., 2003; Kung et al., 2004). Unfortunately, (R)-[125I]2-iodonisoxetine 
also failed the in vivo tests; it displayed high nonspecific binding resulting in a high 
background uptake (Kiyono et al., 2004; Kung et al., 2004).  
Evaluation of [11C]talopram, [11C]talsupram, [11C]oxaprotiline and 
[11C]lortalamine demonstrated lack of selective NET binding in vivo, even though 
their in vitro potentials were promising (McConathy et al., 2004; Ding et al., 2005; 
Schou et al., 2005). 
 
 
Figure 3.7 Structure of NET radioligands 
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Recently, 11C and 18F labelled analogues of reboxetine (Figure 3.8) have been 
synthesized and evaluated as PET radioligands in rodents, monkeys and humans. 
In vivo evaluation of (S,S)-[11C]methylreboxetine (MeNER) displayed a regional 
distribution consistent with the known distribution of NET. Blocking studies in 
mice demonstrated the selectivity towards NET. Further evaluation of (S,S)-
[11C]MeNER in nonhuman primates and human brain showed that no 
equilibrium was used during the PET measurement. This together with a 
somewhat noisy final signal at later time points lead to the preparation and 
evaluation of radiofluorinated analogues to extend the PET scanning time (Schou 
et al., 2003; Wilson et al., 2003; Ding et al., 2003; Severance et al., 2007). Its 
[18F]fluoromethyl analogue, (S,S)-[18F]FMeNER, displayed not only significant 
uptake in the NET-rich regions but also showed a high bone uptake due to in vivo 
defluorination. With the intention of reducing the in vivo defluorination, the di-
deuterated analogue, (S,S)-[18F]FMeNER-D2 was developed. PET studies 
indicated that the extent of defluorination was significantly reduced while the 
selectivity and affinity towards NET was retained (Schou et al., 2004; Seneca et 
al., 2005; Lin et al., 2005). These data encourage further PET studies using (S,S)-
[18F]FMeNER-D2 in humans (Schou et al., 2005; Arakawa et al., 2008, Takano et 
al., 2008). 
 
 
Figure 3.8 Structures of (S,S)-reboxetine (A), (S,S)-[11C]MeNER (B) and (S,S)-
[18F]FMeNER-D2 (C) 
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3.2.5. DOPAMINE TRANSPORTER 
 
3.2.5.1. Structure and localization 
 
Human DAT cDNA’s were first isolated using highly homologous rat DNA or 
human NET cDNA sequences. The human DAT gene (SLC6A3) was mapped to 
chromosome 5p15.3. The organization of the entire gene has been reported. It 
spans about 65 kb of the human genome and consists of 15 exons separated by 
14 introns (Giros et al., 1992; Kawari et al., 1997; Bannon et al., 2001). 
Transcription and translation of SLC6A3 results in an 80 kDa large 
transmembrane protein consisting of 620 amino acids (Figure 3.9). 
 
Figure 3.9 Sequence and Topology of the human dopamine transporter (Giros 
and Caron, 1993) 
Cysteines 180 and 189 in the second extracellular loop are disulfide bonded. Asparagine 
residues 181, 188, and 205 in the second extracellular loop are linked with glycosyl 
groups. Methionine residues are indicated as black circles with white letters. 
 
DAT is predominantly present in the brain although it is also found in the 
periphery. In the brain, DAT co-localizes with markers for tyrosine hydroxylase 
and dopamine D2 receptors. Striatum has the highest DAT density whereas 
cerebellum is almost negligible of DAT (Chen and Reith, 2000; Uhl, 2003; Piccini, 
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2003). Peripheral organs expressing DAT are the lungs, the gastro-intestinal 
system (Mitsuma et al., 1998; Mezey et al., 1999) and the pancreas (Mezey et al., 
1996). DAT mediates uptake of dopamine and is an inefficient transporter of 
norepinephrine (Giros et al., 1992). 
 
3.2.5.2. Psychostimulants and DAT 
 
Addiction to psychoactive drugs continues to be one of the most significant 
medical, social, and economic problems facing society. Drug addiction has been 
considered as a brain disorder characterized by compulsive drug-seeking 
behaviour and uncontrollable use of the drug. The major dysfunction and 
dysregulation associated with addictive disorders involves the brain’s natural 
reward system. It has been shown that drugs interact with regions of the brain 
where dopaminergic terminals are abundant, specifically the mesolimbic pathway 
(Koob and Bloom, 1988; Wise, 1996; Koob, 2000; Pierce and Kumaresan, 2006). 
Cocaine and amphetamine, including methamphetamine and 
methylenedioxymethamphetamine (ectasy) are powerful central nervous system 
stimulants which are widely abused (for review see Howell and Kimmel, 2008). 
Currently, no effective pharmacotherapy for psychostimulant abuse has 
demonstrated efficacy for long-term use. Both drugs increase the extracellular 
levels of monoamines. Although cocaine and amphetamines affect all three 
monoamine concentrations, the rewarding, reinforcing and stimulating effects are 
believed to depend primarily on its interaction with DAT (Ritz et al., 1987; Giros 
et al., 1996; Amara and Sonders, 1998; Carboni et al., 2001; Elliott and Beveridge, 
2005).  
Cocaine, a naturally occurring molecule that can be isolated from Erythroxylon 
coca, exerts its action by blocking dopamine reuptake, thereby increasing the 
concentration of dopamine in the synapse, which then causes overstimulation of 
dopamine receptors (Figure 3.10) (Witkin et al., 1991; Kuhar and Boja, 1991; 
Volkow et al., 1997; Geracitano et al., 2006).  
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Figure 3.10 Influence of drugs on the function of DAT (Torres et al., 2003) 
Amph = amphetamine; DA = dopamine; DAT = dopamine transporter; L-DOPA = L- 
dihydroxyphenyl-alanine 
 
Amphetamine is a substrate-type releaser (Figure 3.10) (For review see 
Fleckenstein et al., 2007). It binds to the transporter protein and is subsequently 
transported into the cytoplasma of the nerve terminals. Extracellular transmitter 
concentrations are elevated by a two-pronged mechanism: (1) the amphetamines 
promote efflux of transmitter by a process of transporter-mediated exchange and 
(2) they increase cytoplasmic levels of transmitter by disrupting storage of 
transmitters in vesicles. This latter action increases the pool of neurotransmitters 
available for release by transporter-mediated exchange (Kahlig and Galli, 2003; 
Rothman and Baumann, 2003; Geracitano et al., 2006). It is important to 
emphasize that a number of synthetic stimulants, including amphetamines are 
useful medication in the treatment of ADHD, narcolepsy and obesity. The same 
drug can thus be a therapeutic entity or an abused substance depending upon the 
context in which the drug is administrated. Methamphetamine for example is 
widely abused for its ability to increase wakefulness and physical activity and 
decrease appetite (Rothman and Baumann, 2003). 
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3.2.5.3. Role of DAT in human disorders  
 
Parkinson’s disease (PD), ADHD and schizophrenia each have abnormal 
dopamine function in addition to many other disabling features (Bannon, 2005). 
As mentioned before, ADHD is mainly treated with psychostimulants. These 
psychostimulants, for example methylphenidate (Rilatine®) exhibit their function 
by inhibiting the reuptake of dopamine. Several genetic findings indicated that 
specific alleles of the DAT gene seemed to be associated with ADHD (Cook et 
al., 1995; Gill et al., 1997). The results of different studies on the up- or 
downregulation of DAT in ADHD are inconsistent. Higher DAT density in the 
striatum have been reported (Krause et al., 2000; Cheon et al., 2003) as well as 
DAT decrements (Volkow et al., 2007; Hesse et al., 2009) and unchanged DAT 
density (van Dyck et al., 2002). 
Idiopathic PD is a progressive neurodegenerative disorder which manifests itself 
by bradykinesia in combination with rigidity, tremor and postural instability (Gelb 
et al., 1999). PD affects approximately 0.2 % of the population and the 
prevalence increases with age. To date, PD remains an incurable disease. The 
available treatments are able to offer only symptomatic relief for patients. The 
drugs used to treat PD either boost the levels of dopamine in the brain or mimic 
the effects of dopamine. L-DOPA is the key compound in the treatment of PD, 
acting as a precursor of dopamine (for review see Schapira, 2007; Singh et al., 
2007). The disease is neuropathologically characterized by the presence of Lewy 
bodies and by degeneration of dopamine-containing neurons in the ventral 
mesencephalon with loss of their nerve terminals in the basal ganglia structures, 
especially in the striatum (Stoof et al., 1999; Singh et al., 2007). 
PD diagnosis is based on clinical symptoms and the presence of Lewy bodies 
(Gelb et al., 1999). The clinical symptoms however are manifested when already 
50 – 80 % of the nigrostriatal neurons are lost. Clinical diagnosis fails to identify 
individuals before such a significant loss of dopamine neurons is reached. Lewy 
bodies also occur in patients suffering from other diseases like Alzheimer disease 
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and ataxia telangiectasia. Taken together, clinical diagnostic criteria are not always 
sufficient to make a confident, early diagnosis of PD. PD is also characterized by 
loss of dopamine neurons. Since DAT is exclusively localized on dopamine 
synthesizing neurons, it is a good marker for the integrity of these neurons. Over 
the last decade, radiotracers suitable for DAT imaging have been proposed as 
possible diagnostic tools and for monitoring the treatment of patients with PD 
(Figure 3.11). The high sensitivity and specificity of SPECT and PET 
(semi)quantitative images makes DAT imaging, at present, the best biomarker for 
evaluating dopamine neuron loss, which is responsible for most of the motor 
symptoms in PD patients (Stoof et al., 1999; Poewe and Scherfler, 2003; Shih et 
al., 2006).   
 
Figure 3.11 SPECT axial images in healthy control (right) and Parkinson’s disease 
patient (left) (Seibyl et al., 1998) 
Subjects were injected with 333 MBq (9 mCi) [123I]FP-CIT. Tracer uptake showed a 
marked reduction in Parkinson’s disease patient with greater abnormality in putamen. 
 
3.2.5.4. Imaging of DAT 
 
Several radioligands of different chemical classes have been developed for the 
visualization of DAT (for review see Guilloteau and Chalon, 2005; Volkow et al., 
1996; Elsinga et al., 2006). A limitation of many of these radioligands is their lack 
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of selectivity towards DAT. They mostly have also high affinity for one of the 
other monoamine transporters. 
 
 
Figure 3.12 Structure of cocaine (A), [123I]β-CIT (B), [11C]β-CFT (C) and 
[123I]FP-CIT (D) 
 
The first DAT radioligand developed for PET was [11C]nomifensine. Although it 
has favourable kinetics, [11C]nomifensine is unsuitable as a tracer for DAT  due to 
its high affinity binding at the NET (Aquilonius et al., 1987). The radiolabelling of 
cocaine with [11C] initiated development of many promising labelled cocaine 
derivatives (Figure 3.12). [11C]cocaine itself is not suitable due to high binding to 
SERT and NET in addition to low specific-to-nonspecific binding ratio and its 
very fast kinetics (Fowler et al., 1989; Volkow et al., 1996). The cocaine analogue 
[123I]β-CIT also known as [123I]RTI-55 has high affinity for DAT and a high 
specific-to-nonspecific binding. The major drawbacks of [123I]β-CIT are its low 
selectivity towards DAT and rather slow kinetics. Striatal activity increases for 15 
to 20 hours after bolus injection of the tracer. Consequently, SPECT 
measurements with [123I]β-CIT in the human brain usually requires a delay of 24 
hours between injection and imaging (Boja et al., 1992; Brucke et al., 1993; 
Laruelle et al., 1994). Consequently, PET measurements with [11C]RTI-55 must 
be conducted far from equilibrium (Farde et al., 1994). [11C]β-CFT  better known 
as [11C]WIN 35,428, also does not achieve a maximum value of striatal binding 
within the time constraints of PET experiments (Wong et al., 1993). Because of 
the high affinity of [11C]β-CFT, Laakso et al. (1998) recommended an 18F labelled 
analogue, [18F]β-CFT, enabling prolonged PET-scanning since striatal binding 
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peaked at 225 min p.i. (Laakso et al., 1998). However, from a practical point of 
view, such a long scanning protocol is not desirable for clinical studies. 
Therefore, numerous compounds have been investigated to improve selectivity 
and obtain accurate kinetics. Among those, [11C]PE2I (Halldin et al., 2003; Shetty 
et al., 2007), [18F]FECNT (Goodman et al., 2000; Deterding et al., 2001; Davis et 
al., 2003) and [123I]FP-CIT (Booij et al., 1997 and 1998) showed favourable brain 
kinetics although their selectivity towards DAT is still not optimal. [123I]FP-CIT is 
since 2000 commercially available in Europe by the name DatSCANTM and is 
used for diagnosis of PD (Vlaar et al., 2008; Booij and Kemp, 2008). 
Furthermore, useful [99mTc] labelled tropane analogues have been described such 
as [99mTc]TRODAT-1 (Kung et al., 1996; Hwang et al., 2002) and 
[99mTc]TropaBAT (Cleyhens et al., 2005; Kieffer et al., 2006).  
Although most radioligands for DAT imaging are tropane derivatives ligands, 
GBR 13119 has also proven to be a good lead compound. Several derivatives 
have been prepared and displayed good in vitro properties (Kimura et al., 2003; 
Boos et al., 2006; Rothman et al., 2008). Radiolabelling of these derivatives could 
result in new improved radiotracers for DAT. 
 
3.3.      Monoamine oxidase 
 
3.3.1. GENERAL INTRODUCTION 
 
The enzyme monoamine oxidase (MAO) was discovered 80 years ago in beef 
liver as tyramine oxidase (Hare, 1928). Almost 10 years later, it was established 
that epinephrine, norepinephrine and dopamine were also substrates for this 
enzyme and it was renamed monoamine oxidase. MAO (EC 1.4.3.4.) is a flavin-
containing (Kearney et al., 1971) mitochondrial membrane-bound protein 
(Schnaitman et al., 1967) which catalyzes the oxidative degradation of biogenic 
and xenobiotic amines to their corresponding aldehydes by the production of 
hydrogen peroxide and ammonia (Dostert et al., 1989; Tipton et al., 2004). MAO 
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(For review see Weyler et al., 1990) exists as two isoforms in many tissues of 
humans and other mammals, termed MAO-A and MAO-B. The two isoforms are 
distinguished by their substrate preference and by selective inhibitors, as well as 
by their physical properties (Housley et al., 1976; Schoepp and Azzaro, 1981). In 
general, it has been suggested that in the CNS intraneural MAO protect neurons 
from exogenous amines, terminate the actions of amine neurotransmitters, and 
regulate the contents of intracellular amine stores (Youdim et al., 2006). 
 
3.3.2. EXPRESSION AND STRUCTURE  
 
MAO-A and MAO-B (Figure 3.13) are different gene products with molecular 
weights of about 59.7 and 58.8 kDa respectively and a 70 % degree of homology 
in their amino acid sequence is present. Both genes are located on the X 
chromosome (Xp11.23), each comprising 15 exons with identical intron - extron 
organization (Lan et al., 1989; Bach et al., 1988; Shih, 1991).  
 
Figure 3.13 Crystal structures of human MAO-A (A) and human MAO-B (B) 
(Edmondson et al., 2007) 
The flavin binding domain is labelled in blue, red denotes the substrate binding domain 
and green denotes the membrane binding domain 
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The X-ray crystal structure of human MAO-B was first reported by Binda et al. 
(2002). The subsequent successes in the crystallization and structural elucidation 
of human MAO-A has provided insights into the structure and mechanism of 
both enzymes, allowing a detailed comparison of the active sites of both enzymes 
(De Colibus et al., 2005). Both proteins are predominantly located in the outer 
membrane of mitochondria, to which they are anchored by the C-terminal 
domain (Rebrin et al., 2001). 
 
MAO is present in most mammalian tissues but the two isoforms occur with 
different ratios in different organs of different species (Shih et al., 1999; Inoue et 
al., 1999). In humans, MAO-B predominates in the brain, heart, kidneys and 
spleen, while MAO-A is most abundant in the lungs and duodenum. The highest 
levels of MAO activity were observed in liver and the spleen displayed the lowest 
MAO activity among the tissues investigated (Rodríguez et al., 2001; Saura et al., 
1992; Saura et al., 1996a). There are regional differences in MAO activity in the 
brain. In the human brain, the basal ganglia and hypothalamus show the highest 
levels of activity, whereas low levels of activity are observed in the cerebellum and 
neocortex (Youdim et al., 2006). MAO-A is predominantly found in the locus 
coeruleus and the highest concentration of MAO-B is found in the raphne nuclei. 
(Jahng et al., 1997; Saura et al., 1996b; Willougby et al.,1988). While the human 
brain profoundly express MAO-B, rat brain has higher concentrations of MAO-
A.  
 
3.3.3. SUBSTRATES AND INHIBITORS 
 
The two isoforms are distinguished by their substrate preference and by different 
selective inhibitors. As shown in Table 3.1, MAO-A catalyses the oxidation of 
serotonin, epinephrine and norepinephrine preferentially, whereas MAO-B is 
active towards benzylamine and 2-phenethylamine. Dopamine, tryptamine and 
tyramine are oxidized by both isoforms in most species. Irrespective of tissue- 
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and species-based differences in substrate specificity, the two isoenzymes are best 
distinguished based on pharmacological criteria: MAO-A is selectively inhibited 
by low doses clorgyline, whereas MAO-B is blocked by low doses of L-deprenyl. 
Clorgyline as well as L-deprenyl form a covalent bond with the enzyme, 
indicating they are both irreversible inhibitors (Doster et al., 1989; Youdim et al., 
2006). L-deprenyl with the combination of L-DOPA has been widely used in the 
treatment of PD (Birkmayer, 1983).  
 
Table 3.1 Structures of MAO substrates/inhibitors 
 Substrates Inhibitors 
MAO-A 
 
serotonin                 norepinephrine 
 
Clorgyline 
MAO-B  
 
phenylethylamine           benzylamine 
 
L-deprenyl 
MAO-A 
and 
MAO-B 
 
 
dopamine                     tyramine  iproniazid         phenelzine 
 
Since the two isoforms of MAO share 70 % sequence identity, they show similar 
susceptibility to some inhibitors such as iproniazid, phenelzine and 
tranylcypromine (Riederer et al., 2004). Iproniazid, a drug used to treat 
tuberculosis (Ornstein, 1958), was found to produce mood elevation in patients 
and was subsequently discovered to be a MAO inhibitor useful in the treatment 
of depression. An undesirable and sometimes lethal side effect of MAO non-
selective inhibitors was the so-called “cheese reaction”. This refers to the 
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hypertensive crisis in individuals who were taking non selective irreversible MAO 
inhibitors together with food that contain large quantities tyramine. Tyramine is 
normally broken down by MAO in the digestive organs. However when MAO is 
inhibited, tyramine levels are elevated causing dangerous surges in blood pressure 
(Crane, 1956; Anderson et al., 1993).  
 
3.3.4. PHYSIOLOGICAL ROLE IN HEALTH AND DISEASE   
 
MAO regulates concentrations of important neurotransmitters in the brain, as 
well as protects the body by oxidizing xenobiotics and dietary amines in 
peripheral tissues which could act as false neurotransmitters. MAO is involved in 
a wide range of neurological diseases, psychiatric disorders and behavioural traits 
(Shih and Thompson, 1999; Kebir et al., 2009, Bortolato et al., 2008; Meyer et al., 
2006).  
 
MAO-A knock-out mice have elevated brain levels of serotonin, causing a 
distinct behavioural syndrome, including enhanced aggression. This observation 
in MAO-A knock-out mice is in accordance with the abnormal aggression 
reported in males from a Dutch family with a complete MAO-A deficiency due 
to a point deletion in the gene encoding MAO-A (Brunner et al., 1993). Recent 
studies showed that the low MAO-A genotype was associated with antisocial 
behaviour and high self-reported trait aggression with children exposure to 
maltreatment. Alia-Klein et al. (2008) reported that a 15 % reduction in brain 
MAO-A activity is associated with elevated trait aggression.    
 
PD is related with an elevated MAO-B activity in the substantia nigra, causing an 
increased oxidation of dopamine and subsequently higher levels of toxic H2O2. 
This leads to the degradation of dopamine-synthesizing neurons (Shih et al., 
1999).  
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MAO-B converts 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to the 
toxic metabolite 1-methyl-4-phenylpyridinium (MPP+) which selectively destroys 
nigrostriatal neurons. The neurodegeneration induced by MPTP is similar to the 
neuronal damage in PD and is prevented by the MAO-B inhibitor L-deprenyl. 
Thus, MAO-B is also involved in the pathogenesis of MPTP-induced 
Parkinsonism (Shih et al., 1999). 
 
Several lines of evidence suggest a link between cigarette smoke and MAO 
inhibition. Cigarette smokers have reduced levels of MAO-A and B (Fowler et al., 
1996; Berlin et al., 1995). Likewise, the activities of MAO-A and MAO-B are 
decreased in animals exposed to cigarette smoke. The mechanism underlying this 
reduced MAO activity has not yet been elucidated. Although nicotine is the main 
pharmacologically active compound in tobacco, it is not the cause of the reduced 
MAO activity. Characterization of the compounds in tobacco smoke that inhibit 
MAO activity is still in progress (Lewis et al., 2007). 
MAO may also be involved in alcoholism because lower levels of MAO-B activity 
are present in alcoholics. Furthermore, MAO-A mutations may underlie the 
susceptibility of individuals to alcoholism (shih et al., 1999). 
 
 
3.3.5. IMAGING OF MAO 
 
 
Given the pharmacological role of MAO and their importance in psychiatric and 
neurological diseases as well as in addiction, PET and SPECT are valuable tools 
for the non-invasive in vivo study of these enzymes. Studies in humans are of 
special value because species variability in MAO subtype distribution limits the 
relevance of animal measurements. Only a few compounds have been proposed 
as MAO-radiotracers. The first developed radiotracers for MAO were the 
selective irreversible MAO inhibitors clorgyline and L-deprenyl labelled with 11C 
Since both radiotracers are covalently bound to MAO-A or MAO-B, they 
visualize MAO by the suicide inactivator approach (MacGregor et al., 1985; 
Catecholamine system in the brain - Chapter 3 
 
 66 
Fowler et al., 1987; Arnett et al., 1987; Lammertsma et al., 1991). The drawback 
of [11C]clorgyline is that it displays an unexplained species difference. In contrast 
to results in humans clorgyline was not retained in baboon brain (Fowler et al., 
2001). A number of different classes of selective, reversible inhibitors of MAO-A 
and MAO-B have been proposed as MAO-radiotracers. Derivatives of the 
harmine alkaloids have been labelled with 11C and evaluated in the monkey brain 
for the assessment for MAO-A. [11C]harmine (Figure 3.14), [11C]methylharmine, 
[11C]harmaline and [11C]brofarmine were compared and only [11C]harmine and 
[11C]methylharmine had kinetic patterns in monkey brain that are compatible with 
a binding to MAO-A. [11C]harmine however is extremely metabolized in plasma 
making absolute quantification difficult (Bergstrom et al., 1997a and 1997b). 
[11C]befloxatone (Figure 3.14) shows good characteristics for imaging brain 
MAO-A but it is synthesized via a cyclization reaction with [11C]phosgene which 
is toxic and rather rare available (Dolle et al., 2003; Bottlaender et l., 2003).  
 
Figure 3.14 Structure of radiotracers for MAO-A and MAO-B 
 
Examples of MAO-B tracers are [11C]SL25.1188 (Bramoullé et al., 2007), [125I]2-
IBPO (Figure 3.14) (Hirata et al., 2002) and [12 3I]-Ro-43-0463 (Figure 3.14) (Beer 
et al., 1995). For review on MAO imaging see Fowler et al. (2002; 2005). 
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SCOPE AND AIMS 
 
SCOPE 
 
Psychiatric disorders are highly prevalent and have important personal, social and 
economic impacts. An estimated 26.2 % of Americans aged 18 and older suffer 
from a diagnosable mental disorder in a given year. The most common mental 
disorders in adults in the United States are major depression and anxiety 
disorders, both of which affect up to 10 % of the adult population each year 
(Voshol et al., 2003). Psychiatrists face many problems during the assessment and 
differential diagnosis for individuals with mental disorders. Simplify the diagnosis 
from a better understanding of the neurobiological basis of brain disorders would 
increase the diagnostic validity, reliability and precision (Barnhill, 2008). Medical 
imaging technique can map structural and functional changes in the brain and 
thus are unique tools for clinical researchers to elucidate and understand the 
pathophysiology of neuropsychiatric disorders.  
SPECT and PET are non-invasive imaging techniques in which radiotracers are 
used to study biochemical and physiological functions in the living brain. In vivo 
brain mapping with PET or SPECT can be of great importance in drug 
development as well as in the effective diagnosis, treatment and management of 
neurological and psychiatric disorders and substance abuse. Therefore, the 
development of new and more specific and selective radiotracers is of great 
importance in neuroimaging (Gee, 2003). 
 
Monoamine transporters and enzymes that cause degradation of the monoamines 
(for example MAO) are responsible for the homeostasis of neurotransmitter 
pools at the nerve endings and control the duration and intensity of 
neurotransmitter action. The transporters and enzymes are main actors of the 
Scope and Aims 
 82 
neuronal communication, being therefore involved in the physiology and diseases 
of the CNS. Distribution, density, and activity of these transporters and enzymes 
in the brain can be visualized by using specific radioligands and SPECT and PET 
imaging. Further studies of the molecular mechanisms of the various transmitter 
systems can improve our understanding of complex brain functions and can 
provide more insight into the causes and consequences of neurological and 
psychiatric disease interaction (Wong and Brasic, 2001; Guilloteau and Chalon, 
2005). 
 
A prerequisite of efficient drug treatment of CNS disorders is that sufficient 
amounts of the drug enter the brain. Active transport by P-gp has a major impact 
on drug resistance to psychotropic drugs, affects the pharmacokinetics of many 
drugs and can be inhibited by the administration of modulators or competitive 
substrates (Linnet and Ejsing, 2008). Moreover, changes or abnormalities in P-gp 
expression and function are involved in the etiology and pathogenesis of several 
neurological diseases (Rapposelli et al., 2009). PET and SPECT can be applied to 
evaluate the efficacy of candidate P-gp-modulators in vivo and to investigate the 
effect of P-gp on the brain uptake of new psychotropic drugs. In addition, 
visualization of P-gp in the normal brain and during various pathologic conditions 
could be of great value to elucidate the relationship between P-gp 
function/expression and neuronal and neuropsychiatric disorders.  
 
AIMS 
 
As discussed above, an accurate and selective PET or SPECT tracer provides a 
useful clinical tool for the diagnosis and treatment of psychiatric and neurological 
disorders. Therefore, the aim of this thesis was the development of novel 
radiotracers for two distinct brain elements being the monoamine system and the 
P-gp transporter. The first objective was the design of radiotracers for, NET 
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(Chapter 5), MAO (Chapter 6) and DAT (Chapter 7) which are all responsible 
for neurotransmitter inactivation in the monoamine system. By the discovery that 
the radiotracer designed in Chapter 7 is modulated by P-gp, the focus of this 
thesis was redirected towards imaging of the P-gp transporter (Chapter 8 and 9). 
 
Since no valuable SPECT radiotracer for visualization of the norepinephrine 
transporter is available, we will synthesize and subsequently label a reboxetine 
analogue with 123I. The radiotracer will be evaluated in vivo in a biodistribution 
study in mice to determine brain uptake (Chapter 5).  
The objective of Chapter 6 is to label a suitable reversible inhibitor for mapping 
MAO-A in vivo with PET. We will select appropriate candidates from the 
literature. The chosen molecules will be radiolabelled with 11C and evaluated in 
vivo in a biodistribution study in mice. The selectivity of the radiotracers for 
MAO-A will be assessed in a blocking study in mice and imaging studies in rats. 
Stability of the tracers will be determined in vivo in mice.  
In a following part, we will develop a SPECT tracer that is more selective towards 
DAT compared to the existing radiotracers for DAT imaging. FMIP was picked 
out a report by Boos et al. (2006) based on its nanomolar affinity for the 
dopamine transporter and good selectivity over the other monoamine 
transporters. FMIP and the precursor molecule for the 123I labelling will be 
synthesized. The potency of [123I]-FMIP to visualize the dopamine transporter in 
vivo will be investigated in a biodistribution study in mice, a blocking study in 
mice and a regional brain distribution study in rats. Stability of the tracer will be 
assessed in vitro as well as in vivo. These studies are described in Chapter 7. 
All reported radiotracers for the P-gp transporter are aimed to visualize P-gp 
function but not the expression of P-gp and they all have at least one limitation. 
Moreover, no iodinated SPECT tracer has been reported so far. In the last part of 
this thesis, we will label and evaluate a SPECT (Chapter 8) and a PET (Chapter 
9) radiotracer for imaging P-gp function or expression. 
Scope and Aims 
 84 
The potential SPECT tracer, [123I]-FMIP will be evaluated in vivo in a 
biodistribution study in wild-type and P-gp knock-out mice. The influence of 
CsA, a P-gp modulator, on the tissue distribution of the 123I labelled tracer in 
wild-type and P-gp knock-out mice will be determined. The metabolic profile will 
be evaluated in wild-type mice with and without CsA pretreatment as well as in P-
gp knock-out mice. [123I]-FMIP will be further evaluated in a µSPECT study. 
These studies are described in Chapter 8. 
Additionally, we will label an in vitro characterized substrate of the P-gp pump, 
with 11C and evaluate this tracer in vivo in a biodistribution study in wild-type and 
P-gp knock-out mice. The influence of CsA and the unlabeled molecule on the 
biodistribution profile of the radiotracer will be explored. The stability of the 
tracer will be investigated in vivo in wild-type mice with and without CsA 
pretreatment as well as in P-gp knock-out mice (Chapter 9). 
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Chapter 4 
 
Materials and Methods 
 
4.1. General 
 
All solvents and chemicals were purchased from Acros (Geel, Belgium) or Sigma-
Aldrich (Bornem, Belgium) unless otherwise mentioned and were used without 
further purification. HPLC solvents were purchased from Chemlab NV 
(Belgium). Cyclosporin A (Sandimmune®) was obtained from Novartis Pharma 
(250 mg/5 mL, Vilvoorde, Belgium). 
No carrier added (n.c.a.) [123I] sodium iodide (in 0.05 M NaOH) was purchased 
from GE Healthcare (Cygne, The Netherlands). 
Unless otherwise mentioned, the HPLC system used consisted of a Waters 515 
HPLC pump, a Waters 2487 UV detector (Waters, Milford, USA), a Ludlum 
model 2200 scaler ratemeter equipped with a Geiger Müller tube (Ludlum 
Measurements Inc., Sweetwater, USA), and a Shimadzu C-RSA chromatopac data 
analyser. Absorption units full scale were set at 0.0001 and wave length was set at 
254 nm, unless otherwise mentioned. The columns, mobile phases and flow rates 
used are indicated in the chapters.  
Radioactivity was counted with an automated gamma-ray spectrometer equipped 
with five 1x1 inch NaI(Tl) crystals (Cobra Autogamma, Packard Canberra) or  
with a Capintec dose calibrator (CRC-15R, Ramsey, USA). 
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4.2. Animals 
 
All animal studies were conducted following the principles of laboratory animal 
care and the Belgian Law on the protection of animals. The performed 
experiments were approved by the local Ethics Committee of Ghent University.  
All wild type mice (FVB and NMRI) and rats (Sprague-Dawley) were purchased 
from Bioservices or Charles River. The mdr1a (-/-) mice were obtained from 
Taconic (Hudson, USA).  
The mdr1a (-/-) mouse strain was developed in the laboratory of Dr. Alfred 
Schinkel from the Netherlands Cancer Institute. Taconic maintained the colony. 
The mdr1a (-/-) mouse strain was healthy and fertile and did not display clear 
physiological abnormalities or a decreased life span. Mice homozygous for a 
disruption of the mdr1a gene have completely lost all detectable P-gp in brain 
capillaries. Also P-gp density in gut epithelium is dramatically decreased. They 
displayed an increase in mdr1b RNA in liver and kidney, probably to compensate 
for the loss of excretory capacity caused by the mdr1a disruption (Schinkel et al., 
1994; 1997). Since mdr1a (-/-) mice were made on a FVB background, the wild 
type mice used as control group were FVB mice. 
 
4.3. Carbon-11 as radionuclide 
 
4.3.1. GENERAL 
 
Decay of 11C to the stable nuclei 11B occurs for the most part by positron 
emission (99.8 % by β+ emission, 0.19 % by electron capture). The maximum 
kinetic energy of the positron is 0.96 MeV and the mean kinetic energy is 0.385 
MeV. A theoretical specific activity of 3.4 105 GBq/µmol (9.2 103 Ci/µmol) can 
be obtained for 11C. The short half-live of 11C (20.4 min) demands a fast 
production of the precursor molecule as well as the radiotracer itself. The several 
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steps that must be completed to obtain a radiotracer labelled with 11C are 
depicted in Figure 4.1. 
 
Figure 4.1 Major steps in routine preparation of PET radiopharmaceuticals 
 
The development of a rapid labelling synthesis is often highly dependent on the 
availability of suitable labelled precursors. For 11C-chemistry, the most used 
primary precursors are 11CO2 and 11CH4. Regarding secondary precursors, 
[11C]methyl triflate and [11C]methyl iodide are widely used as alkylating agents for 
the introduction of 11C into organic molecules (Stöcklin and Pike, 1993). In this 
dissertation 11CH4 is used as primary precursor for the synthesis of 11CH3I, which 
is used as such. 
 
4.3.2. PRODUCTION OF 11CH4 
 
11CH4 was produced in a Cyclone 18 twin cyclotron (IBA, Ghent, Belgium) via 
the 14N(p,α)11C reaction induced by irradiation of N2 gas containing 5 % H2 with  
a proton beam (18 MeV, 14 µA) for 20 min. 
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4.3.3. SYNTHESIS OF 11CH3I 
 
11CH4 was transferred from the cyclotron target to a home made synthesis 
module housed in a hot cell. 11CH4 was trapped on a loop filled with Porapak N 
(divinylbenzene/vinyl pyrolidone polymer) that was cooled in liquid argon. Once 
all 11CH4 was released from the target, the loop was flushed with helium to 
remove N2/H2 and allowed to warm to room temperature. The 11CH4 was swept 
off the loop with a helium flow and mixed with I2 vapours at 50°C, after which 
the mixture was passed through an oven heated to 600°C to yield 11CH3I. After 
the reaction, the remaining iodine and produced hydrogen iodide were trapped in 
ascarite, while 11CH3I was collected on a Porapak N trap at room temperature. 
The unreacted 11CH4 was further circulated until no more 11CH3I was produced. 
11CH3I was released from the Porapak N trap by heating the trap to 120°C.  
 
4.4. Iodine-123 as radionuclide 
 
4.4.1. GENERAL 
 
Iodine-123 decays by electron capture; mainly (83 %) emitting γ-rays with an 
energy of 159 keV, which makes it a very suitable isotope for diagnostic SPECT 
imaging. 123I has a theoretical maximum specific activity of 8.769 TBq/µmol (237 
Ci/µmol). 
 
4.4.2. NUCLEOPHILIC IODINATION 
 
Several distinct mechanisms are possible for nucleophilic iodination depending 
on the substrate, the leaving group and the reaction conditions. The iodide anion 
serves as the nucleophile. One possible method is the copper-assisted halogen 
exchange. Given the relatively low reactivity of nucleophilic aromatic halogen 
substitution, a copper salt or metal is used as catalyst. For this reaction type, a 
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wide variety of reaction conditions can be employed. For a detailed review of 
possible reaction methods and mechanisms see Coenen et al. (2006). 
 
4.4.3. ELECTROPHILIC IODINATION 
 
Electrophilic iodination is a process in which formally a positively charged iodine 
(I+) attacks a system with high electron density such as an aromatic ring. As a 
result a covalent carbon-iodine bound is formed with loss of a positively charged 
leaving group. The radioiodide can be oxidized in situ using chloramine T (Figure 
4.2). Under certain conditions, chloramine T can release hypochlorite, which 
oxidises iodide under formation of an iodonium ion. The reaction is terminated 
by adding the antioxidant sodium metabisulfite. 
S
N
-
Cl
H3C
O
O Na
+
 
Figure 4.2 Chloramine T 
 
4.5. Experimental procedures 
 
4.5.1. SPECIFIC ACTIVITY 
 
The specific activity of a tracer can be defined as the amount of radioactivity 
present per mole of product. Specific activity is usually expressed as Ci/µmol or 
GBq/µmol.  
Tracer amount was determined by HPLC. Tracer activity was determined by 
Capintec readings. The mass of tracer was calculated by the use of a calibration 
curve of reference compound. In the case no detectable carrier UV-signal could 
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be obtained, the detection limit for the compound was used for the calculation of 
the minimum specific activity.  
 
4.5.2. LOG D7.4 
 
The log D7.4 value gives an indication about the BBB permeability. The log 
partition coefficient was measured according to the shake flask method (Wilson 
et al., 2001; Waterhouse, 2003). An aliquot (10 – 20 µL) of the tracer (185 - 370 
kBq (5 - 10 µCi) for 123I tracers and 1.9 - 3.7 MBq (50 - 100 µCi) for 11C tracers) 
was added to a test tube containing 3 mL n-octanol and 3 mL phosphate buffered 
saline (PBS) (0.01 M, pH 7.4). The mixture was vigorously shaken by hand for 1 
min, vortexed for 2 min and centrifuged for 3 min at 3000 g. 0.5 mL of both 
phases was taken and placed in separate vials, taking care to avoid cross 
contamination between the phases. The remaining aqueous phase was discarded 
and 2.5 mL fresh PBS (0.01 M, pH 7.4) was added to the test tube. The 
procedure was repeated three more times to give four vials of each phase for 
measuring radioactivity. The partition coefficient was calculated as [radioactivity 
in n-octanol (cpm)/radioactivity in phosphate buffer (cpm)]. 
 
4.5.3. METABOLITE STUDIES 
 
Activity was injected through a tail vein and the mice were sacrificed at different 
time points post injection (p.i.). Blood and whole brain were isolated. Blood was 
collected into a vacutest tube containing 3.6 mg K3EDTA and was centrifuged at 
4000 g for 6 min to separate plasma. 200 µL plasma was mixed with 800 µL 
CH3CN whereas the whole brain was mixed with 1.5 mL CH3CN. Both samples 
were vortexed for 30 sec and centrifuged at 3000 g for 3 min. Pellet and 
supernatant were separated and counted for radioactivity. An aliquot (500 µL) of 
the supernatant obtained from the plasma and brain homogenates was subjected 
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to HPLC analysis. The HPLC eluate was collected in 0.5 min fractions and their 
radioactivity was measured. 
To determine the recovery as well as the stability of the radiotracer during 
workup and analysis, control experiments (n=3) were done using plasma and 
brain spiked with authentic radiotracer (2 MBq (54 µCi) or 37 kBq (1 µCi) for 11C 
and 123I respectively). Sample workup was done as described above. Results are 
expressed as percentages of the total activity ± standard deviation (SD). 
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Chapter 5 
 
 Synthesis and preliminary in vivo evaluation of 
[123I]-(S,S)-IPBM for mapping NET 
 
5.1. Abstract 
 
Aim: Abnormalities in brain NET have been implicated in the pathophysiology of 
various neuropsychiatric diseases and neurodegenerative disorders. A selective 
radioligand for mapping NET could further probe the link between NET and 
these disorders. This study reports the development and preliminary evaluation of 
(S,S)-2-[α-(2-[123I]-iodophenoxy)benzyl]morpholine ([123I]-(S,S)-IPBM). 
Methods: Precursor and reference compounds were synthesized by a 
stereoselective nine-step synthetic procedure. Enantiomeric purity was 
investigated using NMR spectroscopy. [123I]-(S,S)-IPBM was obtained by 
electrophilic iododestannylation followed by reduction. A biodistribution study 
was performed in male NMRI mice. 
Results: The precursor was prepared in an overall chemical yield of 8 % with an 
enantiomeric excess of > 95 %. Radiosynthesis afforded [123I]-(S,S)-IPBM with a 
radiochemical purity of > 98 % and a specific activity of > 148 GBq/µmol. 
Biodistribution studies demonstrated high brain uptake (4.62 ± 0.66  % ID/g at 1 
min p.i.) followed by efficient wash-out (0.55 ± 0.17  % ID/g at 180 min p.i.). 
Conclusion: [123I]-(S,S)-IPBM displayed an excellent brain-blood distribution. Since 
[123I]-(S,S)-IPBM was reported by others at the moment we performed our 
biodistribution studies, we did not conduct any further evaluation. Regarding 
their results, the choice to develop [123I]-(S,S)-IPBM as a radiotracer for NET was 
an excellent suggestion. 
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5.2. Introduction 
 
The norepinephrine transporter (NET), which is located at the pre-synaptic 
terminal of noradrenergic neurons, belongs to the superfamily of the Na+/Cl- 
dependent neurotransmitter transporters (Masson et al., 1999). The principal 
physiological role of NET is to regulate the noradrenergic neurotransmission by 
re-uptake of norepinephrine into the presynaptic neuron. Abnormalities in brain 
NET have been implicated in the pathophysiology of various neuropsychiatric 
diseases and neurodegenerative disorders including mood disorders (Ressler and 
Nemeroff, 1999), ADHD (Biederman and Spencer, 1999), depression (Klimek et 
al., 1997) and Alzheimer’s disease (Tejani-Butt el al., 1993). A selective 
radioligand able to image and quantify NET density with PET or SPECT would 
provide more insight in the role of noradrenergic mechanisms in these disorders. 
At the start of this thesis, no suitable radioligand for SPECT imaging had been 
designed so far, directing our focus to the development of a selective 
radioiodinated NET radioligand. Due to the low density and widespread 
distribution of NET-binding sites in the brain, the design of a suitable NET 
radioligand is very challenging.  
Although nisoxetine is selective for NET in vitro, [11C]nisoxetine exhibits a very 
high level of non-specific binding in vivo (Haka et al., 1989). An iodinated 
analogue of nisoxetine was developed and it displayed superior in vitro properties 
compared to nisoxetine. Just as [11C]nisoxetine, (R)-[125I]2-iodonisoxetine 
displayed high non-specific binding in vivo resulting in a high background uptake 
(Kiyono et al., 2004; Kung et al., 2004). Reboxetine is a more potent and selective 
inhibitor of NET and is on the market as an antidepressant (Edronax®). The 
(S,S) enantiomer of reboxetine is approximately 24 times more potent than the 
(R,R) enantiomer (Benedetti et al., 1995). Replacement of the methoxy moiety of 
nisoxetine by iodine resulted in enhanced in vitro properties. Since reboxetine 
structurally resembles nisoxetine, it was suggested that the same effect would be 
observed when substituting the ethoxy group of reboxetine by iodine. This idea 
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prompted us to the development and preliminary evaluation of [123I]-(S,S)-2-[α-
(2-iodophenoxy)benzyl]morpholine ([123I]-(S,S)-IPBM) (Figure 5.1). 
 
 
Figure 5.1 Chemical structures of Reboxetine and Nisoxetine analogues 
 
5.3. Materials & Methods 
 
5.3.1. ORGANIC SYNTHESIS 
 
1H NMR spectra were recorded on a Varian 300 MHz FT-NMR spectrometer 
(Laboratory for Medicinal chemistry, Ghent University, Belgium). Chemical shifts 
were recorded in ppm (δ) relative to an internal tetramethylsilane (TMS) standard 
in either deuterated DMSO or CDCl3. J (Hz) assignments of 1H resonance 
coupling were done. Mass spectrometry was performed on a Waters Micromass 
ZMD mass spectrometer with an electronspray ionization (ESI) probe. Samples 
were dissolved in MeOH – H2O – HCOOH (50 – 50 – 0.1) and recorded in the 
positive (MH+) mode. 
(2S,3S)-phenylglycidol was purchased from Speedchemical Co. LTD (Shangai, 
China). All other chemicals were obtained from Acros (Geel, Belgium) or Sigma-
Aldrich (Bornem, Belgium). Organic reactions were performed under nitrogen 
atmosphere using anhydrous solvents and were monitored by normal phase thin 
layer chromatography (TLC) by UV detection at 254 nm (TLC, Polygram SIL 
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G/UV254, 200 µm, Machery-Nagel, Germany). Purification of organic 
compounds was achieved with column chromatography on silica gel (70-230 
mesh, 60Å, Sigma-Aldrich, Belgium). Solvent systems are indicated in the text. 
For mixed solvent systems, ratios are given with respect to volumes 
 
5.3.1.1.       Cold reference compound synthesis 
 
(S,S)-IPBM or (2S,3S)-9a was synthesized based on the synthetic procedure 
outlined by Melloni et al. (1985). Since (R,R) and (S,S) enantiomers were 
synthesized in the same manner, only the preparation of the (S,S) enantiomers is 
described  
 
(2S,3R)/(2R,3S)-1,2-dihydroxy-3-(2-bromophenoxy)-3-phenylpropane (1a) 
 
A mixture of 2-iodophenol (6.6 g, 30 mmol), methyltributylammonium chloride 
(0.6 mL) and 0.05 M NaOH (30 mL) was stirred at 70°C for 2 h. (2R,3R)-
phenylglycidol (1.5 g, 10 mmol, dissolved in 50 mL H2O) was added drop-wise 
and the resulting mixture was heated for another 3 h. The reaction mixture was 
cooled to room temperature, added to ice-cold NaOH (1 M, 30 mL) and 
extracted with CH2Cl2 (3 x 50 mL). The organic layer was washed with 1 M 
NaOH (100 mL), water (100 mL) and brine (100 mL) and dried over Na2SO4. 
The solvent was removed under reduced pressure to give viscous oil. The crude 
product was purified by column chromatography (eluent: ethyl acetate/hexane 
30/70) to yield 9.5 mmol of (2R,3S)-1a (95 %). 
1H NMR (DMSO): δ 3.70-3.55 (m, 2H, R-CH2-OH), 3.8 (m, 1H, R2-CH-OH), 
4.65 (t, 1H, J = 5.6, R-CH2-OH), 4.95 (d, 1H, J = 5.6, R2-CH-OH), 5.32 (d, 1H, J 
= 6.2, Ar-O-CH-R), 7.74-6.58 (m, 9H, Ar-H). ESI-MS: calcd MW for C15H15O3I: 
370, found 393 [M + Na+]. 
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(2S,3R)/(2R,3S)-2-hydroxy-3-(2-iodophenoxy)-1-(t-butyldimethylsilyloxy)-
3-phenylpropane (2a) 
 
tert-Butyldimethylsilyl chloride (1.6 g, 10.6 mmol) dissolved in 5 mL DMF was 
added drop-wise to an ice-cold solution of (2R,3S)-1a (3.5 g, 9.5 mmol) and 
imidazole (1.6 g, 23.8 mmol) in DMF (8 mL). After stirring for 80 min at 0°C, the 
reaction mixture was added to a separatory funnel containing 100 mL water and 
100 mL ethyl acetate. After extraction, the organic layer was dried over Na2SO4 
and evaporated to give a crude oil, which was used without further purification. 
 
(2S,3R)/(2R,3S)-3-(2-iodophenoxy)-2-mesyloxy-1-(t-butyldimethylsilyloxy) 
-3-phenylpropane (3a) 
 
A mixture of crude (2R,3S)-2a (9.5 mmol), Et3N (1.95 mL, 14 mmol) and ethyl 
acetate (15 mL) was stirred at 0°C. Methanesulfonyl chloride (0.882 mL, 11.4 
mmol) was dissolved in ethyl acetate (5 mL) and added to the reaction mixture 
over 30 min. Afterwards, the mixture was stirred for an additional 2 h at 0°C. The 
organic layer was washed with water, dried over Na2SO4 and evaporated. The 
resulting crude oil, (2R,3S)-3a, was used without further purification.  
 
(2S,3R)/(2R,3S)-3-(2-iodophenoxy)-2-mesyloxy-3-phenyl-1-propanol (4a) 
 
A solution of crude (2R,3S)-3a (9.5 mmol), THF (30 mL) and 1 M 
tetrabutylammonium fluoride solution in THF (15 mL) was stirred for 30 min at 
room temperature. The reaction was quenched with water (5 mL). The layers 
were separated and the aqueous layer was extracted with CH2Cl2. The combined 
organic extract was washed with brine (2 x 100 mL), dried over Na2SO4, and the 
solvent removed under reduced pressure to afford a crude residue. The residue 
was purified with column chromatography (eluent: 30 % ethyl acetate/hexane) to 
yield 8.7 mmol (92 % over the three steps) (2R,3S)-4a. 
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1H NMR (CDCl3): δ 2.7 (s, 3H, S-CH3), 4.02 (dd, 1H, J = 3.0, 12.6, R-CH2-OH), 
4.23 (dd, 1H, J = 5.4, 12.6, R-CH2-OH), 4.88 (m, 1H, R2-CH-OMs), 5.5 (d, 1H, J 
= 5.7, Ar-O-CH-R), 7.7 - 6.5 (m, 9H, Ar-H). ESI-MS: calcd MW for C16H17O5SI: 
448, found 449 [M + H+]. 
 
(2R,3R)/(2S,3S)-1,2-epoxy-3-(2-iodophenoxy)-3-phenylpropane (5a) 
 
A solution of the mesylate (2R,3S)-4a (3.9 g, 8.7 mmol), toluene (20 mL), 4 M 
NaOH (20 mL) and methyltributylammonium chloride (2.45 mL, 10 µmol) was 
stirred vigorously for 2 h at room temperature. The solution was diluted with 
water (50 mL) and the product was extracted into CH2Cl2 (3 x 50 mL). The 
organic layer was dried over Na2SO4, evaporated under reduced pressure 
followed by purification of the product using column chromatography to afford 
(2S,3S)-5a (5 mmol, 57 %).  
1H NMR (CDCl3): δ 2.81 (m, 2H, R-O-CH2-CH-R), 3.48 (m, 1H, Ar-O-CH-CH-
R), 4.95 (d, 1H, J = 6.0, Ar-O-CH-R), 7.8-6.6 (m, 9H, Ar-H). ESI-MS: calcd MW 
for C15H13O2I: 352, found 353 [M + H+]. 
 
(2R,3R)/(2S,3S)-1-amino-2-hydroxy-3-(2-iodophenoxy)-3-phenylpropane 
(6a) 
 
A solution of (2S,3S)-5a (1.76 g, 5 mmol) in MeOH (35 mL) and 30 % NH4OH 
(20 mL) was stirred overnight. The solution was diluted with saturated NaHCO3 
and extracted with CH2Cl2. After filtering over Na2SO4, CH2Cl2 was removed 
under reduced pressure. Purification with column chromatography (5:95 
MeOH:CH2Cl2) yielded (2S,3S)-6a (3.6 mmol, 72 %).  
1H NMR (DMSO): δ 2.38 (dd, 1H, J = 8.1, 12.6, R- CH2-NH2), 2.58 (dd, 1H, J = 
3.9, 12.9, R-CH2-NH2), 3.88 (m, 1H, R-CH-OH), 5.42 (d, 1H, J = 5.7, Ar-O-CH-
R), 7.8 - 6.61 (m, 9H, Ar-H). ESI-MS: calcd MW for C15H16NO2I: 369, found 370 
[M + H+]. 
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(2R,3R)/(2S,3S)-1-chloroacetylamino-2-hydroxy-3-(2-iodophenoxy)-3-
phenylpropane (7a) 
 
The amine (2S,3S)-6a (1.3 g, 3.6 mmol) was dissolved in CH2Cl2 (16 mL) and 
Et3N (0.626 mL, 4.5 mmol). The solution was kept at -10°C and chloroacetyl 
chloride (0.318 mL, 4 mmol) dissolved in CH2Cl2 (7 mL) was added slowly 
followed by stirring for 1 h. The solution was quenched with water and 
subsequently extracted with ethyl acetate. The combined ethyl acetate portion was 
dried over Na2SO4, and the solvent was removed under reduced pressure to 
afford a crude oil. The crude product was purified by column chromatography 
(eluent 35:65 ethyl acetate:hexane) to give 2.9 mmol (81 %) of (2S,3S)-7a.  
1H NMR (DMSO): δ 2.9 - 3 (ddd, 1H, J = 5.4, 8.4, 13.2, R-NH-CH2-R), 3.25 – 
3.45 (ddd, 1H, J = 3.9, 6.0, 13.5, R-NH-CH2-R), 3.95 (m, 1H, R-CH-OH), 4.03 (s, 
2H, R-CH2-Cl), 5.42 (d, 1H, J = 5.1, Ar-O-CH-R), 7.72-6.60 (m, 9H, Ar-H), 8.12 
(t, 1H, R-NH-R). ESI-MS: calcd MW for C17H17NO3ClI: 445, found 468 [M + 
Na+]. 
 
(2R,3R)/(2S,3S)-2-[α-(2-iodophenoxy)benzyl]morpholine-5-one (8a) 
 
A solution of (2S,3S)-7a (1.3 g, 2.9 mmol) in t-butanol (4 mL) and CH2Cl2 (9 mL) 
was added drop-wise over 1 h to a solution of potassium t-butoxide (0.52 g, 4.6 
mmol) in t-butanol (12 mL). The mixture was stirred for one more hour, 
neutralized with 10 % HCl and extracted with CH2Cl2. The organic layer was then 
dried over Na2SO4, and evaporated. The crude product was purified by column 
chromatography (eluent 50:50 ethyl acetate:hexane) to yield (2S,3S)-8a (2.3 mmol, 
79 %).  
1H NMR (DMSO): δ 2.78 (dt, 1H, J = 3.9, 12.0, R-NH-CH2-R), 3.25 (t, 1H, J = 
11.7, R-NH-CH2-R), 3.97 (d, 1H, J = 12.3, R-O-CH2-R), 4.05 (d, 1H, J = 12.6, R-
O-CH2-R), 4.15 (ddd, 1H, J = 3.3, 6.0, 10.5, R-CH-CH2-NH-R), 5.61 (d, 1H, J = 
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5.1, Ar-O-CH-R), 7.72 - 6.56 (m, 9H, Ar-H), 7.92 (d, 1H, R-NH-R). ESI-MS: 
calcd MW for C17H16NO3I: 409, found 448 [M + K+]. 
 
(2R,3R)/(2S,3S)-2-[α-(2-iodophenoxy)benzyl]morpholine (9a) 
 
A mixture of (2S,3S)-8a (0.94 g, 2.3 mmol) and BH3 (12 mL of a 1 M solution in 
THF) in THF (30 mL) was stirred for 2 h at room temperature. The mixture was 
added to acetic acid (50 % in water, 20 mL) and THF was evaporated. Potassium 
carbonate was added until a pH of 9 was reached and the resulting solution was 
extracted with CH2Cl2. The combined CH2Cl2 fractions were dried over Na2SO4, 
concentrated under reduced pressure and then purified by column 
chromatography (eluent 15:85 ethyl acetate:hexane) to yield (2S,3S)-9a, also 
termed (S,S)-IPBM (0.7 mmol, 30 %) as a colourless oil.  
1H NMR (CDCl3): δ 2.45 (m, 1H, R-O-CH2-CH2-R), 2.61 (m, 1H, R-O-CH2-
CH2-R), 3.04 (m, 2H, R-O-CH2-R), 3.58 (m, 1H, R-CH-CH2-NH-R), 3.90 (ddd, 
1H, J = 2.1, 5.1, 11.4, R-CH-CH2-NH-R), 4.00 (dd, 1H, J = 3.6, 5.4, R-CH-CH2-
NH-R), 5.17 (d, 1H, J = 5.1, Ar-O-CH-R), 7.43-6.59 (m, 9H, Ar-H). ESI-MS: 
calcd MW for C17H18NO2I: 395, found 396 [M + H+]. 
 
5.3.1.2. Precursor synthesis 
 
(2S,3S)-9b was synthesized in the same manner as (2S,3S)-9a, using 2-
bromophenol as a starting material instead of 2-iodophenol. 
 
(2S,3R)/(2R,3S)-1,2-dihydroxy-3-(2-bromophenoxy)-3-phenyl-propane (1b) 
 
A mixture of 2-bromophenol (3.5 mL, 30 mmol), methyltributylammonium 
chloride (0.6 mL) and 0.05 M NaOH (30 mL) was stirred at 70°C for 2 h. 
(2R,3R)-phenylglycidol (1.5 g, 10 mmol dissolved in 50 mL H2O) was added 
drop-wise and the resulting mixture was heated for another 3 h. The reaction 
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mixture was cooled to room temperature, added to ice-cold NaOH (1 M, 30 mL) 
and extracted with CH2Cl2 (3 x 50 mL). The organic layer was washed with 1 M 
NaOH (100 mL), water (100 mL) and brine (100 mL), dried over Na2SO4, and 
the solvent was removed under reduced pressure to afford a viscous oil. The 
crude product was purified by column chromatography (eluent: ethyl 
acetate/hexane 30/70) to give 9 mmol of (2R,3S)-1b (90 %). 
1H NMR (DMSO): δ 3.70-3.55 (m, 2H, R-CH2-OH), 3.78 (m, 1H, R2-CH-OH), 
4.65 (t, 1H, J = 5.6, R-CH2-OH), 4.94 (d, 1H, J = 5.6, R2-CH-OH), 5.32 (d, 1H, J 
= 6.2, Ar-O-CH-R), 7.56-6.8 (m, 9H, Ar-H). ESI-MS: calcd MW for C15H15O3Br: 
323, found 346 [M + Na+]. 
 
(2S,3R)/(2R,3S)-2-hydroxy-3-(2-bromophenoxy)-1-(t-butyldimethyl-
silyloxy)-3-phenylpropane (2b) 
 
tert-Butyldimethylsilyl chloride (1.6 g, 10.6 mmol) dissolved in 5 mL DMF, was 
added drop-wise to an ice-cold solution of (2R,3S)-1b (2.9 g, 9 mmol) and 
imidazole (1.5 g, 22.1 mmol) in DMF (8 mL). After stirring for 80 min at 0°C, the 
reaction mixture was added to a separatory funnel containing 100 mL water and 
100 mL ethyl acetate. After extraction, the organic layer was dried over Na2SO4 
and evaporated to afford a crude oil, which was used without further purification. 
 
(2S,3R)/(2R,3S)-3-(2-bromophenoxy)-2-mesyloxy-1-(t-butyldimethyl-
silyloxy)-3-phenylpropane (3b) 
 
A mixture of crude (2R,3S)-2b (9 mmol), Et3N (1.9 mL, 13.7 mmol) and ethyl 
acetate (11 mL) was stirred at 0°C. Methanesulfonyl chloride (0.831 mL, 10.7 
mmol) was dissolved in ethyl acetate (5 mL) and added to the reaction mixture 
over 30 min. Afterwards, the mixture was stirred for an additional 2 h at 0°C. The 
organic layer was washed with water, dried over Na2SO4 and evaporated. The 
resulting crude oil, (2R,3S)-3b, was used without further purification.  
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(2S,3R)/(2R,3S)-3-(2-bromophenoxy)-2-mesyloxy-3-phenyl-1-propanol 
(4b) 
 
A solution of crude (2R,3S)-3b (9 mmol), THF (27 mL) and 1 M 
tetrabutylammonium fluoride solution in THF (14.7 mL) was stirred for 30 min 
at room temperature. The reaction was quenched with water (5 mL). The layers 
were separated and the aqueous layer was extracted with CH2Cl2. The combined 
organic extract was washed with brine (2 x 100 mL), dried over Na2SO4, and the 
solvent was removed under reduced pressure to offer a crude residue. The 
residue was purified with column chromatography (eluent: 30 % ethyl 
acetate/hexane) to yield 8 mmol (89 % over the three steps) (2R,3S)-4b. 
1H NMR (CDCl3): δ 2.65 (s, 3H, S-CH3), 4.02 (dd, 1H, J = 3.0, 12.6, R-CH2-OH), 
4.22 (dd, 1H, J = 5.4, 12.6, R-CH2-OH), 4.88  (m, 1H, R2-CH-OMs), 5.50 (d, 1H, 
J = 5.7, Ar-O-CH-R), 7.46 - 6.62 (m, 9H, Ar-H). ESI-MS: calcd MW for 
C16H17O5SBr: 401, found 402 [M + H+]. 
 
(2R,3R)/(2S,3S)-1,2-epoxy-3-(2-bromophenoxy)-3-phenylpropane (5b) 
 
A solution of the mesylate (2R,3S)-4b (3.2 g, 8 mmol), toluene (18.6 mL), 4 M 
NaOH (18.6 mL) and methyltributylammonium chloride (2.26 mL, 9 µmol) was 
stirred vigorously for 2 h at room temperature. The solution was diluted with 
water (50 mL) and the product was extracted into CH2Cl2 (3 x 50 mL). The 
organic layer was dried over Na2SO4, evaporated under reduced pressure 
followed by purification of the product using column chromatography to afford 
(2S,3S)-5b (5.5 mmol, 69 %).  
1H NMR (CDCl3): δ 2.81 (m, 2H, R-O-CH2-CH-R), 3.48 (m, 1H, Ar-O-CH-CH-
R), 4.95 (d, 1H, J = 6, Ar-O-CH-R), 7.46 - 6.62 (m, 9H, Ar-H). ESI-MS: calcd 
MW for C15H13O2Br: 305, found 328 [M + Na+]. 
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(2R,3R)/(2S,3S)-1-amino-2-hydroxy-3-(2-bromophenoxy)-3-phenylpropane 
(6b) 
 
A solution of (2S,3S)-5b (1.7 g, 5.5 mmol) in MeOH (35 mL) and 30 % NH4OH 
(24 mL) was stirred overnight. The solution was diluted with saturated NaHCO3 
and extracted with CH2Cl2. After filtering over Na2SO4, CH2Cl2 was removed 
under reduced pressure. Purification with column chromatography (5:95 
MeOH:CH2Cl2) yielded (2S,3S)-6b (3.7 mmol, 67 %).  
1H NMR (DMSO): δ 2.31 (dd, 1H, J = 8.1, 12.6, R- CH2-NH2), 2.61 (dd, 1H, J = 
3.9, 12.9, R-CH2-NH2), 3.79 (m, 1H, R-CH-OH), 5.05 (bs, 2H, NH2), 5.42 (d, 1H, 
J = 5.7, Ar-O-CH-R), 7.56 - 6.75 (m, 9H, Ar-H). ESI-MS: calcd MW for 
C15H16O2NBr: 322, found 323 [M + H+]. 
 
(2R,3R)/(2S,3S)-1-chloroacetylamino-2-hydroxy-3-(2-bromophenoxy)-3-
phenylpropane (7b) 
 
The amine (2S,3S)-6b (1.2 g, 3.7 mmol) was dissolved in CH2Cl2 (16 mL) and 
Et3N (0.626 mL, 4.5 mmol). The solution was kept at – 10°C and chloroacetyl 
chloride (0.318 mL, 4 mmol) dissolved in CH2Cl2 (7 mL) was added slowly 
followed by stirring for 1 h. The solution was quenched with water and 
subsequently extracted with ethyl acetate. The combined ethyl acetate portion was 
dried over Na2SO4, and the solvent was removed under reduced pressure to 
afford a crude oil. The crude product was purified by column chromatography 
(eluent 35:65 ethyl acetate:hexane) to give 2.7 mmol (73 %) of (2S,3S)-7b.  
1H NMR (DMSO): δ 2.87 – 2.94 (ddd, 1H, J = 5.4, 8.4, 13.2, R-NH-CH2-R), 3.25 
– 3.45 (ddd, 1H, J = 3.9, 6.0, 13.5, R-NH-CH2-R), 3.95 (m, 1H, R-CH-OH), 4.03 
(s, 2H, R-CH2-Cl), 5.42 (d, 1H, J = 5.1, Ar-O-CH-R), 7.56 - 6.74 (m, 9H, Ar-H), 
8.12 (t, 1H, R-NH-R). ESI-MS: calcd MW for C17H17O3NClBr: 398, found 421 
[M + Na+]. 
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(2R,3R)/(2S,3S)-2-[α-(2-bromophenoxy)benzyl]morpholine-5-one (8b) 
 
A solution of (2S,3S)-7b (1.1 g, 2.7 mmol) in t-butanol (3.5 mL) and CH2Cl2 (8.6 
mL) was added drop-wise over 1 h to a solution of potassium t-butoxide (482 mg, 
4.3 mmol) in t-butanol (10.8 mL). The mixture was then stirred for one more 
hour, neutralized with 10 % HCl and extracted with CH2Cl2. The organic layer 
was then dried over Na2SO4, and evaporated. The crude product was purified by 
column chromatography (eluent 50:50 ethyl acetate:hexane) to yield compound 
(2S,3S)-8b (2.1 mmol, 78 %).  
1H NMR (DMSO): δ 2.78 (dt, 1H, J = 3.9, 12.3, R-NH-CH2-R), 3.25 (t, 1H, J = 
11.7, R-NH-CH2-R), 3.97 (d, 1H, J = 12.3, R-O-CH2-R), 4.05 (d, 1H, J = 12.6, R-
O-CH2-R), 4.15 (ddd, 1H, J = 3.3, 6.0, 10.5, R-CH-CH2-NH-R), 5.61 (d, 1H, J = 
5.1, Ar-O-CH-R), 7.54 - 6.74 (m, 9H, Ar-H), 7.92 (d, 1H, R-NH-R). ESI-MS: 
calcd MW for C17H16O3NBr: 362, found 401 [M + K+]. 
 
(2R,3R)/(2S,3S)-2-[α-(2-bromophenoxy)benzyl]morpholine (9b) 
 
A mixture of (2S,3S)-8b (0.76 g, 2.1 mmol) and 1 M BH3 solution in THF (11 
mL) in THF (30 mL) was stirred for 2 h at room temperature. The mixture was 
added to acetic acid (50 % in water, 20 mL) and THF was evaporated. Potassium 
carbonate was added until pH of 9 was reached and the resulting solution was 
extracted with CH2Cl2. The combined CH2Cl2 fractions were dried over Na2SO4, 
concentrated under reduced pressure and then purified by column 
chromatography (eluent 15:85 ethyl acetate:hexane) to give (2S,3S)-9b (0.8 mmol, 
38 %) as a colourless oil.  
1H NMR (CDCl3): δ 2.52 (m, 1H, R-O-CH2-CH2-R), 2.68 (m, 1H, R-O-CH2-
CH2-R), 3.14 (m, 2H, R-O-CH2-R), 3.68 (td, 1H, J = 2.1, 12.6, R-CH-CH2-NH-
R), 3.90 (ddd, 1H, J = 2.1, 5.1, 11.4, R-CH-CH2-NH-R), 4.08 (dd, 1H, J = 3.6, 
5.4, R-CH-CH2-NH-R), 5.25 (d, 1H, J = 5.1, Ar-O-CH-R), 7.52 - 6.68 (m, 9H, 
Ar-H). ESI-MS: calcd MW for C17H18O2NBr: 348, found 349 [M + H+]. 
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(2R,3R)/(2S,3S)-2-[α-(2-trimethylstannanephenoxy)benzyl]morpholine-5-
one (10) 
 
0.06 mmol (2S,3S)-8b (23 mg), hexamethyldistannane (37 µL, 0.18 mmol), and a 
catalytic amount of tetrakis(triphenylphosphine)palladium were dissolved in 5 mL 
toluene. The mixture was shielded from light and refluxed overnight. The 
reaction mixture was filtered and the solvent was evaporated under reduced 
pressure. Purification of the crude product with preparative TLC (eluent 90:10 
ethyl acetate:hexane) afforded (2S,3S)-10 (0.021 mmol, 35 %) as a yellow oil. 
1H NMR (DMSO): δ 0.27 (s, 9H, 3*Sn-CH3) 2.78 (m, 1H, R-NH-CH2-R), 3.25 
(m, 1H, R-NH-CH2-R), 4.18-3.98 (m, 3H, R-CH-O-CH2-R), 5.61 (d, 1H, J = 5.4, 
Ar-O-CH-R), 7.49 - 6.85 (m, 9H, Ar-H). ESI-MS: calcd MW for C20H25O3NSn: 
445, found 446 [M + H+]. 
 
5.3.2. ENANTIOMERIC PURITY 
 
The enantiomeric purity of the precursor was evaluated using a Bruker DRX500 
300 Mhz NMR spectrometer (Department of Organic Chemistry, Ghent 
University, Belgium). Chemical shifts were recorded in ppm (δ) relative to an 
internal TMS standard in CDCl3. To control enantiomeric purity, 1 equivalent 
chiral shift reagents, europium tris[3-(heptafluoropropylhydroxymethylene)-(-)-
camphorate] (Eu(hfc)3) was added to the NMR sample.  
 
5.3.3. RADIOCHEMISTRY 
 
[123I]-(S,S)-IPBM was obtained in two steps. First, an electrophilic 
iododestannylation on the trimethylstannylprecursor (2S,3S)-10 was 
accomplished. In the following step, [123I]-(2S,3S)-8a was reduced to yield [123I]-
(S,S)-IPBM.  
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The precursor (2S,3S)-10 (200 µg, 0.45 µmol) was dissolved in absolute ethanol 
(50 µL). Chloramine-T (1.0 µmol, 15 µL of a 20 mg/ml aqueous solution), n.c.a. 
[123I]NaI (dissolved in 0.05 M NaOH, 5 – 10 µL, 37 - 185 MBq), and glacial acetic 
acid (5 µL) were added. The radiolabelling proceeded for 10 min at room 
temperature. The reaction was quenched by the addition of sodium metabisulfite 
(1.6 µmol, 15 µL of a 20 mg/ml aqueous solution). After the solution was 
evaporated under nitrogen stream, 100 µL THF and 50 µL BH3 (1 M solution in 
THF) were added to the ice-cold reaction vessel. The mixture was allowed to 
react during 40 min at room temperature. HPLC mobile phase was added (100 
µL CH3CN:H2O:HCOOH 55:45:0.1) and the mixture was injected onto a RP C18 
HPLC column (Alltima, 250 mm * 4.6 mm, 5 µm) for purification at a flow rate 
of 1 mL/min. The fraction corresponding to [123I]-(S,S)-IPBM (Tr = 21 min) was 
collected, diluted with sterile water and concentrated on an activated C18 Sep-pak 
cartridge (Alltech Maxi-Clean Prevail C18). [123I]-(S,S)-IPBM was eluted from the 
Sep-pak column with 1 mL EtOH. Finally the EtOH was diluted with 
physiological saline to obtain an injectable solution (< 10 % (v:v) EtOH). 
 
5.3.4. QUALITY CONTROL 
 
The radioanalytical data were obtained by injecting 100 µL test solution on an 
analytical RP-HPLC (Alltima C18, 250 mm x 4.6 mm, 5 µm) using 55:45:0.1 (v:v) - 
CH3CN:H2O:HCOOH as mobile phase at a flow rate of 1 mL/min. 
Radiochemical purity and identity was determined by co-injection of an aliquot of 
[123I]-(S,S)-IPBM with authentic cold reference product.  
A calibration curve between 10 x 10-3 µM and 0.1 x 10-3 µM and subsequently a 
more detailed calibration curve between 0.6 x 10-3 µM and 0.1 x 10-3 µM was 
determined. Log D7.4 was determined according to the method described in 
Chapter 4. 
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5.3.5. BIODISTRIBUTION STUDY 
 
Male NMRI mice of 5 - 7 weeks old, weighing 22 - 26 g were injected in a tail 
vein with 200 µL 8:92 (v:v) - EtOH:physiological saline containing approximately 
185 kBq (5 µCi) [123I]-(S,S)-IPBM. The mice were awake during the injection. At 
various time points p.i. mice (n=3 for each time point) were sacrificed under 
isoflurane anaesthesia and dissected. Blood, urine and organs were removed, 
weighed and counted for radioactivity in a gamma counter. To remove adhering 
blood, all organs were rinsed with water prior to weighing and counting. For 
calculation of the injected dose, five aliquots of the injection solution were 
weighed and counted for activity. Results are decay corrected and expressed as a 
percentage of the injected dose per gram of tissue (% ID/g) ± SD. 
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5.4.      Results & Discussion 
 
5.4.1. ORGANIC SYNTHESIS 
 
 
Figure 5.2 Synthesis of halogenated reboxetine analogues  
a R1=I; b R1=Br Reagents: (i) 2-halogenated phenol, aq. NaOH; (ii) t-butyldimethylsilyl 
chloride, DMF, imidazole; (iii) methanesulfonyl chloride, Et3N, ethyl acetate; (iv) 
tetrabutylammonium chloride, THF; (v) aq. NaOH, toluene; (vi) 30 % NH4OH, MeOH; 
(vii) chloroacetylchloride, Et3N, CH2Cl2; (viii) potassium t-butoxide, t-butanol; (ix) BH3, 
THF 
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The same procedure by which we were able to synthesize (S,S)-IPBM, was also 
applied to synthesize (R,R)-IPBM, (2S,3S)-9b and (2R,3R)-9b (Figure 5.2).  
The key stereogenic centers of (S,S)-IPBM were created by regioselective ring 
opening with 2-iodophenol of the enantiomerically pure starting compound, 
(2R,3R)-phenylglycidol. The resulting diol, (2R,3S)-1a was isolated in a 95 % 
yield. The primary hydroxyl group of (2R,3S)-1a was selectively protected with a 
trimethylsilyl group to give (2R,3S)-2a. Compound (2R,3S)-4a (yield of 92 %) was 
prepared by reaction of the secondary hydroxyl group of 2a with methanesulfonyl 
chloride, followed by removal of the trimethylsilyl group with 
tetrabutylammonium fluoride. Treatment of (2R,3S)-4a with NaOH in toluene 
afforded the epoxide (2S,3S)-5a in 57 % yield. This reaction occurred via an SN2 
mechanism resulting in inversion of configuration at the chiral C2 carbon. 
Consequently the configuration changed from (2R,3S) to (2S,3S). The reaction of 
(2S,3S)-5a with NH4OH in MeOH yielded the amino alcohol (2S,3S)-6a (72 %). 
Compound (2S,3S)-6a was then transformed into the final morpholine in three 
steps. Treatment of (2S,3S)-6a with chloroacetyl chloride to give compound 
(2S,3S)-7a (81 % yield) was followed by cyclization with potassium t-butyl oxide. 
The resulting morpholinone (2S,3S)-8a (79 % yield) was then reduced to give 
(2S,3S)-9a in a 30 % yield by the use of BH3. Several reducing agents were tested 
but most of them tended to dehalogenate the phenyl group as well. (2S,3S)-9a 
was synthesized in an overall chemical yield of 7 % whereas (2S,3S)-9b was 
obtained with a 8 % overall chemical yield. The low general chemical yields are a 
result of the low yield in the final step. Excluding the last step the overall 
chemical yields were 23 % and 21 % for (2S,3S)-9a and (2S,3S)-9b, respectively.  
 
5.4.2. ENANTIOMERIC PURITY 
 
The optical rotation of both (2S,3S)-9b and (2R,3R)-9b was determined: (2S,3S)-
9b  [α]D= -65.6° (c= 1.25, MeOH) and (2R,3R)-9b [α]D= +72.8° (c= 0.95, 
MeOH). The enantiomeric purity was assessed by NMR analysis with and 
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without the addition of chiral shift reagent. Addition of Eu(hfc)3 to the samples 
resulted in a shift of 0.2 ppm of the signal at 5.25. This indicated that the samples 
have an enantiomeric excess of more then 95 %. 
 
5.4.3. RADIOCHEMISTRY 
 
Since radiosynthesis accomplished by an iodine-bromine exchange reaction is 
often difficult to purify, we choose to produce [123I]-(S,S)-IPBM by electrophilic 
substitution. Unfortunately we were not able to replace the bromine of (2S,3S)-
9b by a tributylstannyl group or trimethylstannyl group. Alternatively, [123I]-(S,S)-
IPBM was synthesized in two steps starting from (2S,3S)-10. The tributylstannyl 
precursor (2S,3S)-10 was synthesized in a 35 % yield. Radioiodination of (2S,3S)-
10, yielded [123I]-(2S,3S)-8a which was immediately reduced to give [123I]-(S,S)-
IPBM. The radiochemical yield was approximately 10 %. 
 
 
Figure 5.3 Radiosynthesis of [123I]-(S,S)-IPBM 
a EtOH, chloramine-T, glacial acetic acid, n.c.a. Na123I b THF, BH3 (1 M in THF) 
 
5.4.4. QUALITY CONTROL AND LOG D7.4 
 
Co-injection of the obtained radiotracer and cold reference compound illustrated 
similar retention times for [123I]-(S,S)-IPBM and (S,S)-IPBM, confirming the 
identity of the radiotracer. Radiochemical purity was > 98 %. Since no UV-signal 
was observed for the amount [123I]-(S,S)-IPBM synthesized, the detection limit 
was applied for calculation of the specific activity. Using the described 
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radioanalytical method, the detection limit for [123I]-(S,S)-IPBM was 0.25 x 10-3 
µM. Specific activity appeared to be at least 148 GBq/µmol (4 Ci/µmol). 
An ideal log D7.4 value for brain radiotracers is between 1.5 and 3.5 (Waterhouse, 
2003). The determined log octanol/PBS partition coefficient was found to be 1.9 
± 0.05 %, which is suitable for brain penetration. 
 
5.4.5. BIODISTRIBUTION STUDY 
 
Results of the biodistribution study are shown in Table 5.1. [123I]-(S,S)-IPBM 
displayed an excellent brain uptake (4.62 ± 0.66 % ID/g at 1 min p.i.) followed 
by a good wash-out (0.55 ± 0.17 % ID/g at 180 min p.i.) At each time point, 
brain activity remained higher than radioactivity uptake in blood (Figure 5.4).  
 
Figure 5.4 Blood-brain distribution of [123I]-(S,S)-IPBM in NMRI mice 
Values are expressed as % ID/g ± SD (n=3) 
 
Other organs with high tracer uptake were heart (12.65 ± 2.43 % ID/g at 1 min 
p.i.) and lungs (69.21 ± 8.02 % ID/g at 1 min p.i.). Radioactivity uptake in liver 
increased until 20 min p.i. and then declined. High uptake was seen in small 
(10.53 ± 3.84 % ID/g at 180 min p.i.) and large intestines (14.90 ± 5.53 % ID/g 
at 180 min p.i.), suggesting biliary clearance of [123I]-(S,S)-IPBM. High kidney 
(10.91 ± 1.07 % ID/g at 5 min p.i.) and urine (data not shown) radioactivity 
uptake, show that urinary clearance of [123I]-(S,S)-IPBM also occurred.
  
Table 5.1 Tissue uptake of radioactivity in male NMRI mice at various time points following i.v. administration [123I]-(S,S)-IPBM 
Time (min) 
 1 3 5 10 20 40 60 120 180 
Blood 1.33 ± 0.26 0.93 ± 0.34 1.00± 0.04 0.82 ± 0.14 0.53 ± 0.17 0.58 ± 0.06 0.43 ± 0.15 0.34 ± 0.07 0.26 ± 0.08 
Brain 4.62 ± 0.66 4.40 ± 1.30 4.21 ± 0.40 4.17 ± 0.47 2.37 ± 0.23 2.03 ± 0.87 1.57 ± 0.65 0.91 ± 0.26 0.55 ± 0.17 
Heart 12.65 ± 2.53 7.80 ± 3.08 5.61 ± 0.56 4.23 ± 0.82 3.53 ± 1.07 2.01 ± 0.62 1.70 ± 0.38 0.84 ± 0.04 0.66 ± 0.06 
Lungs 69.21 ± 8.02 60.48 ± 16.26 51.80 ± 8.53 42.72 ± 5.45 34.57 ± 21.39 11.65 ± 2.61 10.29 ± 3.75 3.62 ± 1.52 3.29 ± 0.93 
Stomach 2.53 ± 1.21 2.60 ± 0.98 2.50 ± 0.71 2.31 ± 1.11 2.47 ± 1.28 1.63 ± 0.80 1.29 ± 0.46 1.53 ± 0.69 2.53 ± 1.22 
Spleen 1.98 ± 0.90 2.48 ± 0.84 3.32 ± 0.58 3.69 ± 0.88 4.61 ± 1.01 2.71 ± 0.85 2.90 ± 1.84 2.39 ± 2.64 1.50 ± 1.72 
Liver 2.57 ± 1.08 2.96 ± 0.87 3.82 ± 0.20 3.46 ± 1.96 5.85 ± 2.97 3.53 ± 1.52 2.70 ± 0.86 2.30 ± 1.91 2.60 ± 1.42 
Kidneys 10.81 ± 4.23 9.62 ± 3.56 10.91 ± 1.07 9.86 ± 3.17 10.92 ± 2.26 6.06 ± 1.55 4.10 ± 0.99 2.83 ± 0.94 1.88 ± 0.75 
Small intestine 1.57 ± 0.38 1.39 ± 0.45 1.50 ± 0.17 3.81 ± 1.26 10.80 ± 4.17 11.18 ± 2.86 18.74 ± 1.06 6.90 ± 1.26 10.53 ± 3.84 
Large intestine 0.88 ± 0.23 0.80 ± 0.06 0.91 ± 0.08 0.92 ± 0.15 0.74 ± 0.20 0.54 ± 0.18 4.01 ± 3.98 12.54 ± 6.09 14.90 ± 5.53 
Pancreas 2.70 ± 2.64 4.67 ± 1.63 4.99 ± 0.29 3.78 ± 1.06 3.33 ± 1.08 1.58 ± 0.28 1.24 ± 0.09 0.88 ± 0.22 0.39 ± 0.07 
Muscle 1.29 ± 0.45 1.38 ± 0.21 1.93 ± 0.51 1.54 ± 0.04 1.38 ± 0.29 0.80 ± 0.18 0.65 ± 0.08 0.34 ± 0.05 0.27 ± 0.07 
Fat 0.70 ± 0.21 0.89 ± 0.31 1.04 ± 0.32 1.34 ± 0.66 1.43 ± 0.55 0.92 ± 0.41 0.66 ± 0.24 0.80 ± 0.44 0.37 ± 0.14 
Values are expressed as %  ID/g ± SD (n=3)
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5.5. Conclusion 
 
As an effort to develop a potential SPECT imaging agent for brain NET, an 
iodinated reboxetine derivate, [123I]-(S,S)-IPBM, was synthesized. Both the 
precursor and cold reference compound were prepared stereoselectively by a 
nine-step synthetic procedure. NMR analysis with Eu(hfc)3 as chiral shift reagent 
showed an enantiomeric excess of 95 % using the described stereoselective 
procedure. [123I]-(S,S)-IPBM was obtained by radioiodination of (2S,3S)-10, 
followed by reduction with a radiochemical purity of > 98 % and a specific 
activity of at least 148 GBq/µmol (4 Ci/µmol). In vivo evaluation showed a rapid 
and marked accumulation in the brain. The radioactivity in blood was cleared 
rapidly, and the brain to blood ratio, an essential factor for brain imaging, was 
high.   
Unfortunately, at the time we performed our biodistribution study, a report about 
the synthesis and evaluation of the same compound, [123/125I]-(S,S)-IPBM was 
published (Kanegawa et al., 2006). Only a few months later, an article concerning 
an in vivo evaluation of [123I]-(S,S)-IPBM in primates was published (Tamagnan et 
al., 2007). Since [123/125I]-(S,S)-IPBM was described by others, we performed no 
further attempts to increase the radiochemical yield and did not conduct 
additional in vivo studies.  
Kanegawa et al. radiosynthesized [125I]-(S,S)-IPBM by bromine-iodine exchange. 
They reported a yield of 65 % but they gave no information about the obtained 
specific activity and chemical purity. They performed a biodistribution study in 
Sprague-Dawley rats using [125I]-(S,S)-IPBM. The accumulation of radioactivity 
was greater in NET-rich regions, such as the thalamus and cortex, than in the 
striatum, a NET-poor region (Tejani-Butt, 1992). The ratio of radioactivity in 
other brain regions to that in the striatum was highest at 180 min p.i. Ex vivo 
autoradiographic analyses demonstrated the highest level of radioactivity in the 
locus coeruleus and anteroventricular thalamic nucleus, which are known to be 
Synthesis & evaluation of [123I]-(S,S)-IPBM for mapping NET – Chapter 5  
 
 118 
rich in NET. The NET-selective agent nisoxetine reduced the accumulation of 
radioactivity in the NET-rich regions to that of the striatum whereas fluoxetine, a 
selective agent for the serotonin transporter, and GBR12909, a DAT-selective 
agent did not affect the accumulation of [125I]-(S,S)-IPBM. Additionally, a SPECT 
study in a marmoset with [123I]-(S,S)-IPBM exhibited a regional localization 
consistent with the known densities of NET and [123I]-(S,S)-IPBM  accumulation 
could be displaced by treatment with nisoxetine (Kanegawa et al., 2005).  
Tamagnan et al. applied the electrophilic substitution method to yield [123I]-(S,S)-
IPBM but no information concerning their radiochemical yield and specific 
activity was added. They performed a dynamic SPECT imaging study in an adult 
female baboon. Regional brain tracer uptake is consistent with the distribution of 
NET in the baboon brain, with the highest uptake in locus coeruleus and 
thalamus, and lowest uptake in cerebellum and striatum. To assess the 
pharmacological specificity, reboxetine was injected which resulted in a reduction 
of radioactivity in all brain regions with the most pronounced reduction in NET-
rich regions. In contrast, displacement with citalopram or methylphenidate did 
not show any displacement of [123I]-(S,S)-IPBM (Tamagnan et al., 2007).   
The lack of data in their study makes it unfeasible to compare the different 
synthetic and radiosynthetic procedures whereas the in vivo data can not be 
compared due to differences in the experimental design.  
 
Regarding the results of Tamagnan et al. (2007) and Kanegawa et al. (2006), we 
can state that the choice to develop [123I]-(S,S)-IPBM as radiotracer for NET was 
an excellent suggestion. 
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Chapter 6 
 
Radiosynthesis and in vivo evaluation of [11C]-
labelled pyrrole-2-carboxamide derivatives for 
MAO-A imaging 
 
6.1. Abstract 
 
Aim: The search for new PET ligands for MAO-A with optimal properties is 
justified by the lack of an ideal ligand and the observation that fluctuations in 
MAO-A functionality are associated with human diseases. This study reports the 
radiolabelling of [11C]-labelled 1H-pyrrole-2-carboxamide derivatives, RS 2315 
and RS 2360, and the characterization of their in vivo properties.  
Methods: The radiolabelling of [11C]-RS 2315 and [11C]-RS 2360 was accomplished 
by methylation of the amide precusors with 11CH3I. Biodistribution, blocking and 
metabolite studies of both tracers were performed in NMRI mice. Finally, a PET 
study in Sprague-Dawley rats was performed for [11C]-RS 2360.  
Results: Both tracers were obtained in a radiochemical yield of approximately 30 
% with radiochemical purity of > 98 %. Biodistribution studies showed high 
brain uptake followed by rapid brain clearance for both radiotracers. In the brain, 
[11C]-RS 2360 was more stable than [11C]-RS 2315. Blocking studies in mice could 
not demonstrate specificity of [11C]-RS 2315 towards MAO-A or B. The blocking 
and imaging study with [11C]-RS 2360 on the other hand indicated specific 
binding at MAO-A at the earliest time points. 
Conclusion: These results indicate that [11C]-RS 2315 is not suitable for mapping 
MAO-A in vivo and that further research is necessary to investigate the potential 
of [11C]-RS 2360 in MAO-A imaging. 
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6.2. Introduction 
 
Because of the ability of MAO to catabolise neurotransmitters, MAO is involved 
in several psychiatric and neurological disorders (Meyer et al., 2006; Heafield and 
Williams, 1992) as well as in behaviour (Shih and Thompson, 1999; Alia-Klein et 
al., 2008; Brunner et al., 1993) and tobacco addiction (Fowler et al., 1996; Berlin 
et al., 1995). A very efficient non-invasive method to study enzymes in vivo is 
visualization with PET. There are only a few PET tracers for MAO-A designed 
and they all have their own drawbacks. The first developed radiotracer, 
[11C]clorgyline, displayed an unexplained species difference (Fowler et al., 2001; 
Bergström et al., 1997). In contrast to results in humans, clorgyline was not 
retained in baboon brain. Another MAO-A tracer, [11C]befloxatone is synthesized 
with [11C]phosgene which is toxic and is rather rare available (Dolle et al., 2003). 
The drawback of [11C]harmine is its extensive metabolism in plasma with only 10 
% intact product at 10 min p.i. (Bergström et al., 1997).  
The search for new ligands with optimal properties is justified by the lack of an 
ideal ligand and the observation that fluctuations in MAO-A functionality are 
associated with human diseases and tobacco addiction.  
A series of new pyrrole derivatives have been synthesized and evaluated for their 
MAO-A and -B inhibitory activity and selectivity (La Regina et al., 2007). Out of 
this new class of MAO inhibitors we selected the most potent inhibitors for 
MAO-A: N-(phenethyl)-N-methyl-1H-pyrrole-2-carboxamide (RS 2315) and (R)-
N-(α-cyclohexylethyl)-N-methyl-1H-pyrrole-2-carboxamide (RS 2360) (Figure 
6.1). Their Ki values are 7 nM and 1.7 nM for MAO-A and 12 nM and 30 nM for 
MAO-B, for RS 2315 and RS 2360, respectively (La Regina et al., 2007).  
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Figure 6.1 Chemical structures of RS 2360 and RS 2315 
 
The present study reports the radiolabelling and purification of 11C labelled RS 
2315 and RS 2360. Their partition coefficient is determined. Specific activity and 
radiochemical purity are reported. [11C]-RS 2315 and [11C]-RS 2360 are both 
evaluated in vivo. First, a biodistribution study in NMRI mice is performed to 
assess their ability to cross the blood-brain barrier. A blocking study is conducted 
to investigate their in vivo selectivity and specificity. Possible metabolism of [11C]-
RS 2315 and [11C]-RS 2360 is verified by analyzing mouse blood and brain 
samples on HPLC. Finally, a PET study in Sprague-Dawley rats is performed for 
the most promising radiotracer.  
 
6.3. Materials & Methods 
 
6.3.1. GENERAL 
 
The starting compounds N-(phenethyl)-1H-pyrrole-2-carboxamide (RS 2115) and 
(R)-N-(α-cyclohexylethyl)-1H-pyrrole-2-carboxamide (RS 2226) as well as the 
cold reference compounds RS 2315 and RS 2360 for this study were kindly 
provided by Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza 
University of Rome, Italy (La Regina et al., 2007).  
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6.3.2. RADIOCHEMISTRY 
 
The alkylating reagent [11C]methyl iodide was prepared from [11C]methane by gas-
phase iodination. The production of both 11CH4 and 11CH3I is described in 
Chapter 4. 
 
6.3.2.1.   [ 11C]-RS 2315 
 
A solution of 3 µmol precursor RS 2115 in DMSO/DMF (189 µL/60 µL) and 1 
µL tetrabutylammonium hydroxide (TBAH) was added to a reaction vessel and 
the mixture was cooled in an ice bath. A stream of helium containing the 
alkylating agent 11CH3I was bubbled through the reaction mixture until maximum 
of 11C activity was trapped. The reaction mixture was heated in an oil bath at 
65°C for 10 min and subsequently diluted with 200 µL HPLC eluent and purified 
with semipreparative C18 HPLC (Econosphere, 10 µm, 10 mm x 250 mm; Grace 
Davison Discovery Sciences, Lokeren, Belgium) using a smartline UV detector 
2500 (Knauer, Berlin, Germany) set at 254 nm. Radiodetection occurred by a 
solar-blind P.I.N. photodiode. Elution was carried out at 6 mL/min flow rate 
with 45 % (v/v) CH3CN in 0.02 M sodium acetate buffer (pH 4.5) as mobile 
phase. The fraction containing [11C]-RS 2315 was collected into a vessel with 40 
mL sterile water and loaded on a C18 Sep-pak (Alltech Maxi-clean SPE Prevail 
C18, previously activated with 1 mL EtOH and 5 mL sterile water). After the 
cartridge was washed with 5 mL sterile water, the desired product, [11C]-RS 2315, 
was eluted with 1 mL EtOH. For biodistribution and blocking studies the EtOH 
fraction was diluted with 10 mL physiological saline. For metabolite analysis, 
EtOH was evaporated to dryness and the residue was redissolved in an adequate 
amount of EtOH/physiological saline (8/92 - v/v). 
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6.3.2.2.    [ 11C]-RS 2360 
 
The same procedure as described for [11C]-RS 2315, with minor modifications 
was applied to synthesize [11C]-RS 2360.  
[11C]-RS 2360 was prepared by methylation with 11CH3I of the normethyl 
derivative RS 2226 (3 µmol) in DMF/DMSO (60 µL/188 µL) for 7 min at 70°C 
using 1.5 µL TBAH. Purification was accomplished using 
CH3CN/H2O/HCOOH (50/50/0.1 – v/v/v) as mobile phase at a flow rate of 6 
mL/min. The collected HPLC fraction containing [11C]-RS 2360 (Tr 8.5 min) was 
diluted with 40 mL 0.01 M PBS before loading onto a Sep-pak column (Alltech 
Maxi-clean SPE Prevail C18, previously activated with 1 mL EtOH and 5 mL 
sterile water). After the cartridge was washed with 5 mL sterile water, the desired 
product, [11C]-RS 2360, was eluted with 1 mL EtOH. For biodistribution and 
blocking studies the EtOH fraction was diluted with 10 mL physiological saline. 
For metabolite and imaging studies, EtOH was evaporated to dryness and the 
residue was redissolved in an adequate amount of EtOH/physiological saline 
(8/92 - v/v). 
 
6.3.3. IN VITRO CHARACTERIZATION 
 
Quality control consisted of the determination of radiochemical purity and 
specific activity, calculated by analytical HPLC assay using a Gracesmart C18 
column (5 µm, 4.6 mm x 250 mm; Grace Davison Discovery Sciences, Lokeren, 
Belgium) at a flow rate of 1 mL/min. The eluents were the same as described for 
the purification.  
A calibration curve of unlabelled reference compound (0.02 µM – 1 µM) was 
made and controlled for its accuracy and reproducibility. Specific activities were 
decay corrected back to the end of purification.  
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Co-injection on analytical HPLC of the final end product and cold reference 
compound was performed to confirm the identity of the obtained radiotracer. 
Log D7.4 was determined according to the method described in Chapter 4. 
 
6.3.4. BIODISTRIBUTION STUDIES 
 
The biodistribution of [11C]-RS 2315 and [11C]-RS 2360 was studied in male 
NMRI mice (approximately 25 g and 6 weeks old). Awake mice (n=3 at each time 
point) were injected in a tail vein with approximately 200 µL containing 7.5 – 11 
MBq (0.2 – 0.3 mCi) [11C]-RS 2315 or [11C]-RS 2360. At 1, 10, 30 and 60 min p.i. 
mice were euthanized and dissected. Blood, urine and organs were weighed and 
counted for radioactivity. All organs were rinsed with water prior to weighing and 
counting. For calculation of the injected dose, five aliquots of the injection 
solution were weighed and counted for activity. Results are decay-corrected and 
expressed as % ID/g ± SD. 
 
6.3.5. BLOCKING STUDIES 
 
Blocking studies were carried out with preinjection of 100 µL clorgyline 
hydrochloride (MAO-A inhibitor) or R-(-)-deprenyl hydrochloride (MAO-B 
inhibitor) i.v. both in a dose of 10 mg/kg (Arnett et al., 1987; Fowler et al., 2001; 
Hirata et al., 2002; Jensen et al., 2008). 9 ± 1 MBq (243 ± 27 µCi) 11C tracer (100 
µL) was injected 30 min later via a tail vein. The mice (n=3 at each time point) 
were awake during the injections. The mice were sacrificed and dissected at 1, 10 
and 30 min after 11C tracer injection. Blood, urine and organs were weighed and 
counted for radioactivity. All organs were rinsed with water prior to weighing and 
counting. For calculation of the injected dose, five aliquots of the injection 
solution were weighed and counted for activity. Results are decay-corrected and 
expressed % ID/g ± SD. Statistical analysis was performed using one-sided, 
unpaired student’s t-test. Only p-values < 0.05 are considered significant. 
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6.3.6. METABOLITE ANALYSIS 
 
The in vivo metabolic stability of [11C]-RS 2315 and [11C]-RS 2360 in plasma and 
brain was studied in male NMRI mice. 22 – 37 MBq (0.59 - 1 mCi) of [11C]-RS 
2315 or [11C]-RS 2360 dissolved in 200 µL was injected through a tail vein and 
the mice (n=3 for each time point) were sacrificed at 1, 10 or 30 min p.i. Sample 
workup was done as described in Chapter 4. HPLC analysis was performed using 
the same conditions as used for purification (see 6.3.2.). 
 
6.3.7. IMAGING STUDY 
 
Additional in vivo tests with [11C]-RS 2360 were performed using microPET 
imaging technology. Awake Sprague-Dawley rats (n=4 for each treatment group) 
were injected with physiological saline, clorgyline hydrochloride (10 mg/kg) or 
(R)-(-)-deprenyl hydrochloride (10 mg/kg) 30 min prior to their microPET scan. 
The latter acquisitions are performed using the Gamma Medica Ideas labPET 8, a 
state-of-the-art microPET device existing of 2 × 2 × 10 mm3 LYSO/LGSO 
scintillators in a 8-pixel, quad-APD detector module arrangement. This system is 
capable of delivering 1 mm spatial resolution in rodents at a sensitivity of 4 % 
thereby covering a field-of-view of 10 cm transaxially by 8 cm axially.   
All animals were injected with 35 – 40 MBq (0.95 - 1.08 mCi) [11C]-RS 2360 on 
the camera bed at the start of a dynamic acquisition.  Frames of 4 x 0.5 min, 3 x  
1 min, and 1 x 5 min were accordingly sequentially recorded.  The resulting data 
were reconstructed using 30 iterations of the Maximum Likelihood Expectation 
Maximization algorithm in 160 x 160 x 63 images of 0.5 mm x 0.5 mm x 1.175 
mm voxel size.  An a posteriori three-dimensional Gaussian filter of 2 x 2 x 2 mm 
was applied to all frames. Statistical analysis was performed using one-sided, 
unpaired student’s t-test. Only p-values < 0.05 are considered significant. Images 
were analysed with PMOD whereby volumes of interest (VOIs) were drawn on 
the brain region (Figure 6.2) and the background region (Figure 6.3) of each 
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animal. Since the selection of the background region is critical, we delineated the 
background VOI on the last frame of 5 min acquisition. In this way, noise is 
eliminated and a robust reference value is obtained to normalize brain uptake for 
injected activity in all other frames on an individual animal basis.  We selected the 
background region so that no specific muscle activity was present.   
 
Figure 6.2 Example VOI for the brain region 
 
 
Figure 6.3 Example VOI for the background region 
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6.4. Results & Discussion 
 
6.4.1. RADIOSYNTHESIS 
 
The synthesis of radioligands [11C]-RS 2315 and [11C]-RS 2360 is shown in Figure 
6.4. Their respective amide precursors were labelled with 11CH3I prepared from 
11CH4, in the presence of TBAH as a base through N-[11C]methylation and 
isolated by semipreparative HPLC.  
 
 
Figure 6.4 Radiosynthesis of [11C]-RS 2315 and [11C]-RS 2360 
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6.4.1.1.    [11C]-RS 2315 
 
A typical UV- and radio-chromatogram for a [11C]-RS 2315 synthesis purification 
run is shown in Figure 6.5. 
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Figure 6.5 UV (blue) and radio-chromatogram (pink) of a typical [11C]-RS 2315 
purification 
 
[11C]-RS 2315 elutes with a retention time of 10 min. Extraction efficiency of the 
Sep-pak column was calculated to be 82 ± 8 % (n=6). Based on the amount 
11CH3I added to the reaction vial, the radiochemical yield was 28 ± 4 % (n=6). 
The total synthesis, from the end of 11CH3I delivery to reaction vessel to delivery 
for in vivo studies was completed in 35 min. 
 
6.4.1.2.    [11C]-RS 2360 
 
The overall synthesis, purification (Figure 6.6) and formulation time to obtain 
[11C]-RS 2360 was 30 min. In a typical experiment, target tracer [11C]-RS 2360 was 
provided in a radiochemical yield of 30 ± 6 % (n=6), decay-corrected to start of 
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the reaction, based on the amount 11CH3I added. Almost all activity was released 
from the Sep-pak column (93 ± 4 % (n=6)). 
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Figure 6.6 UV (blue) and radio-chromatogram (pink) of a typical synthesis 
purification of [11C]-RS 2360 
 
6.4.2. IN VITRO CHRACTERIZATION 
 
6.4.2.1. Quality control, specific activity and stability 
 
The identity of both tracers was confirmed by co-elution with authentic reference 
compound after co-injection on HPLC. Calculation of specific activity resulted in 
a range from 25 – 92 GBq/µmol (0.68 – 2.49 Ci/µmol) for [11C]-RS 2315 (n=6) 
and 41 – 106 GBq/µmol (1.11 – 2.87 Ci/µmol) for [11C]-RS 2360 (n=6). 
Radiochemical purity of the tracer recovered at the end of the experiment was > 
98 % for both radiotracers. [11C]-RS 2315 and [11C]-RS 2360 remained stable 
during the time span of the experiments. 
 
6.4.2.2. Log D7.4 
 
We determined log D7.4 as an indicator for lipophilicity and blood-brain-
permeability. Octanol – buffer partition coefficient measurements gave a log D7.4 
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of 1.65 ± 0.19 for [11C]-RS 2315, slightly higher than the log D7.4 of [11C]-RS 2360 
(1.48 ± 0.04). The higher log D7.4 value of [11C]-RS 2315 is in accordance with 
what we can predict from the replacement of cyclohexane by a benzene ring. 
Both values are suitable for brain penetration (Waterhouse, 2003).  
 
6.4.3. BIODISTRIBUTION STUDIES 
 
Following i.v. injection of [11C]-RS 2315 into NMRI mice, the time course of 
radioactivity was determined in several tissues (Figure 6.7). High initial uptake in 
heart, lungs, pancreas and kidneys (5.52 ± 0.41 % ID/g, 5.96 ± 1.11 % ID/g, 
5.19 ± 1.63 % ID/g and 6.81 ± 3.23 % ID/g, respectively at 1 min p.i.) was 
observed but except for the kidneys (8.34 ± 1.09 % ID/g at 60 min p.i.), the 
studied organs did not show any retention of [11C]-RS 2315. In the liver, the 
activity peaked at 9.09 ± 0.97 % ID/g at 10 min p.i. and decreased over time. The 
activity in intestines had the highest increase between 10 min p.i. (4.36 ± 1.68 % 
ID/g) and 30 min p.i. (10.62 ± 2.81 % ID/g), indicating hepatobiliary clearance. 
Urinary clearance was also observed (data not shown). 
 
Figure 6.7 Tissue distribution of [11C]-RS 2315 in male NMRI mice  
Values are expressed as % ID/g ± SD (n=3) 
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The blood-brain distribution of both [11C]-RS 2315 and [11C]-RS 2360 is shown in 
Figure 6.8. [11C]-RS 2315 entered the brain quickly and was rapidly cleared (from 
4.75 ± 1.62 % ID/g at 1 min p.i. to 0.24 ± 0.07 % ID/g at 60 min p.i.). [11C]-RS 
2360 displayed a rapid and high brain uptake of 7.08 ± 0.95 % ID/g at 1 min p.i., 
indicating a good penetration of the radiotracer into the brain. This high brain 
uptake was followed by an efficient wash-out (0.51 ± 0.06 % ID/g at 30 min p.i.). 
 
 
Figure 6.8 Blood-brain distribution of [11C]-RS 2315 (A) and [11C]-RS 2360 (B) 
in male NMRI mice 
Values are expressed as % ID/g ± SD (n=3) 
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Figure 6.9 summarizes the tissue time-course distribution of [11C]-RS 2360 in 
male NMRI mice. The lungs, heart and pancreas showed high initial uptake 
(respectively, 23.62 ± 4.22 % ID/g, 11.51 ± 0.93 % ID/g and 3.93 ± 1.78 % 
ID/g at 1 min p.i.) followed by a fast wash-out (6.01 ± 2.28 % ID/g, 1.75 ± 0.16 
% ID/g and 1.66 ± 0.37 % ID/g at 30 min p.i.). As for [11C]-RS 2315, the uptake 
in the liver was also increased at 10 min after injection (7.45 ± 0.35 % ID/g) after 
which it decreased (4.24 ± 0.99 % ID/g at 60 min p.i.). Clearance of radioactivity 
occurred by both the hepatobiliary and urinary pathway (data not shown).  
 
Figure 6.9 Tissue distribution of [11C]-RS 2360 in male NMRI mice 
Values are expressed as % ID/g ± SD (n=3) 
 
6.4.4. BLOCKING STUDIES 
 
In vivo selectivity and specificity of both radiotracers was examined by pre-
injection of clorgyline hydrochloride (MAO-A inhibitor) and R-(-)-deprenyl 
hydrochloride (MAO-B inhibitor). Uptake of radioactivity in brain (Figure 6.10) 
and peripheral organs was measured at 1, 10 and 30 min after injection. of the 11C 
tracer. 
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[11C]-RS 2315 brain uptake could not be decreased by administrating clorgyline or 
R-(-)-deprenyl. Surprisingly, a significantly higher brain uptake is observed at 30 
min p.i. both after MAO-A and MAO-B inhibition. The effect on the 
brain/blood ratio however is not significant. A raise in brain uptake also occurred 
at 1 min p.i. but since the blood activity increased as well, the brain/blood ratio 
was not affected. Peripherally, an increased liver uptake is observed at 1 min p.i. 
both after clorgyline (from 3.63 ± 0.56 % ID/g to 7.15 ± 3.02 % ID/g) and after 
R-(-)-deprenyl (from 3.63 ± 0.56 % ID/g to 7.81 ± 0.73 % ID/g) pretreatment. 
At 10 and 30 min p.i., a raise in intestinal activity (from 4.36 ± 1.68 % ID/g to 
7.84 ± 3.21 % ID/g after clorgyline pretreatment and to 5.74 ± 0.73 % ID/g 
after R-(-)-deprenyl pretreatment at 10 min p.i.) is seen, suggesting an enhanced 
hepatobiliary clearance after administration of clorgyline and R-(-)-deprenyl. This 
peripheral redistribution after pretreatment with clorgyline and R-(-)-deprenyl 
could be the reason of the observed higher brain uptake. Another possible 
hypothesis for the higher brain uptake is that clorgyline or R-(-)-deprenyl 
administration caused a shift in metabolism pattern. 
 
 
Figure 6.10 Brain uptake of [11C]-RS 2315 (A) and [11C]-RS 2360 (B) in control 
mice and in mice pretreated with clorgyline or (R)-(-)-deprenyl  
Values are expressed as % ID/g ± SD (n=3), * p < 0.05, student’s t-test 
 
At 1 min p.i., pretreatment with clorgyline resulted in a significant decrease in 
brain uptake of [11C]-RS 2360 (p = 0.02). (R)-(-)-deprenyl administration also 
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lowered brain uptake but this decrease was not significant. This effect is in 
accordance with what we would expect from the in vitro properties (Ki = 1.7 nM 
for MAO-A and Ki = 30 nM for MAO-B). At 10 and 30 min p.i however, no 
effect of clorgyline or R-(-)-deprenyl pre-administration could be observed. In the 
peripheral organs, no clear effect of blocking MAO-A or MAO-B could be 
distinguished (data not shown).  
 
6.4.5. METABOLITE ANALYSIS 
 
Control experiments with spiked plasma and brain revealed extraction efficiencies 
of 96 ± 1 % for plasma and 93 % for brain samples for [11C]-RS 2315 and 93 ± 6 
% for plasma and 85 ± 6 % for brain samples for [11C]-RS 2360, respectively. 
Plasma and brain obtained from mice at 1, 10 and 30 min p.i. were analyzed by 
RP-HPLC to investigate the metabolism pattern of [11C]-RS 2315 and [11C]-RS 
2360 (Table 6.1).  
 
Table 6.1 Metabolic profile of [11C]-RS 2315 and [11C]-RS 2360 in NMRI mice 
  Retention time on RP-HPLC 
Tissue Time 2.5 min 4.5 min 10 min 
Plasma [11C]-RS-2315 1 min   > 96 % 
 10 min 55 ± 5 % 24 ± 5 % 21 ± 2 % 
 30 min 83 ± 1 % 8 % 9 ± 2 % 
     
Brain [11C]-RS-2315 1 min   > 99 % 
 10 min 10 ± 1 % 28 ± 4 % 62 ± 3 % 
 30 min 28 ± 5 % 19 ± 3 % 53 ± 7 % 
     
Plasma [11C]-RS-2360 1 min   > 99 % 
 10 min 64 ± 10 % 8 % 29 ± 10 % 
 30 min 75 ± 5 % 5 ± 1 % 21 ± 5 % 
     
Brain [11C]-RS 2360 1 min   > 99 % 
 10 min 10 ± 3 % 10 ± 1 % 81 ± 4 % 
 30 min 27 ± 4 % 8 % 66 ± 4 % 
Values are expressed as percent of total radioactivity ± SD (n=3) 
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RP-HPLC analysis of mouse plasma showed that [11C]-RS 2315 (Figure 6.11) was 
rapidly metabolized with only 21 ± 2 % parent compound remaining at 10 min 
p.i. All detected metabolites were more polar than the original radiotracer. The 
percentage of radioactivity in mouse brain extracts derived from unmetabolized 
[11C]-RS 2315 was > 99 % at 1 min p.i., 62 ± 3 % at 10 min p.i. and 53 ± 7 % at 
30 min p.i. respectively. 
 
 
Figure 6.11 Metabolite chromatogram of [11C]-RS 2315 at 10 min (A)  
and 30 min (B) p.i. 
Values are the mean of three experiments and are expressed as percent of total activity  
 
The relative percentage of intact [11C]-RS 2360 (Figure 6.12) in plasma as a 
function of time after injection was 29 ± 10 % at 10 min p.i and 21 ± 5 % at 30 
min p.i. HPLC analysis of the brain samples showed that 81 ± 4 % and 66 ± 4 % 
of the radioactivity existed of unchanged [11C]-RS 2360 at 10 and 30 min p.i. 
respectively. At 1 min p.i., no degradation products were found in plasma neither 
in brain. 
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Figure 6.12 Metabolite chromatogram of [11C]-RS 2360 at 10 min (A)  
and 30 min (B) p.i. 
Values are the mean of three experiments and are expressed as percent of total activity  
 
At all time points examined, the extent of metabolism was higher for [11C]-RS 
2315 than for [11C]-RS 2360. It seems quite likely that the hydrophilic degradation 
fragments with the retention time of 2.5 min were methanol, formaldehyde or 
formic acid; which were formed after demethylation of the radiotracer. The 
metabolite at 4.5 min could be the result of the breaking of the amide bond. In 
the case of [11C]-RS 2360, the metabolite could also be caused by hydroxylation 
on the phenyl group.  
 
6.4.6. PET SCANS 
 
The results shown in Figure 6.13 illustrate that for [11C]-RS 2360 an overall 
significant inhibition by clorgyline of 30 % can be concluded when compared to 
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injection of physiological saline (p = 0.006). An inhibition of 16 % by R-(-)-
deprenyl is noticeable, albeit not significant (p = 0.07). These observations 
indicated that [11C]-RS 2360 is more selective towards MAO-A than to MAO-B 
which is in accordance with the in vitro determined Ki values. When we investigate 
the influence of clorgyline pretreatment at each time frame separately, a 
significant inhibition is observed at the first 5 time frames but not at the latter 
three time frames. R-(-)-deprenyl administration caused no significant inhibition 
of brain uptake at any of the separate time frames. These observations are in 
accordance with those of the blocking study. The impossibility to show specificity 
towards MAO-A at the latter time points could be due to the extensive 
metabolism of [11C]-RS 2360.  
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Figure 6.13 Results for the PET imaging experiments  
Values are the mean of four experiments 
 
6.5. Conclusion 
 
The radiosynthesis of both radiotracers was achieved by nucleophilic substitution 
of the desmethyl precursor with 11CH3I in the presence of TBAH. After HPLC 
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purification, the radiochemical yields were 28 ± 4 % and 30 ± 6 % for [11C]-RS 
2315 and [11C]-RS 2360, respectively and radiochemical purity appeared > 98 % 
for both radiotracers. The authenticity of the tracers was determined by co-
elution with the non-radioactive reference compound. Specific activity ranged 
from 25 – 92 GBq/µmol (0.68 – 2.49 Ci/µmol) for [11C]-RS 2315 and 41 – 106 
GBq/µmol (1.11 – 2.87 Ci/µmol) for [11C]-RS 2360. For the duration of the 
experiments, [11C]-RS 2315 as well as [11C]-RS 2360 remained stable. The 
determined log D7.4 of 1.65 ± 0.19 for [11C]-RS 2315 was slightly higher than the 
log D7.4 of [11C]-RS 2360 (1.48 ± 0.04) as expected when comparing the chemical 
structures. Both values are suitable for brain penetration. 
Upon intravenous administration, high initial levels of activity were observed in 
mouse brain indicating an excellent passage through the BBB of both [11C]-RS 
2315 and [11C]-RS 2360. The brain activity diminished very quickly and at 10 min 
p.i. for [11C]-RS 2315 and 30 min p.i. for [11C]-RS 2360 brain activity did no 
longer exceeded blood activity. Metabolism studies revealed that at 1 min p.i. 
almost no degradation occurred neither in plasma or brain. At 10 and 30 min p.i., 
[11C]-RS 2315 and [11C]-RS 2360 were extensively metabolized in plasma and 
remained more stable in brain. At all time points examined, the extent of 
metabolism was greater for [11C]-RS 2315 than for [11C]-RS 2360. The blocking 
study failed to proof specificity of [11C]-RS 2315 at all time points. [11C]-RS 2360 
showed specificity towards MAO-A at 1 min p.i. At 10 and 30 min p.i however, 
no effect of clorgyline pretreatment could be observed. The absence of selectivity 
at the later time points might be explained by the appearance of metabolites in 
the brain. Administration of R-(-)-deprenyl had no significant effect on the brain 
uptake of [11C]-RS 2360. In the imaging study with [11C]-RS 2360, administration 
of R-(-)-deprenyl caused a decreased brain uptake although this effect is not 
significant. Clorgyline pretreatment on the other hand, showed an overall 
significant reduced uptake of [11C]-RS 2360 indicating specific binding at MAO-
A. These observations indicate that [11C]-RS 2360 is more selective towards 
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MAO-A than to MAO-B which is in accordance with the in vitro determined Ki 
values. 
Based on these results, we can conclude that [11C]-RS 2315 is not suitable for 
visualization of MAO-A in vivo. [11C]-RS 2360 on the other hand might have 
potential for mapping MAO-A when PET scan is performed directly after 
injection of the tracer. Further studies are necessary to evaluate the potential role 
of [11C]-RS 2360 in MAO-A imaging in humans. It is possible that the 
metabolism pattern in humans is different from that obtained in rodents. 
Therefore it is useful to compare the metabolism pattern of [11C]-RS 2360 in 
whole rodent blood spiked with [11C]-RS 2360 with the metabolism in whole 
human blood spiked with [11C]-RS 2360 to have an initial notion about the 
difference in metabolism in humans and rodents. A slower metabolism in 
humans could result in improved selectivity at later time points.  
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Chapter 7 
 
Synthesis, radiosynthesis and in vivo evaluation of 
[123I]-FMIP for imaging the dopamine transporter 
 
7.1. Abstract 
 
Aim: 4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine (FMIP) 
has nanomolar affinity for DAT and better selectivity over the other monoamine 
transporters compared to the already existing ligands for DAT imaging with 
SPECT. The aim of this study was to synthesize and evaluate the usefulness of 
[123I]-FMIP as an in vivo tracer for DAT. 
Methods: [123I]-FMIP was synthesized by electrophilic destannylation. 
Biodistribution, blocking and metabolite studies of [123I]-FMIP were performed in 
male NMRI mice whereas a more detailed brain dissection was done in male 
Sprague-Dawley rats.  
Results: The tributylstannyl precursor was synthesized with an overall yield of 
approximately 25 %. The mean radiochemical yield of [123I]-FMIP was 40 ± 10 % 
and after purification, the radiochemical purity appeared to be > 98 %. The 
specific activity of the compound was at least 667 GBq/µmol. Biodistribution 
studies showed brain uptake of 0.96 ± 0.53 % ID/g at 0.5 min p.i. and 0.26 ± 0.02 
% ID/g at 180 min p.i. High blood activity was observed at all time points. 
Blocking studies indicated no selectivity of [123I]-FMIP towards DAT. A 
metabolite study demonstrated that in brain, over 80 % was present as intact [123I]-
FMIP at 60 min p.i. In rats, regional brain distribution of [123I]-FMIP was not in 
agreement with DAT localization demonstrating lack of selectivity towards DAT. 
Conclusion: These results indicate that [123I]-FMIP is not suitable for mapping DAT 
in vivo. 
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7.2. Introduction 
 
It has been demonstrated that DAT neuroimaging is useful in PD diagnosis, 
providing information on the integrity of the dopaminergic neurotransmission 
system in vivo (Poewe and Sherfler, 2003; Dhawan and Eidelberg, 2001; Shih et al., 
2006). Because of the crucial role of DAT in the etiology of PD as well as other 
neurological disorders and addiction, several DAT ligands have been developed for 
in vivo SPECT imaging (Volkow et al., 1996; Elsinga et al., 2006). These ligands all 
share the same problem of being not selective towards SERT. The commercially 
available [123I]-FP-CIT (DaTSCAN, GE Healthcare, Little Chalfont, UK) has a Ki 
value of 3.5 nM for DAT, 0.11 nM for SERT and 63 nM for NET, indicating lack 
of selectivity for DAT (Neumeyer et al., 1991; 1996; Scheffel et al., 1997). Other 
drawbacks of [123I]FP-CIT are the lack of good in vivo kinetics and the formation of 
4 labelled metabolites in plasma (Bergstrom et al., 1996; Emond et al., 1997). 
Another investigated DAT radioligand, [123I]PE2I, has Ki values of 17 nM, 500 nM 
and over 1000 nM, for DAT, SERT and NET respectively so a SERT/DAT 
selectivity of 29 was calculated. Another disadvantage of [123I]PE2I is in vivo 
deiodination of the iodo vinyl group (Guilloteau et al., 1997). These shortcomings 
indicate that there is still a need for selective radioligands for DAT. 
 
A study by Boos et al. (2006) has concentrated on the development of novel 
analogues of 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine 
(GBR 12909). GBR 12909 (Figure 7.1) is a high affinity, selective, long-lasting 
inhibitor of dopamine reuptake and a noncompetitive blocker of DAT in rats (van 
der Zee et al., 1980; Rothman et al., 1991). The newly developed analogues were 
pharmacologically evaluated to identify ligands with varying transporter affinity 
and selectivity. 
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Figure 7.1 Structure of GBR 12909 
 
For the compound investigated in this study, 4-(2-(bis(4-
fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine (FMIP), they reported Ki 
values of 1.9 nM for DAT, 205 nM for SERT and 4110 nM for NET. These values 
indicate that FMIP has good in vitro selectivity over the other monoamine 
transporters (108 for SERT/DAT and 2163 for NET/DAT). Compared to 
[123I]FP CIT and [123I]PE2I, the in vitro properties of FMIP are promising. We 
therefore evaluated the potential of [123I]-FMIP as a suitable tracer for DAT in vivo 
(Figure 7.2).  
 
 
 
Figure 7.2 Structure of [123I]-FMIP 
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In this Chapter we present the synthesis of the precursor and reference molecule. 
The radiosynthesis of [123I]-FMIP, along with its purification, quality control, log 
D7.4, stability and specific activity is reported. [123I]-FMIP is evaluated in vivo in 
NMRI mice. Metabolic assays are performed on blood and brain of NMRI mice. 
The selectivity of [123I]-FMIP towards DAT is investigated by a regional brain 
distribution in Sprague-Dawley rats and a blocking study in NMRI mice.  
 
7.3. Materials & Methods 
 
7.3.1. ORGANIC SYNTHESIS 
 
The starting material, 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperidine (1), was 
described and synthesized by Boos et al. (2006). All melting points (m.p.) were 
determined on a Thomas–Hoover melting point apparatus and are uncorrected. 
The 1H NMR spectra were recorded on a Varian XL-300 instrument with DMSO-
d6 as solvent, δ values were recorded in ppm (TMS as internal standard), J (Hz) 
assignments of 1H resonance coupling were done. Electron ionization (EI) mass 
spectra were obtained using a VG-Micro Mass 7070F mass spectrometer. TLC was 
performed on 250 mm Analtech GHLF silica gel plates. Visualization was 
accomplished under UV at 254 nm. Elemental analyses were performed by 
Atlantic Microlabs, Inc. (Norcross, GA).  
 
7.3.1.1. (4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)piperidin-1-yl)(4-hydroxyphenyl)-
methanone (2) 
 
A solution of 4-hydroxybenzoic acid (2.0 g, 14.5 mmol) and N-
hydroxybenzotriazole  (1.9 g, 13.3 mmol) in CH2Cl2 (200 mL) was stirred for 15 
min, prior to the addition of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)piperidine (1) 
(4.0 g, 12.1 mmol) and 1-ethyl-3-(3'-dimethylaminopropyl)carbodiimide 
hydrochloride (5.1 g, 26.6 mmol). The solution was stirred for 96 h after wich the 
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solvent was removed under reduced pressure. The semi-solid was dissolved in 
ethyl acetate (250 mL) and the organic layer was washed with 1 M HCl (250 mL), 
10 % potassium carbonate (250 mL), and brine (250 mL). The organic layer was 
dried over anhydrous Na2SO4 and the solvent was removed under reduced 
pressure. TLC analysis (9:1 (v:v) – CHCl3:MeOH) identified a small amount of 
unreacted starting material not removed in the acid washing. Flash 
chromatography provided two compounds that co-migrated in the 9:1 (v:v) – 
CHCl3:MeOH solvent system. Both compounds were dried under high vacuum 
and underwent alane reduction without further purification. 
 
7.3.1.2. 4-((4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)piperidin-1-yl)methyl)phenol (3) 
 
To a flame dried flask, lithium aluminiumhydride (1.3 g, 33 mmol) was added and 
cooled to 0°C under argon. THF (10 mL) was added drop-wise while stirring. 
Upon the completion of the addition of THF, sulphuric acid (1.1 g, 17 mmol) in 
THF (10 mL) was added drop-wise. The solution was stirred at 0°C for 45 min. To 
the ice-cold solution was added 2 (3.0 g, 6.6 mmol) in THF (10 mL). The solution 
was stirred for an additional 15 min at 0°C, then allowed to warm to room 
temperature and stirred for 2 h. 10 % NaOH (200 mL) and ethyl acetate (75 mL) 
were added to the solution. The layers were separated and the aqueous layer was 
further extracted with ethyl acetate (2 x 75 mL). The organic extracts were 
combined and washed with H2O (200 mL) and brine (200 mL). The organic layer 
was dried over anhydrous Na2SO4 and the solvent was removed under reduced 
pressure to yield 3 as a solid. TLC analysis identified a small quantity of starting 
material.  The solid was dissolved in ether and 1.1 equivalent of oxalic acid was 
added.  2.6 g (5.9 mmol) of 3 as the oxalate salt was obtained. The yield of the 
reaction was 89 %. 
1H NMR (DMSO-d6, 300 MHz): δ 6.7 - 7.4 (m, 12H, ar); 5.5 (s, 1H, CH-O); 3.8 
(bs, 2H, CH2NH); 3.0-3.4 (m, 4H); 2.5-2.9 (m, 3H); 1.3-1.7 (m, 6H). HRMS (EI) 
calcd for C27H30F2NO2 m/z, 438.2245; found 438.2243. Anal. calcd for 
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C27H29F2NO2.0.5 C2H2O4: C, 69.69; H, 6.27; N, 2.90. Found: C, 69.17; H, 6.21; N, 
2.88. m.p.  198-199.5oC. Rf= 0.53 (9:1-CHCl3:MeOH). 
 
7.3.1.3. 4-((4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)piperidin-1-yl)methyl)phenyltrifluoro-
methanesulfonate (4) 
 
N-Phenyltriflouromethanesulfonimide (1.4 g, 3.8 mmol), 3 (1.3 g, 3.0 mmol) and 
N,N-diisopropylethylamine (1.0 mL, 6.0 mmol) were combined in CH2Cl2 (20 mL) 
and stirred under argon, overnight. To the solution was added H2O (50 mL) and 
CH2Cl2 (50 mL). The organic layer was separated and subsequently washed with a 
10 % NaHCO3 solution, H2O (50 mL) and brine (50 mL). The organic layer was 
dried over anhydrous Na2SO4 and the solvent was removed under reduced 
pressure. After chromatography on silica gel using 9:1 (v:v) - CHCl3:MeOH as 
solvent system, 4 was obtained as a clear oil 1.5 g (2.6 mmol). The yield of the 
reaction was 87 %. 
1H NMR (DMSO-d6, 300 MHz): δ 7.0 - 7.4 (m, 12H, ar); 5.5 (s, 1H, CH-O); 4.0 (s, 
2H, CH2NH); 3.2-3.4 (m, 4H); 3.1(m, 2H); 1.2-1.7(m, 7H). HRMS (EI) calcd for 
C28H29F2NO4S m/z, 570.1737; found 570.1738. Anal. calcd for C28H28F2NO4S.2 
H2O: C, 55.53; H, 5.32; N, 2.31. Found: C, 55.71; H, 5.27; N, 2.31. 
 
7.3.1.4. 4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)-1-(4-(tributylstannyl)benzyl)piperidine (5) 
 
1.1 g (1.9 mmol) of 4 was dissolved in anhydrous dioxane (15 mL) and to the 
solution was added bis(tributyltin) (1.5 g, 2.5 mmol). Under argon, lithium chloride 
(0.2 g, 5.7 mmol), tetrakis(triphenylphosphine)palladium (0.7 g, 0.06 mmol) and a 
catalytic amount of 2,6-di(tert)-butyl-4-methylphenol were added. The solution was 
heated to reflux and stirred overnight. The reaction was quenched upon the 
addition of ethyl acetate (50 mL) and a 10 % aqueous NaOH solution (50 mL). 
The organic layer was filtered through a pad of celite. The filtrate was washed with 
H2O (50 mL) and brine (50 mL). The organic layer was dried over anhydrous 
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Na2SO4. Chromatography with 7:3 (v:v) - hexane:ethyl acetate as solvent system 
provided 0.46 g (0.6 mmol) of 5 as a chromatographically pure, clear oil. The 
reaction yield was 68 %.  
1H NMR (DMSO-d6, 300 MHz): δ 7.1 - 7.4 (m, 12H, ar); 5.5 (s, 1H, CH-O); 3.3-
3.4 (m, 8H); 0.8-1.5(m, 30H). HRMS (EI) calcd for C39H56F2NOSn m/z, 712.3352; 
found 710.3344. Anal. calcd for C39H55F2NOSn.0.5 H2O: C, 65.09; H, 7.84; N, 
1.95. Found: C, 64.83; H, 7.81; N, 1.95. 
 
7.3.1.5. 4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine (FMIP) 
 
To a solution of 1 (0.5 g, 1.4 mmol) and potassium carbonate (0.6 g, 4.2 mmol) in 
DMF (15 mL) was added a catalytic amount of NaI and 4-iodobenzyl bromide (0.5 
g, 1.5 mmol). The solution was stirred overnight. TLC analysis identified no 
remaining starting material and the solution was poured into H2O (200 mL) and 
extracted with ethyl acetate (3 x 100 mL). The combined extracts were washed 
with H2O (2 x 200 mL) and brine (200 mL). The organic layer was dried over 
anhydrous Na2SO4 and the solvent was removed under reduced pressure. The 
resulting oil was dissolved in EtOH (50 mL) and 1.1 equivalent of oxalic acid in 
EtOH was added. Upon cooling, crystals were formed and an additional 
recrystallization provided 0.4 g (0.7 mmol) of a FMIP oxalate as white solid. The 
reaction proceeded with a yield of 50 %. 
 1H NMR (DMSO-d6, 300 MHz): δ 7.1 - 7.8 (m, 12H, ar); 5.5 (s, 1H, CH-O); 4.0 
(bs, 2H, CH2NH); 3.1-3.5 (m, 4H); 2.5-2.7 (m, 3H); 1.2-1.8 (m, 6H). HRMS (ESI) 
calcd for C27H29IF2NO m/z, 548.1262; found 548.1264. Anal. calcd for 
C27H28IF2NO·C2H2O4: C, 54.64; H, 4.74; N, 2.20. Found: C, 54.37; H, 4.95; N, 
2.18. m.p. 157-158 °C. 
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7.3.2. RADIOCHEMISTRY 
 
[123I]-4-(2-(Bis(4-fluorophenyl)methoxy)ethyl)-1-(4-iodobenzyl)piperidine ([123I]-
FMIP) was prepared by electrophilic radioiododestannylation of 5. Briefly, EtOH 
(50 µL), glacial acetic acid (8 µL), chloramine-T (1.0 µmol, 300 µg in 15 µL 
deionized H2O) and n.c.a. [123I]NaI (37 MBq in 10 µL 0.05 M NaOH) were added 
to a reaction vial containing 5 (200 µg, 0.281 mmol). The mixture was allowed to 
react for 10 min at ambient temperature. The reaction was quenched by adding 
sodium metabisulfite (1.6 µmol, 300 µg in 15 µL deionized H2O). Purification was 
performed by HPLC on a Apollo C18 column (250 mm x 4.6 mm, 5 µm) using 
90:10:0.1 (v:v) - MeOH:H2O:NH4OH as solvent system at a flow rate of 1 
mL/min.  [123I]-FMIP eluted with a retention time of 24-25 min. The collected 
fraction was diluted with sterile water and concentrated on an activated C18 Sep-
pak cartridge (Alltech Maxi-Clean Prevail C18). [123I]-FMIP was eluted from the 
Sep-pak with 1 ml EtOH. Finally the EtOH was diluted with isotonic saline to 
obtain an injectable solution (< 10 % (v:v) EtOH). 
 
7.3.3. IN VITRO CHARACTERIZATION 
 
The radioanalytical data were obtained by injection of 100 µL test solution on a RP 
analytical HPLC (Alltima C18, 250 mm x 4.6 mm, 5 µm) using 91:9:0.1 (v:v) - 
MeOH:H2O:NH4OH as mobile phase at a 1 mL/min flow rate. 
Radiochemical purity and identity were determined by co-injection of an aliquot of 
[123I]-FMIP (after Sep-pak purification) with authentic cold reference product 
(FMIP).  
To test the in vitro stability, [123I]-FMIP was maintained in 0.01 M PBS (pH 7.4) and 
in the injection solution, at room temperature. After 24 h, [123I]-FMIP was 
analyzed by HPLC. 
For calculating specific activity, a calibration curve between 10 x 10-3 µM and 0.1 x 
10-3 µM and subsequently a more detailed calibration curve between 0.5 x 10-3 µM 
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and 0.1 x 10-3 µM was obtained. Log D7.4 was determined according to the method 
described in Chapter 4. 
 
7.3.4. BIODISTRIBUTION STUDY 
 
Male NMRI mice of 4 - 6 weeks old, weighing 22 - 30 g were injected in a tail vein 
with 200 µL 8:92 (v:v) - EtOH:physiological saline containing approximately 185 
kBq (5 µCi) of [123I]-FMIP. The mice were awake during the injection. At various 
time points p.i. mice (n=3 for each time point) were sacrificed under isoflurane 
anaesthesia and dissected. Blood, urine and organs were removed, weighed and 
counted for radioactivity in a gamma counter. To remove adhering blood, all 
organs were rinsed with water prior to weighing and counting. For calculation of 
the injected dose, five aliquots of the injection solution were weighed and counted 
for activity. Results are decay corrected and expressed as % ID/g ± SD. 
 
7.3.5. REGIONAL BRAIN DISTRIBUTION STUDY 
 
Male rats (250 - 300 g, Sprague-Dawley) were injected in a tail vein with 7.4 MBq 
(200 µCi) of [123I]-FMIP dissolved in 300 µL 8:92 (v:v) – EtOH:physiological 
saline. The rats were awake during the injection. At 10, 30, 60, 180 or 360 min, 
animals (n=3 for each time point) were sacrificed by i.v. injection of T61. Blood 
was taken and the brain was removed and dissected. Blood samples and the 
different brain parts were weighed and counted for radioactivity with a gamma 
counter. For calculation of the injected dose, five aliquots of the injection solution 
were weighed and counted for activity. Results are decay corrected and are 
expressed as % ID/g ± SD. 
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7.3.6. BLOCKING STUDY 
 
To determine the specific tissue uptake of the labelled compound, blocking studies 
were performed in male NMRI mice of 4 - 6 weeks old, weighing approximately 25 
g. Prior to tracer injection, mice received a tail vein injection of 150 µl (95:5 – 
physiological saline:EtOH) containing a selective ligand (5 mg/kg) for respectively 
the DAT (GBR 12909), SERT (citalopram) or NET (reboxetine mesylate). The 
control group received a tail vein injection of 150 µl (95:5 – physiological 
saline:EtOH) without ligand. After 20 min, the mice were injected with 
approximately 185 kBq (5 µCi) of [123I]-FMIP dissolved in 100 µl 
EtOH:physiological saline solution (8:92). The mice were awake during the 
injections. The animals (n=3 for each time point) were sacrificed at 2, 5, 60 or 180 
min p.i. All tissues were treated as previously described. For calculation of the 
injected dose, five aliquots of the injection solution were weighed and counted for 
activity. The concentration of radioactivity in tissues is decay-corrected and 
expressed as % ID/g ± SD. Statistical analysis was performed using one-sided, 
unpaired student’s t-test. Only p-values < 0.05 are considered significant. 
 
7.3.7. PLASMA BINDING 
 
Plasma protein binding was determined according to literature procedures 
(Gandelman et al., 1994; Fowler et al., 2007). In brief, a known amount of 
radiotracer (37 kBq (1 µCi)) was added to 500 µL mouse plasma and the mixture 
was incubated for 10 min at room temperature. Three aliquots (30 µL) of spiked 
plasma were counted for radioactivity. The remaining plasma was transferred onto 
a Centrifree device with a nominal molecular weight limit of 30 kDa (Amicon inc, 
Millipore) and centrifuged for 15 min at 4000 g. The top part of the Centrifree 
tube was discarded, and 3 aliquots (30 µL) of the solution remaining in the bottom 
cup (unbound fraction) were counted for radioactivity. The plasma protein binding 
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was determined by calculating the free fraction as the ratio of the counts of filtered 
aliquot to the counts of non-centrifuged aliquot. 
 
7.3.8. METABOLITE ANALYSIS 
 
200 µL 92:8 (v:v) - Isotonic saline:EtOH containing 1.85 - 3.7 MBq (50 – 100 µCi) 
[123I]-FMIP was injected in a tail vein of awake male NMRI mice (5 - 7 weeks old, 
weighing 25 - 30 g). At 10 or 60 min p.i., the mice (n=3 for each time point) were 
sacrificed and blood and brain were taken and treated as described in Chapter 4. 
HPLC analysis was performed using a RP C18 HPLC column (Econosphere C18 
250 mm x 10 mm, 10 µm) attached to a precolumn (Alltima C18 33 mm x 7 mm, 10 
µm) with 91:9:0.1 (v:v) methanol:H2O:NH4OH as solvent system at a flow rate of 
6 mL/min.  
 
7.3.9. BLOOD-BRAIN BARRIER TRANSPORT INHIBITION STUDY 
 
To investigate if the low brain uptake of [123I]-FMIP is due to P-gp interference, a 
biodistribution study with pretreatment of the mice with CsA was performed. A 50 
mg/kg dose and a 30 min time period between CsA and tracer injection has been 
reported to inhibit the efflux action of P-gp pumps in rodent brain (Ishiwata et al., 
2007). Male NMRI mice with a body mass of approximately 25 g (n=3 for each 
time point) were i.v. injected with either 50 mg/kg CsA (test group) or the same 
volume of physiological saline (control group). After 30 min, [123I]-FMIP (185 kBq 
(5 µCi), 150 µL) was injected via a tail vein. The mice were awake during the 
injections. The mice were sacrificed and dissected at 2, 60 or 180 min p.i. of [123I]-
FMIP. Blood and organs were weighed and counted for radioactivity. TO remove 
adhering blood, all organs were rinsed with water prior to weighing and counting. 
For calculation of the injected dose, five aliquots of the injection solution were 
weighed and counted for activity. Results are decay-corrected and expressed as % 
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ID/g ± SD. Statistical analysis was performed using one-sided, unpaired student’s 
t-test. Only p-values < 0.05 are considered significant. 
 
7.3.10. REGIONAL BRAIN DISTRIBUTION AFTER CSA PRETREAMENT 
 
Male rats (250 - 300 g, Sprague-Dawley) were injected in a tail vein with 7.4 MBq 
(200 µCi) of [123I]-FMIP dissolved in 300 µL 8:92 (v:v) – EtOH:physiological 
saline. 30 min prior to tracer injection, a solution of 50 mg/kg CsA (test group) or 
physiological saline (control group) was administered intravenously. At 30, 60, 180 
and 360 min after [123I]-FMIP injection, animals (n=3 for each time point) were 
sacrificed by intravenous injection of T61. Blood was taken and the brain was 
removed and dissected. Blood samples and the different brain parts were weighed 
and counted for radioactivity with a gamma counter. For calculation of the injected 
dose, five aliquots of the injection solution were weighed and counted for activity. 
Radioactivity is decay corrected and results are expressed as % ID/g ± SD. 
Statistical analyses were performed using the one-side unpaired student’s t test. A 
p-value < 0.05 is interpreted as statistically significant. 
 
7.4. Results & Discussion 
 
7.4.1. ORGANIC SYNTHESIS 
 
As mentioned in Chapter 4, iodination can be accomplished by electrophilic as well 
as nucleophilic substitution. Several attempts to produce [123I]-FMIP by 
nucleophilic substitution failed due to the unefficient radiochemical yield. In order 
to radiosynthesize [123I]-FMIP by elctrophilic substitution, the synthesis of the 
tributylstannyl precursor was necessary.  
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7.4.1.1. Precursor synthesis 
 
The precursor molecule was synthesized in four steps as is depicted in Figure 7.3. 
The starting material 1 was prepared by Boos et al. (2006).  
 
 
Figure 7.3 Synthesis of the tributylstannylprecursor 5 
Reagents: (a) 4-hydroxybenzoic acid, N-hydroxybenzotriazole, 1-ethyl-3-(3'-
dimethylaminopropyl)carbodiimide, CH2Cl2; (b) lithiumaluminiumhydride, sulphuric acid, 
THF; (c) N-phenyltriflouromethanesulfonimide, N,N-diisopropylethylamine, CH2Cl2; (d) 
bis(tributyltin), tetrakis(triphenylphosphine)palladium, lithium chloride, dioxane 
 
The most direct route to the tributylstannyl precursor is generally a palladium 
catalyzed stannylation using hexabutyldistannane and tetrakis(triphenylphosphine)-
palladium where a bromine-atom is replaced by a tributylstannyl group. Several 
attempts to synthesize 5 by this route were unsuccessful, requiring another route. 
It was found that the triflate analogue was a suitable substrate for the Stille 
coupling. In this way, the tributylstannyl precursor 5 was synthesized starting from 
1 through the triflate intermediate in an overall yield of 25 %. First, the secondary 
cyclic amine 1 was coupled with 4-hydroxybenzoic acid, resulting in 2 which was 
used without further purification. Reduction of 2 yielded the tertiary amine 3 (89 
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%). The hydroxyl function of 3 was converted into the triflate (87 %), making it a 
better leaving group. Finally, the precursor molecule was obtained by replacing the 
triflate by tributylstannyl using bis(tributylstannane) (68 %). 
 
7.4.1.2. Synthesis of FMIP 
 
Nucleophilic substitution of 1 yielded the cold iodinated product FMIP in a yield 
of 50 % (Figure 7.4). FMIP is required as reference compound in HPLC analysis. 
 
 
Figure 7.4 Synthesis of 4-(2-(bis(4-fluorophenyl)methoxy)ethyl)-1-(4-
iodobenzyl)piperidine 
 
7.4.2. RADIOSYNTHESIS 
 
[123I]-FMIP was obtained in a radiochemical yield of 40 ± 10 % by electrophilic 
iododestannylation of the tributylstannyl precursor 5 (Figure 7.5).  
 
 
Figure 7.5 Radiosynthesis of [123I]-FMIP 
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7.4.3. IN VITRO CHARACTERIZATION 
 
The radiolabelled compound [123I]-FMIP was co-injected with the cold compound.  
Similar retention times were observed for [123I]-FMIP and FMIP, confirming the 
identity of the synthesized product (Figure 7.6). The average radiochemical purity 
of [123I]-FMIP was found to be > 98 %. After 24 h, the radiochemical purity of 
[123I]-FMIP remained higher than 95 % both in PBS buffer and in the injection 
solution.  
 
Figure 7.6 HPLC chromatogram of [123I]-FMIP and FMIP co-injection 
The upper part of the figure shows the UV-chromatogram, the radiochromatogram is 
shown in the lower part. 
 
Since no UV-signal was observed for the amount of [123I]-FMIP synthesized, the 
detection limit was used for calculation of the specific activity. Using the described 
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radioanalytical method, the detection limit for [123I]-FMIP was 1.5 x 10-6 M. 
Specific activity appeared to be at least 667 GBq/µmol (18 Ci/µmol). 
 
An ideal log D7.4 value for brain radiotracers is between 1.5 and 3.5 (Waterhouse, 
2003). The determined log octanol/PBS partition coefficient was found to be 1.42 
± 0.12, which is suitable for brain penetration. 
 
7.4.4. BIODISTRIBUTION STUDY 
 
Results of the biodistribution study are shown in Table 7.1. Radioactivity 
concentrations for [123I]-FMIP in blood and brain of NMRI mice are shown in 
Figure 7.7. Uptake of the tracer in mouse brain was demonstrated with a maximum 
value of 0.96 ± 0.53 % ID/g in brain at 0.5 min p.i. The tracer was rapidly cleared 
out of the blood. At all time points, blood activity remained higher than brain 
activity.  
 
Figure 7.7 Blood-brain distribution of [123I]-FMIP in male NMRI mice  
Values are expressed as % ID/g ± SD (n=3) 
 
Other organs with high tracer uptake were heart (11.14 ± 3.79 % ID/g at 0.5 min 
p.i.) and lungs (43.27 ± 15.46 % ID/g at 0.5 min p.i.). The heart and lungs are the 
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first organs that are passed by the blood flow after intravenous injection of the 
radiotracer in the blood. The radioactivity uptake in these organs is therefore 
probably a reflection of the blood pool radioactivity. Since radioactivity uptake in 
stomach is low (1.33 ± 0.55 % ID/g at 0.5 min p.i.) and does not change between 
the various time points (1.06 ± 0.08 % ID/g at 180 min p.i.), [123I]-FMIP is 
probably not sensitive to dehalogenation in vivo. 
High uptake was seen in liver (11.43 ± 4.53 % ID/g at 20 min p.i.), kidneys (4.91 
± 2.14 %ID/g at 0.5 min p.i.) and urine (data not shown) and uptake in the 
intestines was low, suggesting mainly urinary and no biliary clearance of [123I]-
FMIP during the investigated timeframe. 
 
 
 
   
Table 7.1 Tissue uptake of radioactivity in male NMRI mice at various time points following i.v. administration [123I]-FMIP 
Time (min) 
 0.5 1 2 3 5 10 20 40 60 120 180 300 
Blood 11.14 ± 2.28 8.95 ± 3.97 3.02 ± 0.96 1.73 ± 0.65 1.01± 0.35 0.99 ± 0.45 0.67 ± 0.24 0.50 ± 0.11 0.30 ± 0.11 0.31 ± 0.01 0.37 ± 0.02 0.22 ± 0.05 
Brain 0.96 ± 0.53 0.41± 0.11 0.26± 0.08 0.21 ± 0.07 0.14 ± 0.02 0.23 ±0.07 0.22 ±0.07 0.21 ± 0.04 0.13 ±0.04 0.20 ± 0.06 0.26 ± 0.02 0.16 ± 0.06 
Heart 11.14 ± 3.79 5.48 ± 1.29 4.91± 0.59 4.54 ± 2.12 3.20 ±1.22 5.01 ±1.36 4.24 ±1.01 2.35 ± 0.72 1.15 ±0.36 0.96 ± 0.23 1.06 ± 0.14 0.71 ± 0.23 
Lungs 43.27 ± 15.46 20.03 ± 1.3 14.32 ± 1.54 17.51 ± 8.73 11.80 ± 3.42 13.37 ± 6.75 9.12 ±7.17 5.70 ±1.44 3.87 ±1.35 3.66 ± 1.13 3.73 ± 0.51 2.23 ± 1.03 
Stomach 1.33 ± 0.55 0.81± 0.17 0.83 ± 0.25 1.11 ± 0.47 0.50 ± 0.12 0.94 ± 0.29 0.85 ± 0.02 1.65 ± 1.15 0.61 ± 0.28 0.67 ± 0.27 1.06 ± 0.08 0.88 ± 0.52 
Spleen 3.23 ± 1.45 2.42 ± 0.56 3.85 ± 1.78 6.34 ± 3.87 4.23 ± 1.43 6.61 ± 0.69 5.99 ± 1.36 3.84 ± 1.66 1.85 ± 0.82 2.08 ± 0.5 2.46 ± 0.84 1.77 ± 0.74 
Liver 4.91 ± 2.97 3.53 ± 0.86 5.04 ± 1.06 5.17 ± 2.04 3.99 ± 1.17 9.03 ± 1.8 11.43 ± 4.53 10.09 ± 2.76 8.10 ± 4.27 10.30 ± 3.02 14.20 ± 4.35 8.70 ± 4.28 
Kidneys 4.91 ± 2.14 3.67± 0.85 3.61 ± 1.05 3.97 ± 1.91 2.76 ± 0.87 4.65 ± 0.3 4.46 ± 1.04 3.55 ± 1.11 2.53 ± 1.35 2.88 ± 0.79 3.00 ± 0.86 2.09 ± 0.86 
Small 
intestine 0.68 ± 0.28 0.49± 0.06 0.53 ± 0.2 0.65 ± 0.21 0.35 ± 0.06 0.74 ± 0.12 0.71 ± 0.21 0.69 ± 0.03 0.48 ± 0.24 0.80 ± 0.15 1.20 ± 0.13 0.91 ± 0.49 
Large 
intestine 0.37 ± 0.16 0.25± 0.03 0.24 ± 0.07 0.29 ± 0.12 0.16 ± 0.05 0.38 ± 0.11 0.28 ± 0.11 0.31 ± 0.06 0.20 ± 0.09 0.36 ± 0.11 0.63 ± 0.22 0.69 ± 0.28 
Bladder 1.25 ± 0.65 0.73± 0.08 0.64 ± 0.1 0.68 ± 0.28 0.63 ± 0.28 0.82 ± 0.15 0.85 ± 0.04 1.01 ± 0.32 0.95 ± 0.34 1.34 ± 0.73 1.64 ± 0.54 0.93 ± 0.15 
Pancreas 1.54 ± 055 1.05± 0.25 1.08 ± 0.21 1.45 ± 0.96 0.1 ± 0.98 1.54 ± 0.18 1.5 ± 0.33 1.19 ± 0.73 1.05 ± 0.42 1.68 ± 0.28 2.4 ± 0.34 2.54 ± 1.14 
Muscle 0.91 ± 0.28 0.57± 0.13 0.75 ± 0.09 0.84 ± 0.15 0.66 ± 0.19 1.30 ± 0.58 0.88 ± 0.07 0.88 ± 0.21 0.61 ± 0.26 0.65 ± 0.17 0.75 ± 0.03 0.38 ± 0.11 
Fat 0.93 ± 0.15 0.85± 0.62 0.85 ± 0.34 4.27 ± 5.57 0.72 ± 0.43 0.81 ± 0.38 0.76 ± 0.27 1.12 ± 0.77 1.10 ± 0.56 1.25 ± 0.11 2.03 ± 0.34 0.93 ± 0.51 
Values are expressed as % ID/g of tissue ± SD (n=3) 
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7.4.5. REGIONAL BRAIN DISTRIBUTION STUDY 
 
The uptake of radioactivity in various rat brain regions as a function of time 
following intravenous administration of [123I]-FMIP is shown in Table 7.2.  
 
Table 7.2 Tissue uptake of radioactivity in different brain regions in rats at various 
time points following i.v. administration of [123I]-FMIP 
                                Time (min) 
 10 30 60 180 360 
Blood 0.086 ± 0.060 0.089 ± 0.097 0.123 ± 0.084 0.116 ± 0.049 0.087 ± 0.094 
Striatum 0.022 ± 0.016 0.013 ± 0.012 0.036 ± 0.031 0.053 ± 0.038 0.016 ± 0.012 
Cerebellum 0.013 ± 0.007 0.024 ± 0.019 0.042 ± 0.051 0.029 ± 0.025 0.026 ± 0.012 
Frontal cortex 0.013 ± 0.008 0.009 ± 0.011 0.036 ± 0.041 0.027 ± 0.035 0.015 ± 0.011 
Occipital cortex 0.018 ± 0.009 0.027 ± 0.033 0.043 ± 0.063 0.015 ± 0.007 0.018 ± 0.016 
Temporal 
cortex 
0.015 ± 0.008 0.010 ± 0.013 0.017 ± 0.013 0.019 ± 0.012 0.021 ± 0.025 
Parietal cortex 0.015 ± 0.010 0.019 ± 0.024 0.037 ± 0.039 0.026 ± 0.028 0.010 ± 0.007 
Hippocampus 0.015 ± 0.008 0.077 ± 0.065 0.007 ± 0.008 0.049 ± 0.058 0.027 ± 0.018 
Hypothalamus 0.014 ± 0.006 0.023 ± 0.026 0.030 ± 0.020 0.027 ± 0.013 0.010 ± 0.011 
Thalamus 0.003 ± 0.003 0.015 ± 0.013 0.016 ± 0.021 0.026 ± 0.006 0.013 ± 0.012 
Pons & medulla 0.022 ± 0.011 0.023 ± 0.019 0.064 ± 0.050 0.073 ± 0.055 0.038 ± 0.032 
Total brain 0.017 ± 0.010 0.020 ± 0.010 0.042 ± 0.035 0.052 ± 0.036 0.032 ± 0.026 
Values are expressed as % ID/g of tissue ± SD (n=3) 
 
In the brain, DAT is predominantly localized in the striatum. The cerebellum 
seems to receive negligible dopaminergic innervation (Kaufman et al., 1991; Ciliax 
et al., 1995). The regional distribution of [123I]-FMIP in the rat brain was almost 
homogenous, which is not consistent with this current knowledge of DAT 
localization. The uptake in the striatum was not higher compared to the uptake in 
the other brain regions. No difference in radioactivity uptake was observed 
between the striatum (0.053 ± 0.038 % ID/g at 180 min p.i.) and the reference 
region (cerebellum (0.029 ± 0.025 % ID/g at 180 min p.i.)) suggesting that no 
specific binding of [123I]-FMIP to DAT is accomplished.  
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7.4.6. BLOCKING STUDY 
 
The inability to show specific binding in the striatum could be due to the overall 
low brain uptake. This leads to high relative standard errors that could possibly 
influence the outcome of the study. DAT is not only present in the brain but is 
also found in several peripheral organs. Therefore, the specificity for DAT 
peripherally should also be investigated. For these reasons a blocking study with 
selective ligands for the monoamine transporters was performed in mice.  
Results of the blocking study on the blood and brain uptake of [123I]-FMIP are 
shown in Table 7.3. No differences in radioactivity uptake are observed between 
the four treatment regiments at none of the selected time points.  
 
Table 7.3 Tissue uptake of radioactivity of [123I]-FMIP after injection of 
physiological saline (control), GBR 12909 (A), citalopram (B) or reboxetine 
mesylate (C) 
                                         Time (min) 
  2 5 60 180 
Control group Blood 1.35 ± 0.42 0.77 ± 0.32 0.28 ± 0.20 0.54 ± 0.37 
 Brain 0.11 ± 0.04 0.11 ± 0.05 0.08 ± 0.04 0.13 ± 0.08 
      
Test group A Blood 1.30 ± 0.63 0.45 ± 0.03 0.40 ± 0.23 0.21 ± 0.03 
 Brain 0.13 ± 0.03 0.07 ± 0.03 0.11 ± 0.02 0.11 ± 0.04 
      
Test group B Blood 0.90 ± 0.31 0.44 ± 0.20 0.10 ± 0.04 0.12 ± 0.04 
 Brain 0.13 ± 0.07 0.16 ± 0.05 0.09 ± 0.03 0.15 ± 0.09 
      
Test group C Blood 1.55 ± 1.00 0.63 ± 0.37 0.17 ± 0.08 0.11 ± 0.04 
 Brain 0.22 ± 0.14 0.12 ± 0.05 0.11 ± 0.05 0.09 ± 0.05 
Values are expressed as % ID/g of tissue ± SD (n=3) 
 
Outside the central nervous system, localization of DAT is found in the 
gastrointestinal tract, stomach, pancreas (Mezey et al., 1999) and kidneys (Lee, 
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1993). Therefore uptake of [123I]-FMIP in peripheral organs was also measured 
(data not shown) and no influence of pretreatment with GBR 12909, citalopram or 
reboxetine mesylate could be demonstrated. These results suggest that no specific 
binding of [123I]-FMIP to DAT is accomplished.  
 
7.4.7. PLASMA PROTEIN BINDING AND METABOLITE ANALYSIS  
 
Determination of plasma protein binding revealed that 96 ± 2 % of [123I]-FMIP 
was bound to plasma proteins. Control experiments with spiked plasma and brain 
revealed an extraction efficiency of 76 ± 4 % for plasma and 82 ± 7 % for brain 
samples. These extraction efficiencies indicate that the binding of [123I]-FMIP to 
plasma proteins is reversible. HPLC analysis of the spiked samples showed that all 
extracted radioactivity complies with [123I]-FMIP, so no degradation of [123I]-FMIP 
occurred during the extraction procedure.  
 
Metabolite analysis of plasma demonstrated that at 10 min p.i. 70 ± 4 % and at 60 
min p.i. 55 ± 5 % of intact [123I]-FMIP is remaining (Figure 7.8). [123I]-FMIP eluted 
at 18.5 min. Degradation products in plasma were iodide-123 (17 ± 11 % at 10 min 
p.i. and 37 ± 2 % at 60 min p.i.) and a lipophilic compound with a retention time 
of 15.5 min that eluted just before the parent compound (12 ± 7 % at 10 min p.i. 
and 8 ± 6 % at 60 min p.i.). This compound will probably have a structure close to 
the parent compound and is most likely caused by a hydroxylation on a phenyl 
group or defluorination of the phenyl ring. 
In the brain, percentages of intact [123I]-FMIP were 82 ± 11 % at 10 min p.i. and 
83 ± 7 % at 60 min p.i. (Figure 7.8). The detected metabolites were iodide-123 (9 
± 3 % at 10 min p.i. and 13 ± 3 % at 60 min p.i.) and another hydrophilic 
degradation product with a retention time of 5 min (10 ± 8 % at 10 min p.i. and 4 
± 5 % at 60 min p.i.). This metabolite is possibly the result of N-dealkylation. 
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Figure 7.8 Metabolite analysis at 10 min p.i. (above) and 60 min p.i. (below) of 
brain and plasma samples from mice 
Values are the mean of three experiments and are expressed as percent of total activity 
 
These values indicate that the tracer shows a relative good in vivo metabolic profile. 
Radioactivity in brain was mainly (> 80 %) present as intact [123I]-FMIP at the two 
time points. Besides the presence of free iodide, only 1 metabolite was found in 
plasma and another, more hydrophilic one in brain. 
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7.4.8. BLOOD-BRAIN BARRIER TRANSPORT INHIBITION STUDY 
     
P-gp is an efflux pump for a wide range of xenobiotics at the BBB. Hence, P-gp 
can be a severe obstacle for the accumulation of drugs into the brain. The efflux 
action of P-gp pumps can be reduced by so-called modulators of which CsA is an 
example.  
 
Table 7.4 Blood-brain distribution of [123I]-FMIP  
               Control groupa                   Test groupb 
 2 min 60 min 180 min 2 min 60 min 180 min 
Blood 1.35 ± 0.42 0.28 ± 0.20 0.54 ± 0.37 2.7 ± 1.15 0.39 ± 0.29 0.50 ± 0.24 
Brain 0.11 ± 0.04 0.08 ± 0.04 0.13 ± 0.08 0.45 ± 0.14 0.42 ± 0.13 0.70 ± 0.25 
Brain/Blood 0.08 ± 0.01 0.35 ± 0.16 0.33 ± 0.18 0.18 ± 0.06 1.32 ± 0.47 1.48 ± 0.27 
a pretreatment with physiological saline  
b 
Values are expressed as % ID/g ± SD (n=3). Values in bold: p < 0.05 (Student’s t test, 
one-sided, compared with control) 
pretreatment with CsA 
 
Pretreatment of mice with CsA indicated a significantly higher brain uptake 
compared to the control group (p = 0.02 at all time points). Blood values were not 
affected by CsA pretreatment (p = 0.09 at 2 min p.i.; p = 0.32 at 1 h p.i.; p = 0.45 
at 3 h p.i.). CsA treatment increased both the brain uptake (4.2 – 5.1 – 5.2 fold) 
and subsequently the brain-to-blood ratio. These findings are a possible 
explanation for the low brain accumulation of [123I]-FMIP. Further research to 
validate the usefulness of [123I]-FMIP as a SPECT tracer for P-gp pumps in vivo is 
reported in Chapter 8. 
 
7.4.9. REGIONAL BRAIN DISTRIBUTION AFTER CSA 
PRETREATMENT 
 
We wanted to investigate if CsA also raises brain radioactivity in rats and if this 
increased brain uptake is homogenous or limited to DAT rich regions. If the 
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increased brain radioactivity is homogenous, it will be pointed out that [123I]-FMIP 
is not selective towards DAT in vivo.  
CsA administration resulted in a significantly higher brain uptake at 30 min (p = 
0.036), 180 min (p = 0.003) and 360 min (p = 0.014) p.i. compared to control 
group. At 60 min p.i. an increase in brain uptake was also observed although this 
increase was not significant. Blood activity was not affected by pretreatment with 
CsA. Unfortunately, the increased brain radioactivity was homogenous and not 
restricted to DAT rich regions (Figure 7.9). Radioactivity uptake increased in both 
striatum and cerebellum. These findings direct us to conclude that the non-ability 
to prove DAT selectivity in brain was not due to the low brain uptake of [123I]-
FMIP but due to its lack of selectivity towards DAT in brain. 
 
Figure 7.9 Tissue uptake of [123I]-FMIP with CsA or physiological saline 
pretreatment  
Values are expressed as % ID/g ±SD (n=3) 
 
7.5. Conclusion 
 
The preparation and purification of the precursor molecule, as well as the 
reference compound were accomplished with sufficient yields and without any 
significant problems. The radiosynthesis of [123I]-FMIP was achieved by 
electrophilic destannylation. Using a one-pot synthetic procedure, [123I]-FMIP was 
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prepared in a 40 ± 10 % yield and with good specific activity. After purification, 
the radiochemical purity appeared to be higher than 98 %. The authenticity of the 
tracer was determined by co-elution with the nonradioactive reference compound. 
In vitro, [123I]-FMIP remained stable for at least 24 h. The determined log D7.4 was 
1.42 ± 0.12 %, which is suitable for brain penetration. 
Upon intravenous administration, low levels of activity were observed in mouse 
brain indicating low blood-brain penetration of [123I]-FMIP. At none of the 
selected time points, radioactivity concentration in the brain exceeded blood 
activity. A possible reason for the low brain uptake of [123I]-FMIP is the 
contribution of P-gp pumps or other multidrug resistance protein transporters in 
the brain distribution of [123I]-FMIP. A significant increase in brain uptake (4.2 – 
5.2 fold) of [123I]-FMIP was observed after CsA administration compared to the 
control group indicating [123I]-FMIP is transported by the P-gp pumps out of the 
brain. The effect of P-gp modulation on the biodistribution of [123I]-FMIP will be 
further explored and reported in Chapter 8.  In rat brain, the regional distribution 
of DAT was not reflected in the radioactivity distribution. A blocking study also 
failed to proof selectivity of [123I]-FMIP towards DAT. Even more, [123I]-FMIP did 
not display selectivity towards one of the monoamine transporters.  
 
Although FMIP is selective for DAT in vitro, it did not display the expected 
selective distribution in vivo in brain neither peripheral. A possible reason can be 
the selectivity of FMIP towards other receptors. In vitro, FMIP was only tested for 
its affinity to the monoamine transporters. Sigma receptors are a class of receptors 
distributed uniformly in the brain (Bouchard P and Quirion R, 1997). This 
distribution is in accordance with the observed homogenous brain uptake. A 
blocking study with selective inhibitors for this class of receptors should be 
performed to proof this assumption. Based on these results, one can conclude that 
[123I]-FMIP is not suitable as radioligand for in vivo SPECT visualization of DAT.  
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Chapter 8 
 
In vivo evaluation of [123I]-FMIP for imaging the  
P-glycoprotein transporter 
 
8.1. Abstract 
 
Aim: P-gp is an energy-dependent drug efflux transporter that contributes to the 
efflux of a wide range of xenobiotics at the BBB playing a role in drug-resistance 
or therapy failure. In this study, we evaluated [123I]-FMIP as a novel SPECT 
tracer for imaging of P-gp at the brain in vivo. 
Methods: The tissue distribution and brain uptake as well as the metabolic profile 
of [123I]-FMIP in wild-type and mdr1a (-/-) mice after pretreatment with 
physiological saline or CsA (50 mg/kg) was investigated. The influence of 
increasing doses CsA on brain uptake of [123I]-FMIP was explored. µSPECT 
images of mice brain were obtained for different treatment strategies.  
Results: Modulation of P-gp with CsA as well as mdr1a gene depletion results in a 
significant increase in cerebral uptake of [123I]-FMIP with only a minor effect on 
blood activity. [123I]-FMIP is quite stable in vivo with > 80 % intact [123I]-FMIP in 
brain at 60 min p.i. in the different treatment regiments. A dose-dependent 
sigmoidal increase in brain uptake of [123I]-FMIP with increasing doses of CsA 
was observed. In vivo ROI-based SPECT measurements correlated well with the 
observations of the biodistribution studies.  
Conclusion: These findings indicate that [123I]-FMIP is an effective SPECT tracer 
for imaging P-gp at the BBB.  
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8.2. Introduction 
 
P-gp is an energy-dependent drug efflux transporter that contributes to the efflux 
of a wide range of xenobiotics at the BBB. Hence, P-gp can play a major role in 
drug-resistance or therapy failure (Schinkel et al., 1996; Linnet and Ejsing, 2008). 
Apart from its role in the central nervous system, P-gp is overexpressed in 
tumors and therefore implicated in the resistance to chemotherapeutics and in the 
pathogenesis of cancer (Gottesman and Pastan, 1993; Gottesman et al., 2002). 
Imaging of P-gp function and expression with PET or SPECT could be of great 
importance in drug development and medicine. Non-invasive monitoring of P-gp 
could be applied to elucidate the role of P-gp in several human diseases and to 
evaluate the efficacy of new P-gp modulators. Several PET tracers have already 
been evaluated for P-gp modulation among which [11C]verapamil (Hendrikse et 
al., 1998; Lee et al., 2006) and [11C]N-desmethyl-loperamide (Lazarova et al., 
2008). The only reported SPECT radioligands for P-gp are [99mTc]sestamibi 
(Kostakoglu et al., 1997; Ballinger et at., 1995) and [99mTc]tetrofosmin (Ballinger 
et al., 1996). However, [99mTc]sestamibi and [99mTc]tetrofosmin are not only 
substrates for P-gp but are also involved in efflux mediated by multidrug 
resistance-associated protein and are not suitable for P-gp imaging in the brain 
(Hendrikse et al., 1997; Barbarics et al., 1998; Ballinger et al., 1996). To date, no 
iodinated SPECT ligands for P-gp functionality imaging have been published.  
This study describes the in vivo evaluation of [123I]-FMIP, a possible P-gp tracer. 
[123I]-FMIP was originally designed as a tracer for the dopamine transporter but 
did not display the anticipated in vivo behaviour. Brain uptake was only minor 
which lead to the hypothesis that [123I]-FMIP might be a substrate for the P-gp 
transporter (Chapter 7). Therefore we investigated the influence of P-gp blocking 
with CsA as well as the influence of gene depletion on the biodistribution and 
brain penetration of [123I]-FMIP. A dose-response study is performed to assess 
the impact of increasing CsA dose on the brain uptake of [123I]-FMIP. The 
influence of CsA pretreatment and mdr1a gene depletion on the metabolism of 
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[123I]-FMIP is investigated. Finally, a multipinhole µSPECT study of the brain 
uptake of [123I]-FMIP is performed using the Milabs U-SPECT-II in wild-type 
mice (with and without CsA administration) and in P-gp knock-out mice (mdr1a 
(-/-) mice).  
 
8.3. Materials & Methods 
 
8.3.1. BIODISTRIBUTION STUDIES IN MICE 
 
The biodistribution of [123I]-FMIP was studied in male wild-type (=FVB) mice 
and mdr1a (-/-) mice of 5 – 7 weeks weighing 20 – 25 g. Wild-type mice and 
mdr1a (-/-) mice were divided into two groups. One group received an injection 
of CsA in a 50 mg/kg dose. The second group received the same volume 
physiological saline as control. After 30 min, approximately 185 kBq (5 µCi) [123I]-
FMIP was injected intravenously and mice (n=3 for each group and each time 
point) were sacrificed at 1, 10, 30, 60 or 180 min after [123I]-FMIP injection. 
Organs and tissues were removed and weighed. To remove adhering blood, all 
organs were rinsed with water prior to weighing and counting. For calculation of 
the injected dose, five aliquots of the injection solution were weighed and 
counted for activity. The radioactivity was measured using an automated gamma-
counter. Radioactivity concentrations were decay-corrected and results are 
expressed as % ID/g ± SD. Statistical analysis was performed using a one-sided, 
unpaired student’s t-test. Only p values < 0.05 are considered significant. 
 
8.3.2. DOSE ESCALATION STUDY 
 
Adult male NMRI mice weighing 22 – 28 g were injected in a tail vein with 
increasing amounts of CsA. The dosages used were 10, 20, 25, 30, 40, 50 and 60 
mg/kg. Due to the toxicity of CsA, higher doses CsA are not recommended. Side 
effects that can occur are nephrotoxicity, pancreatitis, liver toxicity, 
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gastrointestinal tract dysfunctions and edemia. These undesired effects of CsA 
were not problematic since CsA was administrated just before the radiotracer and 
the animals were terminated afterwards.  
[123I]-FMIP (185 kBq (5 µCi)) was administrated intravenously 30 min after CsA 
injection. The mice were awake during the injections. The mice (n=3 for each 
dosage) were sacrificed at 40 min p.i. of [123I]-FMIP. Three control animals 
receiving physiological saline were subjected to the same protocol. Blood and 
organs were removed, weighed and counted for radioactivity in an automated 
gamma counter. All organs were rinsed with water prior to weighing and 
counting. For calculation of the injected dose, five aliquots of the injection 
solution were weighed and counted for activity. Decay-corrected results are 
expressed as % ID/g ± SD. 
Using Graphpad, a dose-response curve was fitted by a sigmoidal curve that is 
described by the four parameter logistic equation:  
y = y0 + (ymax -  y0) / (1 + 10 ((log EC50-x)*n)) 
y is the response, x is the logarithm of concentration, EC50 the half-maximum 
effect dose and n the Hill coefficient.  
 
8.3.3. METABOLITE ANALYSIS 
 
The metabolic pattern of [123I]-FMIP and the influence of CsA pretreatment, as 
well as the influence of depletion of the mdr1a gene were investigated. 
Male FVB (wild-type) or mdr1a (-/-) mice (approximately 6 weeks old and 25 g) 
were injected with CsA (50 mg/kg) or physiological saline 30 min prior to the 
administration of 1.85 – 3.7 MBq (50 – 100 µCi) [123I]-FMIP. The mice were 
awake during the injections. At 10 min (n=3) and 60 min (n=3) p.i., the mice were 
sacrificed and blood and brain were removed and processed as described in 
Chapter 4. HPLC analysis was performed on a RP C18 HPLC column (Alltima 
C18 250 mm × 10 mm, 10 µm) using 91:9:0.1 (v:v) MeOH:H2O:NH4OH as 
solvent system at a flow rate of 6 mL/min.  
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8.3.4. U-SPECT SCAN 
 
Mice were divided into three groups (n=3 for each group). The first group, test 
group A, was injected with 50 mg/kg CsA 30 min before tracer injection, whereas 
the control group and test group B received physiological saline instead of CsA. 
In test group A and the control group, wild-type (FVB) mice were used. Test 
group B on the other hand, consisted of mdr1a (-/-) mice.  
Dynamic scanning in 12 frames of 5 minutes was performed at 30 min p.i. of 
[123I]-FMIP using the Milabs U-SPECT-II (Milabs, Utrecht, The Netherlands). 
This µSPECT scanner is equipped with collimators consisting of a tungsten 
cylinder with 5 rings of 15 pinhole apertures of 0.6 mm diameter. All pinholes 
focused on a single volume in the center of the tube. For imaging mice brain, the 
animal bed was translated in 3 dimensions using an XYZ stage into 12 different 
bed positions. This aforementioned combination enabled a multiple-position 
acquisition and dynamic imaging at a time scale of a few minutes. Mice were 
injected with 11.1 MBq (0.3 mCi) [123I]-FMIP and anesthetized throughout the 
µSPECT scan by inhalation of 1.5 % isoflurane. The 20 % photopeak was 
centered at 159 keV and a double 10 % energy window correction at 135 keV and 
190 keV was applied. The data were reconstructed on 0.375 voxels by 3 iterations 
of 16 OSEM subsets. The images were postfiltered by a Gaussian postfilter of 
1.125 mm and color scales were normalized. A cylindrical brain ROI of 25 mm3 
(4 mm diameter and 2 mm height) was drawn on the brain for further analysis. 
Statistical analysis was performed using a one-sided, unpaired student’s t-test. 
Only p-values < 0.05 are considered significant. 
 
 
 
 
 
 
In vivo evaluation of [123I]-FMIP for P-gp imaging – Chapter 8 
 
 182 
8.4. Results & Discussion 
 
8.4.1. RADIOCHEMISTRY 
 
[123I]-FMIP was prepared in a 40 ± 10 % radiochemical yield, as previously 
described (Figure 8.1). The specific activity was > 667 GBq/µmol (18 Ci/µmol) 
and radiochemical purity appeared to be higher than 98 % (see Chapter 7). [123I]-
FMIP was formulated in a 8:92 (v:v) - EtOH:physiological saline solution for in 
vivo studies. 
 
 
Figure 8.1 Radiosynthesis of [123I]-FMIP 
 
8.4.2. BIODISTRIBUTION STUDIES 
 
Figure 8.2 shows the tissue distribution of radioactivity uptake after intravenous 
injection of 185 kBq (5 µCi) [123I]-FMIP in wild-type and mdr1a knock-out mice 
with physiological saline or CsA pre-administration.  
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Figure 8.2 Tissue distribution of [123I]-FMIP in wild-type and mdr1a knock-out 
mice with saline or CsA pre-administration 
Values are mean of three experiments, A pretreatment with saline in wild-type mice, B 
pretreatment with CsA in wild-type mice, C pretreatment with saline in mdr1a (-/-) mice, 
D pretreatment with CsA in mdr1a (-/-) mice * P < 0.05 (student’s t test) compared to 
group A ** P < 0.05 (student’s t test) compared to group C  
 
 
8.4.2.1. Biodistribution study in wild-type mice 
 
The brain uptake was low at each time point investigated (0.67 ± 0.15 % ID/g at 
1 min p.i. and 0.41 ± 0.24 % ID/g at 60 min p.i.). Although [123I]-FMIP was 
rapidly cleared out of the blood, blood activity remained higher than brain activity 
at all time points (Figure 8.2). At 60 min p.i., the highest tracer uptake was 
observed in the liver with 36.38 ± 18.12 % ID/g (Figure 8.2). Other peripheral 
organs with high tracer uptake at 60 min p.i. were lungs (9.74 ± 6.01 % ID/g), 
kidneys (7.23 ± 2.46 % ID/g) and spleen (7.34 ± 4.90 % ID/g).  
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8.4.2.2. Influence of CsA pretreatment 
 
Modulation of P-gp with 50 mg/kg CsA resulted in significant changes in 
cerebral uptake of [123I]-FMIP at each time point investigated (Figure 8.3).  
 
Figure 8.3 Brain distribution of [123I]-FMIP in wild-type mice with saline and 
CsA pretreatment  
Values are expressed as % ID/g ± SD (n=3); p-values are calculated using the one-sided 
student’s t test 
 
Brain uptake raised 2.6 – 5.1 fold compared to mice without CsA pretreatment. 
At 10 min p.i. the highest raise was observed (5.09 ± 1.48). Since CsA 
pretreatment had no effect on blood activity, the brain/blood ratio was also 
significantly increased. At 60 and 180 min p.i. a slight decrease in intestinal uptake 
was observed after CsA pretreatment. This is possibly due to a slower excretion 
caused by P-gp modulation. Furthermore, no significant differences could be 
observed at any of the selected time points in the peripheral organs (Figure 8.2). 
 
8.4.2.3. Influence of gene depletion 
 
The influence of genetic disruption of P-gp in mice on brain radioactivity uptake 
is shown in Figure 8.4.  
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Figure 8.4 Brain distribution of [123I]-FMIP in wild-type mice with saline and 
mdr1a (-/-) mice with saline pretreatment (n=3) 
Values are expressed as % ID/g ± SD (n=3); p-values are calculated using the one-sided 
student’s t test 
 
In mdr1a (-/-) mice, [123I]-FMIP content was increased in the brain at all selected 
time points. Brain uptake raised 2.9 – 5.0 fold compared to wild-type mice with 
the highest increase at 30 min p.i. (4.95 ± 0.81). In contrast, no significant 
differences in [123I]-FMIP levels in plasma were measured between the two types 
of mice at the chosen time points. Consequently, brain/blood ratios were 
significant higher in mdr1a (-/-) mice (except at 180 min p.i.). Although liver, 
kidneys and intestines displayed a decreased radioactivity uptake in the mdr1a (-/-
) mice, this decrease was not significant. None of the peripheral organs displayed 
significant changes at any of the selected time points except the pancreas at 60 
min p.i. (Figure 8.2). 
 
8.4.2.4. Influence of CsA pretreatment in mdr1a (-/-) mice 
 
Pretreatment of mdr1a (-/-) mice with CsA had no additional significant effect on 
brain activity except at the earliest time point (Figure 8.5). At 1 min p.i., not only 
brain but also blood uptake was increased resulting in similar brain/blood ratio. 
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Heart and lung uptake was significantly increased, an effect that is probably 
caused by the increased blood pool activity and not P-gp mediated. At 60 and 180 
min p.i. a significant increase in intestinal uptake was observed after CsA 
pretreatment. This effect could be P-gp mediated but could also be the result of a 
shift in excretion after CsA administration. In conclusion, it can be stated that 
CsA administration in mdr1a (-/-) mice did not cause significant changes in the 
brain uptake of [123I]-FMIP (Figure 8.5). 
 
Figure 8.5 Brain distribution of [123I]-FMIP in mdr1a (-/-) with saline and CsA 
pretreatment (n=3) 
Values are expressed as % ID/g ± SD (n=3); p-values are calculated using the one-sided 
student’s t test 
 
8.4.3. DOSE ESCALATION STUDY 
 
The effect of increasing doses CsA on the brain uptake and blood concentration 
of [123I]-FMIP was investigated (Figure 8.6). The experiment showed a sigmoid 
relationship between the concentration of CsA administrated and the uptake of 
[123I]-FMIP in the brain. The EC50 value was 24.48 ± 0.73 mg/kg. With a higher 
dose of CsA, a higher brain uptake was observed with stagnation from 30 mg/kg 
CsA. Between 30 mg/kg (0.61 ± 0.13 % ID/g) and 60 mg/kg (0.56 ± 0.23 % 
ID/g) CsA, there was no significant difference in brain uptake. The effect of CsA 
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administration on brain uptake was significant at each dosage used compared to 
the control group. Only a minor increase in blood activity was observed after 
administration of increasing doses of CsA. Blood uptake of radioactivity without 
CsA pretreatment was 0.29 ± 0.14 % ID/g and increased to 0.51 ± 0.06 % ID/g 
at the highest dose CsA used but the increase was not significant.  
 
Figure 8.6 Effect of various doses CsA on brain uptake and blood activity of 
[123I]-FMIP 
Values are expressed as % ID/g ± SD (n=3) 
 
8.4.4. METABOLITE ANALYSIS 
 
Table 8.1 summarizes the metabolic profile of [123I]-FMIP. Metabolite analysis of 
plasma in wild-type mice demonstrated that at 10 min p.i. 70 ± 6 % and at 60 min 
p.i. 54 ± 8 % of intact [123I]-FMIP is remaining (Figure 8.7). Degradation 
products in plasma were 123I- (13 ± 1 % at 10 min p.i. and 39 ± 4 % at 60 min 
p.i.) and a lipophilic metabolite with a retention time of 9 min that elutes just 
before the parent compound (17 ± 7 % at 10 min p.i. and 8 ± 4 % at 60 min p.i.). 
This compound is believed to have a structure close to the parent compound and 
probably originates from a hydroxylation on a phenyl group or defluorination of 
a phenyl ring. 
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In brain, percentages of intact [123I]-FMIP were 86 ± 2 % at 10 min p.i. and 85 ± 
3 % at 60 min p.i. (Figure 8.7). The detected metabolites were iodide-123 (8 ± 2 
% at 10 min p.i. and 12 ± 4 % at 60 min p.i.) and a hydrophilic degradation 
product with a retention time of 5.5 min (5 ± 1 % at 10 min p.i. and 4 ± 1 % at 
60 min p.i.). This metabolite is possibly the result of N-dealkylation. 
 
 
Figure 8.7 Metabolite chromatogram of [123I]-FMIP in FVB and mdr1a (-/-) 
mice after saline and CsA pretreatment  at 10 min p.i. (A) and 60 min p.i. (B) 
Values are the mean of three experiments and are expressed as percent of total activity 
 
Pretreatment with CsA resulted in less degradation in the brain with 94 ± 3 % 
and 93 ± 5 % intact [123I]-FMIP at 10 min and 60 min p.i., respectively. The 
formation of an extra metabolism product (2 ± 1 % at 10 min p.i. and 1 ± 1 % at 
60 min p.i.) with the same retention time of that found in plasma was observed. 
In plasma, pretreatment with CsA caused an increase in metabolism of [123I]-
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FMIP at 10 min p.i. while at 60 min p.i. the fraction of [123I]-FMIP remained 
unchanged. 
Depletion of the mdr1a gene had no effect on the fraction of radioactivity 
present as [123I]-FMIP in brain. Just as observed with CsA pretreatment, the same 
extra metabolism product was found (3 ± 3 % at 10 min p.i. and 2 ± 0 % at 60 
min p.i.). In plasma, on the other hand, a high increase in the fraction of iodide-
123 was observed. At 60 min p.i., 123I- was the only extracted degradation product.  
 
Table 8.1 Metabolic profile of [123I]-FMIP at 10 min and 60 min p.i. 
                                                          Retention time on RP-HPLC 
 Tissue Time  
(min) 
 3 min 
123I- 
5.5 min 9 min 11 min  
[123I]-FMIP 
Controla  Brain 10  8 ± 2         5 ± 1          86 ± 2 
  60  12 ± 4 4 ± 1  85 ± 3 
       
 Plasma 10  13 ± 1  17 ± 7 70 ± 6 
  60  39 ± 4  8 ± 4         54 ± 8 
       
Test Ab Brain 10  2 ± 2 2 ± 1 2 ± 1 94 ± 3 
  60  3 ± 1 3 ± 3 1 ± 1 93 ± 5 
       
 Plasma 10  17 ± 12  24 ± 19 59 ± 5 
  60  33 ± 12  16 ± 2 51 ± 14 
       
Test Bc Brain 10  5 ± 4 11 ± 8 3 ± 3 81 ± 10 
  60  6 ± 3 6 ± 2 2 ± 0 86 ± 5 
       
 Plasma 10  36 ± 11  3 ± 5 64 ± 12 
  60  61 ± 8   39 ± 8 
Values are expressed as percent of total activity ± SD (n=3) 
a pretreatment with saline in wild-type mice, b pretreatment with CsA (50 mg/kg) in wild-
type mice, c pretreatment with saline in mdr1a (-/-) mice 
 
8.4.5. U-SPECT SCAN 
 
The µSPECT images obtained are shown in Figure 8.8. A low homogenous brain 
uptake was observed after injection of [123I]-FMIP. As seen in Figure 8.8, almost 
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no activity was visible on the µSPECT scan. Radioactivity uptake in brain, 
integrated over the full scan time of 60 min, was considerably higher after CsA 
pretreatment as well as in mdr1a (-/-) mice. In the experiment in which CsA had 
been preadministrated to block P-gp, radioactivity concentration was on average 
3.94 ± 0.84 fold higher compared to the baseline experiment. The ratio of brain 
radioactivity in test group B to that in the control group was about 4.27 ± 1.20 
times increased.  
 
Figure 8.8 µSPECT image of mice brain at 60 min p.i. of [123I]-FMIP 
 ROI’s were drawn around the middle of the brain, a pretreatment with CsA in wild-type 
mice, b pretreatment with saline in wild-type mice, c pretreatment with saline in mdr1a (-/-
) mice 
 
The regional distribution of [123I]-FMIP in mice brain was homogenous in the 
control group as well as in test group A and test group B. The uptake in the 
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striatum was not higher compared to the uptake in the other brain regions, 
confirming the previous finding that no specific binding of [123I]-FMIP to the 
dopamine transporter is accomplished (Chapter 7). 
The correlation of the biodistribution studies with µSPECT measurements are 
represented in table 8.2. ROI’s were obtained at 30 min p.i. and at 60 min p.i. for 
an exact comparison with the values of the biodistribution studies. The increase 
in brain uptake after CsA pretreatment and in mdr1a (-/-) mice is slightly higher 
in biodistribution studies compared to measurements obtained from µSPECT 
imaging (Table 8.2). In addition, the standard deviation is higher in the 
biodistribution studies. The low counts obtained when measuring the brain 
radioactivity in wild-type mice with saline pretreatment are a possible reason for 
these higher standard deviations. Another explanation can be the use of aliquots 
of the injection solution for calculation of the injected dose in the biodistribution 
study. These findings indicate not only the advantage of µSPECT imaging in 
small animal studies but also that in vivo ROI-based SPECT measurements 
correlated with the observations of the biodistribution studies.   
 
Table 8.2 Comparison of brain radioactivity uptake ratios of [123I]-FMIP in the 
biodistribution study and µSPECT imaging 
 Experiment 30 min p.i. 60 min p.i.  
Influence CsAa biodistribution  4.92 ± 1.94 4.17 ± 2.79 
 µSPECT imaging 2.87 ± 0.83 3.04 ± 0.73 
    
Influence gene depletionb biodistribution  4.95 ± 2.03 2.92 ± 1.85 
 µSPECT imaging 2.24 ± 0.35 2.92 ± 0.56 
Values are mean of three experiments ± SD, a brain uptake in wild-type mice pretreated 
with Cs A/brain uptake in wild-type mice pretreated with saline, b brain uptake in wild-
type mice pretreated with saline/brain uptake in mdr1a (-/-) mice pretreated with saline 
 
8.5. Conclusion 
 
P-gp is among other localizations expressed in the BBB where it prevents 
accumulation of certain xenobiotics in the brain by an active transport 
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mechanism. Hence, P-gp can play a significant role in the resistance to CNS 
drugs (Schinkel et al., 1996; Linnet and Ejsing, 2008). P-gp has also been 
associated with several human disorders (Lam et al., 2001; Langford et al., 2004; 
Kwan and Brodie, 2005; Kortekaas e tal., 2005; Turgut et al., 2008). Non-invasive 
monitoring of P-gp could be applied to elucidate the role of P-gp in these human 
diseases and to evaluate the efficacy of new P-gp modulators. Several tracers have 
already been evaluated for P-gp modulation but so far, no iodinated SPECT 
tracer for P-gp has been reported. Iodine-123 has a half-life of 13.2 h allowing a 
prolonged scanning time and consequently a longer follow-up of the radioactivity 
distribution is possible.  
The aim of this study was to evaluate the usefulness of [123I]-FMIP for SPECT 
imaging of the P-gp transporters in brain. The synthesis and radiosynthesis of 
[123I]-FMIP were reported in Chapter 7.  
The biodistribution studies revealed a 2.6 – 5.1 increase in brain uptake after 
blocking P-gp with CsA. The effect on blood activity was negligible indicating 
that the increased brain uptake is the result of a decreased tracer efflux and not 
due to an improved influx to the brain. Additional proof of P-gp involvement 
was obtained in the study with mdr1a (-/-) mice. In this study, we demonstrated a 
raise in brain radioactivity ranging from 2.9 – 5.0. No significant differences in 
other organs containing P-gp, like liver and kidneys, were observed. These 
finding corresponds with those reported in other studies (Hendrikse et al., 1998; 
Luurtsema et al., 2003) and can be explained by the unique barrier of the brain as 
well as the role of liver and kidneys in excretion and metabolism and 
experimental artefacts (bile ducts are not dissected apart from the liver).  
[123I]-FMIP shows a fairly stable in vivo metabolic profile. One labelled metabolite 
(Tr 9.5 min) is probably also a substrate for P-gp as the metabolite only occurs in 
the brain after CsA pretreatment and in mdr1a (-/-) mice. Radioactivity in brain 
was mainly (> 80 %) present as intact [123I]-FMIP at the two time points in the 
three different treatment regiments. 
In vivo evaluation of [123I]-FMIP for P-gp imaging – Chapter 8 
 193 
A dose escalation study with increasing concentrations CsA revealed a sigmoidal 
dose-response relationship between the dose CsA administrated and the brain 
uptake of [123I]-FMIP. A log EC50 value of 24.48 mg/kg was obtained. This study 
demonstrated that the blockade of [123I]-FMIP efflux by P-gp is saturated and 
complete with a CsA dosage of 30 mg/kg. The dose with maximal tracer uptake 
and the EC50 value are comparable with the values reported for other tracers. 
[11C]Carvedilol for example reached maximum brain uptake at a dosage of 30 
mg/kg (Elsinga et al., 2005). [11C]Verapamil has a EC50 value of 22.76 which is 
comparable with that of [123I]-FMIP (Bart et al., 2003).  
Comparison of biodistribution data with in vivo µSPECT observations shows a 
relative good correlation. With mdr1a (-/-) mice, the biodistribution study 
showed at 60 min p.i. a 2.92 ± 1.85 fold increase in brain uptake of [123I]-FMIP, 
whereas µSPECT measurements revealed an 2.92 ± 0.56 fold increase. In 
biodistribution studies, pretreatment with CsA resulted in 4.17 ± 2.79 higher 
brain uptake which is in agreement with the 3.04 ± 0.73 increase obtained with 
µSPECT imaging. Using µSPECT measurements, the obtained standard errors 
where remarkably lower compared to those of the biodistribution studies. The 
use of a µSPECT device eliminates potential errors due to organ removal, 
weighing and gamma counting in a separate system. Furthermore, the injected 
dose is directly measured in contrast to the biodistribution studies where aliquots 
of the injection solution were employed to calculate the injected dose.   
While the brain was visible as a black cavity when only [123I]-FMIP was 
administrated, CsA administration or the use of mdr1a (-/-) mice improved brain 
uptake of [123I]-FMIP resulting in a better image of the brain. In all treatment 
regiments a homogenous brain distribution was observed, supporting the 
previous finding that [123I]-FMIP is not suitable for mapping the dopamine 
transporter in vivo. 
 
Brain uptake of [123I]-FMIP is very low in wild-type mice with physiological saline 
pre-administration, consistent with the rapid action and high capacity of P-gp. 
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CsA pretreatment as well as mdr1a gene depletion resulted in increase (two- to 
five-fold) of cerebral uptake of [123I]-FMIP in mice. The effect on blood activity 
and radioactivity concentration in other organs was negligible. These findings 
indicate that [123I]-FMIP is a very promising radiotracer to visualize P-gp function 
at the BBB. 
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Chapter 9 
 
 Radiosynthesis and in vivo evaluation of [11C]-
MC80 for P-glycoprotein imaging 
 
9.1. Abstract 
 
Aim: P-gp is an ATP-dependent efflux pump protecting the body against 
xenobiotics. We labelled an in vitro characterized substrate (MC80) of the P-gp 
pump with 11C and evaluated this tracer in vivo for its potential to image P-gp 
function and expression. 
Methods: MC80 was labelled using 11CH3I. Biodistribution studies were performed 
in male FVB or mdr1a (-/-) mice pretreated with physiological saline, CsA (50 
mg/kg) or cold MC80 (15 mg/kg). The metabolic profile of [11C]-MC80 was 
characterized. 
Results: The radiochemical yield was 26 ± 5 % with a total synthesis time of 25 
min. Cerebral uptake was increased in knock-out mice (1.5 – 2 fold) as well as 
after CsA pretreatment (1.3 – 2 fold). Administration of non-radioactive MC80 
caused a reduced uptake in several organs including brain, pancreas and intestine. 
In brain, [11C]-MC80 displayed an excellent metabolic profile (> 90 % intact at 30 
min p.i.). 
Conclusion: [11C]-MC80 is modulated by and shows specific binding to P-gp. Since 
[11C]-MC80 shows specific binding to target organs, this compound may be 
useful for P-gp imaging, especially in the intestines. This compound can also be a 
lead compound for the development of other novel radioligands for measuring 
the expression of P-gp in the brain. 
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9.2. Introduction 
 
P-gp is an ATP-dependent efflux pump that is expressed in several normal tissues 
including liver, kidneys, intestine and brain (Thiebaut et al., 1987; Schinkel and 
Jonker, 2003). The function of this efflux pump is to protect the human body 
against xenobiotics. It prevents accumulation in the brain of a wide range of 
drugs (Schinkel et al., 1996; Linnet and Ejsing, 2008) including anti-epileptics 
(Luna-tortos et al., 2008), anti-HIV drugs (Kim et al., 1998) and antidepressants 
(Szabo et al., 1999). Overexpression of P-gp in tumors is implicated in the 
resistance to chemotherapeutics in some cancers (Gottesmann and Pastan, 1993; 
Gottesman et al., 2002). Besides its role in multidrug resistance, changes or 
abnormalities in P-gp expression and function are involved in the etiology and 
pathogenesis of several neurological diseases (Kwan and Brodie, 2005; Turgut et 
al., 2008; Kortekaas et al., 2005; Langford et al., 2004). A decreased P-gp 
function, for example, diminishes the clearance of amyloid plaques, increasing the 
vulnerability to Alzheimer disease (Lam et al., 2001; Vogelgesang et al., 2002).  
Imaging of P-gp function and expression with PET or SPECT could be of great 
importance in drug development and medicine. Non-invasive monitoring of P-gp 
could be applied to elucidate the role of P-gp in several human diseases and to 
evaluate the efficacy of new P-gp modulators. Several tracers have already been 
evaluated for P-gp modulation among them [11C]verapamil (Hendrikse et al., 
1998; Lee et al., 2006), [11C]N-desmethyl-loperamide (Lazarova et al., 2008; 
Zoghbi et al., 2008) and [99mTc]sestamibi (Kostakoglu et al., 1997; Ballinger et al., 
1995). All these radiotracers have at least one limitation, including significant 
contamination with radiometabolites, difficulty in radiosynthesis or very low 
baseline brain uptake which makes it difficult to see minor changes in P-gp 
expression. Moreover, the reported radiotracers for P-gp are all aimed to visualize 
P-gp function but not the expression and quantification of P-gp.  
In the search for a superior radiotracer to image P-gp function or expression, we 
evaluated [11C]-6,7-dimethoxy-2-(6-methoxy-naphthalen-2-ylmethyl)-1,2,3,4-tetra-
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hydroisoquinoline ([11C]-MC80) for imaging P-gp function and expression. 
Recently, Colabufo et al. (2008) developed several 6,7-dimethoxytetrahydroiso-
quinoline derivatives as novel P-gp modulators. Their P-gp interacting 
mechanism and their potency towards P-gp was evaluated in vitro by combining 
three biological assays: [3H]vinblastine transport inhibition, apparent permeability 
determination and ATP-ase activation. From these assays, MC80 (Figure 9.1) can 
be hypothesized as a transported substrate with an interaction profile similar to 
CsA (Colabufo et al., 2008).  
 
 
Figure 9.1 Chemical structure of MC80 
This study describes the synthesis and purification of [11C]-MC80. The 
development of a HPLC method for quantification is completed. Specific activity, 
radiochemical purity and log D7.4 are reported. We also evaluated [11C]-MC80 in 
vivo in mice. To investigate the P-gp modulation characteristics, [11C]-MC80 is 
appraised in wild-type mice with or without CsA pretreatment in addition to P-gp 
knock-out mice. The metabolic profile of [11C]-MC80 in all three treatment 
groups is determined. Finally, specific binding of [11C]-MC80 is examined by pre-
administration of cold MC80. 
 
9.3. Materials & Methods 
 
9.3.1. GENERAL 
 
The precursor, 6,7-dimethoxy-2-(6-hydroxy-naphthalen-2-yl-methyl)-1,2,3,4-tetra-
hydroisoquinoline (MC90) as well as the cold reference compound, MC80, were 
kindly provided by the University of Bari, Dipartimento Farmaco-Chimico, Italy. 
MC80 was previously reported as compound 7h while MC90 was termed 7g. 
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MC80 was characterized as a transported substrate with an interaction profile 
similar to CsA (Colabufo et al., 2008). 
[11C]N-desmethyl-loperamide has been synthesized and evaluated by another 
PhD student of our lab. Those data are not reported in this thesis but are referred 
to when evaluating [11C]-MC80.  
 
9.3.2. RADIOCHEMISTRY 
 
The alkylating reagent [11C]methyl iodide was prepared from [11C]methane by gas-
phase iodination. The production of both 11CH4 and 11CH3I is described in 
Chapter 4.  
 
Figure 9.2 Radiosynthesis of [11C]-MC80 
 
The radiosynthesis of [11C]-MC80 is shown in Figure 9.2. 11CH3I in carrier helium 
was bubbled into a sealed vial containing 3 µmol MC90 and 7 µL NaH (1 M in 
DMF) in DMF (243 µL). When the radioactivity in the reaction vial reached 
maximum activity levels, the reaction mixture was heated at 30°C for 5 min. 
Afterwards, the crude reaction mixture was diluted with eluent and injected onto 
a semipreparative C18 HPLC column (Econosphere, 10 µm, 10 mm x 250 mm, 
Grace Davison Discovery Sciences, Lokeren, Belgium) that was eluted at 6 
mL/min with (80:20) MeOH:sodium acetate buffer (0.02 M, pH 5.5). The eluate 
was monitored for radioactivity (solar-blind P.I.N. photodiode) and UV 
absorbance (smartline UV detector 2500, Knauer, Berlin, Germany) at 254 nM. 
[11C]-MC80 (Tr = 9.3 min) was collected in 30 mL PBS (pH 7.4, 0.01 M) and 
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loaded on a C18 Sep-pak column (Alltech Maxi-clean SPE Prevail C18, previously 
activated with 1 mL EtOH and 5 mL sterile water). After the cartridge has been 
washed with 5 mL sterile water, the desired product [11C]-MC80 was eluted with 
1 mL EtOH. For biodistribution studies, the EtOH fraction was diluted with 10 
mL physiological saline. For metabolite analysis, EtOH was evaporated to 
dryness and the residue was redissolved in an adequate amount of EtOH/saline 
(8/92 - v/v). 
 
9.3.3. IN VITRO CHARACTERIZATION 
 
Quality control consisted of the determination of radiochemical purity and 
specific activity, calculated by analytical HPLC assay using a Gracesmart C18 
column (5 µm, 4.6 mm x 250 mm, Grace Davison Discovery Sciences, Lokeren, 
Belgium) at a flow rate of 1 mL/min. The mobile phase consisted of a mixture of 
75 % MeOH and 25 % sodium acetate buffer (0.02 M, pH 5.5). 
A calibration curve of unlabelled reference compound (0.02 x 10-3 µM – 1 x 10-3 
µM) was determined and controlled for its accuracy and reproducibility. 
Additionally, the detection limit was determined. Specific activities were decay 
corrected to the end of purification. Log D7.4 was determined according to the 
method described in Chapter 4. 
 
9.3.4. BIODISTRIBUTION STUDIES 
 
Wild-type mice (FVB strain) or mdr1a knock-out mice of 5 – 7 weeks old 
weighing approximately 25 g were used. Mice (n=3 for each time point of each 
treatment group) were injected in a tail vein with about 150 µL 
EtOH:physiological saline (8:92) containing 4.5 MBq (122 µCi) [11C]-MC80. 
Thirty minutes before administration of [11C]-MC80, the mice were either treated 
with physiological saline or with CsA (50 mg/kg). The mice were awake during 
the injections. At various periods after injection of the radioligand, the animals 
Radiosynthesis & evaluation of [11C]-MC80 for P-gp imaging – Chapter 9 
 204 
were sacrificed by cervical dislocation under isoflurane anaesthesia. Blood and 
urine were removed and organs were dissected. Tissues were weighed and 
counted for radioactivity using a gamma counter. To remove adhering blood, all 
organs were rinsed with water prior to weighing and counting. For calculation of 
the injected dose, five aliquots of the injection solution were weighed and 
counted for activity. Results are decay-corrected and expressed as % ID/g ± SD. 
Statistical analysis was performed using one-sided, unpaired student’s t-test. Only 
p-values < 0.05 are considered significant. 
Specific binding of [11C]-MC80 was examined by pretreatment of FVB mice (n=3 
for each time point) with 15 mg/kg non-radioactive MC80. At 30 and 60 min 
after [11C]-MC80 injection, animals were killed and dissected. Tissues were treated 
as described above. Results are decay-corrected and expressed as % ID/g ± SD. 
Statistical analysis was performed using one-sided, unpaired student’s t-test. Only 
p-values < 0.05 are considered significant. 
 
9.3.5. METABOLITE ANALYSIS 
 
200 µL 92:8 (v:v) – physiological saline:EtOH containing approximately 18.5 
MBq (500 µCi) [11C]-MC80 was injected in a tail vein of awake mice (5 - 7 weeks 
old, weighing 25 - 30 g). At 1, 10 and 30 min p.i., the mice were sacrificed and 
blood and brain were taken and treated as described in Chapter 4. HPLC analysis 
was performed using a RP C18 HPLC column (Econosphere C18 250 mm x 10 
mm, 10 µm) attached to a precolumn (Alltima C18 33 mm x 7 mm, 10 µm) with 
80:20 (v:v) MeOH:sodium acetate buffer (0.02 M, pH 5.5) as solvent system at a 
flow rate of 6 mL/min. The same treatment regiments as for the biodistribution 
studies were investigated. 
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9.4. Results & Discussion 
 
9.4.1. RADIOSYNTHESIS 
 
[11C]-MC80 was prepared with an overall decay-corrected yield of 26 ± 5 % 
(n=6). Extraction efficiency of the Sep-pak column was calculated to be 87 ± 3 % 
(n=6). The overall time of preparation was 25 min.  
 
9.4.2. IN VITRO CHARACTERIZATION 
 
9.4.2.1. Quality control, specific activity and stability 
 
The identity of [11C]-MC80 was confirmed by co-elution with MC80 after co-
injection on HPLC. A radiochemical purity of more than 98 % was obtained. 
Specific activity was > 0.3 TBq/µmol (> 8.1 Ci/µmol). The [11C]-MC80 
formulation remained stable during the time span of the study.  
 
9.4.2.2. Log D7.4 
 
The log D7.4 of [11C]-MC80 in octanol was 1.96 ± 0.08. This value is suitable for 
brain penetration (Waterhouse, 2003). 
 
9.4.3. BIODISTRIBUTION STUDIES 
 
9.4.3.1. Biodistribution study in FVB mice 
 
The tissue distribution of [11C]-MC80 in wild-type mice with saline pretreatment 
is depicted in Table 9.1. 
[11C]-MC80 is cleared from plasma via the hepatobiliary system as shown by the 
high liver uptake (8.71 ± 2.44 % ID/g) and the increase in radioactivity uptake 
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over time in small intestine (from 3.89 ± 0.30 % ID/g at 1 min p.i. to 11.78 ± 
3.38 % ID/g at 90 min p.i.) and large intestine (from 1.83 ± 0.72 % ID/g at 1 
min p.i. to 2.18 ± 0.82 % ID/g at 90 min p.i.). [11C]-MC80 also demonstrated 
high initial kidney uptake (11.32 ± 0.95 % ID/g at 1 min p.i.), and subsequently 
urinary clearance was observed (data not shown). Since radioactivity uptake in the 
intestines already occurred at the earliest time point, it is probably not only caused 
by excretion of [11C]-MC80 but is possibly also P-gp mediated.  
 
Table 9.1 Tissue distribution of [11C]-MC80 in wild-type mice 
% ID/g ± SD (n=3) 
 1 min 10 min 30 min 60 min 90 min 
Blood 2.56 ± 0.67 1.12 ± 0.09 0.93 ± 0.09 0.73 ± 0.05 0.85 ± 0.15 
Brain 7.66 ± 1.38 3.73 ± 0.46 2.03 ± 0.20 1.09 ± 0.18 0.90 ± 0.20 
Heart 10.69 ± 2.49 3.19 ± 0.37 2.26 ± 0.24 1.54 ± 0.19 1.27 ± 0.22 
Lungs 31.35±11.60 8.44 ± 0.58 4.24 ± 0.98 2.86 ± 0.56 1.84 ± 0.25 
Stomach 4.60 ± 0.39 6.00 ± 1.39 7.72 ± 6.74 3.37 ± 0.62 4.05 ± 1.68 
Spleen 3.24 ± 0.75 2.84 ± 0.27 2.53 ± 0.38 1.52 ± 1.12 1.47 ± 0.35 
Liver 7.68 ± 0.27 8.71 ± 2.44 6.10 ± 0.20 4.86 ± 0.33 5.71 ± 1.51 
Kidneys 11.32 ± 0.95 5.31 ± 2.08 3.62 ± 0.59 2.46 ± 1.61 3.00 ± 0.80 
Small 
intestine 
3.89 ± 0.30 4.51 ± 0.69 8.03 ± 0.91 11.68 ± 0.13 11.78 ± 3.38 
Large 
intestine 
1.83 ± 0.72 1.58 ± 0.20 1.33 ± 0.07 1.45 ± 0.78 2.18 ± 0.82 
Bladder 4.27 ± 0.63 5.28 ± 2.11 4.45 ± 1.16 4.00 ± 1.77 7.08 ± 1.31 
Pancreas 7.13 ± 1.77 9.99 ± 3.35 10.63 ± 1.68 6.85 ± 0.66 5.12 ± 1.64 
Testes 1.66 ± 0.41 2.23 ± 0.28 2.83 ± 0.36 2.46 ± 0.51 1.91 ± 0.16 
 
[11C]-MC80 displayed good uptake in mouse brain (7.66 ± 1.38 % ID/g at 1 min 
p.i.) followed by efficient wash-out (0.90 ± 0.20 % ID/g at 90 min p.i.). Blood 
activity never exceeded brain uptake. Compared to [11C]verapamil (Hendrikse et 
al., 1998; Lee et al., 2006) and [11C]N-desmethyl-loperamide, [11C]-MC80 
displayed a high baseline brain uptake. This could be an advantage for imaging 
small fluctuations in P-gp expression or function. With a low initial brain uptake, 
it is not possible to image a small increase in P-gp function or a small reduction in 
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P-gp expression. It will be difficult to observe significant reductions in brain 
radioactivity uptake in the very low brain radioactivity levels.  
 
9.4.3.2. Biodistribution study after CsA pretreatment 
 
Pretreatment of animals with CsA caused a significant increase (except at 90 min 
p.i.) of radioactivity uptake in mice brain compared to FVB mice treated with 
physiological saline (Figure 9.3). The calculated p-values are 0.003, 0.007, 0.011, 
0.009 and 0.293 at 1, 10, 30, 60 and 90 min p.i., respectively. Brain uptake raised 
1.3 - 2 fold compared to mice without CsA pretreatment.  
 
Figure 9.3 Blood-brain distribution of [11C]-MC80 in FVB mice with saline or 
CsA pretreatment  
Values are expressed as % ID/g ± SD (n=3); * p < 0.05 with the student’s t-test 
 
Except at 1 min p.i., CsA also increased the uptake of [11C]-MC80-derived 
radioactivity in several peripheral organs including testes (from 2.56 ± 0.51 % 
ID/g to 3.73 ± 0.66 % ID/g at 60 min p.i.), pancreas (from 6.85 ± 0.66 % ID/g 
to 8.19 ± 0.79 % ID/g at 60 min p.i.), spleen (from 1.52 ± 1.12 % ID/g to 2.31 
± 0.15 % ID/g at 60 min p.i.), kidneys (from 2.46 ± 1.61 % ID/g to 4.53 ± 0.28 
% ID/g at 60 min p.i.), and liver (from 4.86 ± 0.33 % ID/g to 8.25 ± 0.99 % 
ID/g at 60 min p.i.) (Figure 9.4). This increase however was not significant at 
every time point. Compared to mice treated with saline, radioactivity uptake in 
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blood (from 2.56 ± 0.67 % ID/g to 4.97 ± 0.26 % ID/g), heart (from 10.69 ± 
2.49 % ID/g to 28.55 ± 1.35 % ID/g) and lungs (from 31.35 ± 11.60 % ID/g to 
71.59 ± 15.79 % ID/g) was already higher at 1 min p.i. and remained higher at 
each time point. These observations suggest a slower distribution of [11C]-MC80 
to the peripheral organs after CsA administration. In contrast, intestinal uptake 
was significantly lower with CsA pretreatment. A possible reason is the reduced 
binding to P-gp caused by CsA modulation. Taken together, CsA administration 
has an effect on tissue uptake of [11C]-MC80 suggesting P-gp plays a role in the 
kinetics of [11C]-MC80. 
 
Figure 9.4 Tissue distribution of [11C]-MC80 in FVB mice with saline (A) or CsA 
(B) pretreatment  
Values are expressed as % ID/g ± SD (n=3); * p < 0.05 with the student’s t-test) 
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9.4.3.3. Biodistribution study in mdr1a (-/-) mice 
 
In mdr1a (-/-) mice, cerebral uptake of [11C]-MC80 (Figure 9.5) was significantly 
increased at 10 min (p = 0.014) and 60 min p.i. (p = 0.001) compared to wild-
type mice. The highest increase in brain uptake was 1.96 ± 0.38 (from 1.09 ± 0.18 
% ID/g to 2.15 ± 0.65 % ID/g) at 60 min p.i. Significant differences in [11C]-
MC80 levels in plasma were measured between the two types of mice at 10 min 
(p = 0.021) and 30 min (p = 0.032) p.i.  
 
Figure 9.5 Blood-brain distribution of [11C]-MC80 in normal FVB mice or 
mdr1a (-/-) mice  
Values are expressed as % ID/g ± SD (n=3); * p < 0.05 with the student’s t-test 
 
At 1 min p.i. most organs displayed a reduced radioactivity uptake. In contrast 
lungs (from 31.35 ± 11.60 % ID/g to 45.85 ± 13.79 % ID/g) and heart (from 
10.69 ± 2.49 % ID/g to 13.06 ± 1.72 % ID/g) showed an increased uptake at 1 
min p.i. As with CsA, these observations suggest also a slower distribution of 
[11C]-MC80 to peripheral organs when using mdr1a (-/-) mice (Figure 9.6). 
Genetic disruption of the mdr1a gene appears to affect retention of the tracer in 
the excretory organs. Radioactivity uptake in the kidney raised from 2.46 ± 1.61 
% ID/g to 4.41 ± 0.63 % ID/g at 60 min p.i., and liver uptake increased from 
4.86 ± 0.33 % ID/g to 8.47 ± 0.57 % ID/g at 60 min p.i. The elevation in testes 
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(significant at 10 min (p = 0.015) and 30 min (p = 0.003) p.i.) uptake is in 
accordance with P-gp distribution. Contrary to the effect seen with CsA 
pretreatment, intestinal uptake did not alter. This can be explained by the fact that 
mdr1b encoded P-gp is also found in the gastrointestinal tract resulting in an 
unchanged intestinal uptake when using mdr1a (-/-) mice.   
 
Figure 9.6 Radioactivity uptake in tissues of [11C]-MC80 in normal FVB mice (A) 
and mdr1a (-/-) mice (B)  
Values are expressed as % ID/g ± SD (n=3); * p < 0.05 with the student’s t-test 
 
9.4.3.4. Biodistribution study after pretreatment with cold compound 
 
The tissue distribution of [11C]-MC80 in wild-type mice with and without cold 
MC80 pretreatment is depicted in Table 9.2. 
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Table 9.2 Tissue distribution of [11C]-MC80 in FVB mice with and without 
administration of non-radioactive MC80 (15 mg/kg) 
% ID/g ± SD (n=3) 
                                Control group                                             Test group                     
 30 min                   60 min                   30 min                 60 min                   
Blood 0.93 ± 0.09 0.73 ± 0.05  0.82 ± 0.06 0.78 ± 0.13 
Brain 2.03 ± 0.20 1.09 ± 0.18  1.64 ± 0.28* 0.89 ± 0.16 
Heart 2.26 ± 0.24 1.54 ± 0.19  1.75 ± 0.25* 1.21 ± 0.16* 
Lungs 4.24 ± 0.98 2.86 ± 0.56  3.08 ± 0.33 1.70 ± 0.11* 
Stomach 7.72 ± 6.74 3.37 ± 0.62  2.21 ± 1.17 2.46 ± 0.71 
Spleen 2.53 ± 0.38 1.52 ± 1.12  1.80 ± 0.70 1.31 ± 0.13 
Liver 6.10 ± 0.20 4.86 ± 0.33  5.39 ± 0.80 5.63 ± 0.26 
Kidneys 3.62 ± 0.59 2.46 ± 1.61  2.99 ± 0.93 2.10 ± 0.31 
Small intestine 8.03 ± 0.91 11.68 ± 0.13  4.77 ± 0.88* 6.54 ± 1.62* 
Large intestine 1.33 ± 0.07 1.45 ± 0.78  0.98 ± 0.02* 0.95 ± 0.10* 
Bladder 4.45 ± 1.16 4.00 ± 1.77  3.86 ± 0.60 4.71 ± 1.34 
Pancreas 10.63 ± 1.68 6.85 ± 0.66  5.15 ± 0.30* 3.53 ± 0.37* 
Testes 2.26 ± 0.24 1.54 ± 0.19  2.15 ± 0.12* 2.10 ± 0.28 
* p < 0.05 using one-sided, unpaired student’s t-test 
 
The brain uptake of [11C]-MC80 was reduced by 20 % after pretreatment of the 
animals with non-radioactive MC80. This reduced uptake was significant at 30 
min p.i. (p = 0.037). In the pancreas, pretreatment caused the most outstanding 
decline in tracer uptake (reduction with 52 % and 49 % at 30 min and 60 min p.i., 
respectively). A significantly decreased uptake of [11C]-MC80 was also noticed in 
the heart (reduction with 22 % and 21 % at 30 min and 60 min p.i.), lungs 
(reduced with 47 % at 60 min p.i.), small intestines (reduction with 41 % and 44 
% at 30 min and 60 min p.i., respectively), large intestines (reduction with 26 % 
and 35 % at 30 min and 60 min p.i., respectively) and testes (reduced with 24 % 
at 30 min p.i.). This study indicates that MC80 act as an inhibitor for the P-gp 
transporter and not as a substrate (an increased brain uptake should be observed 
since MC-80 will compete with [11C]-MC80 for its interaction with P-gp). 
Summarizing, the highest amount of specific binding of [11C]-MC80 occurred in 
the pancreas, lungs and intestine. A lower fraction of specific binding occurred in 
the brain (reduction with 19 % and 18 % at 30 min and 60 min p.i., respectively), 
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testes and heart. This tissue distribution of the specific binding of [11C]-MC80 is 
in accordance with the known expression levels of P-gp (see Chapter 2).  
 
9.4.4. METABOLITE ANALYSIS 
 
The stability of [11C]-MC80 in vivo was studied at 10 min and 30 min p.i. After 
protein elimination, the recovery of radioactivity in the supernatant solutions was 
97 ± 1 % in plasma and 87 ± 7 % in brain. HPLC measurements of plasma and 
brain spiked with [11C]-MC80, displayed one radioactive peak (Tr = 10 min). This 
peak corresponds with [11C]-MC80 as it was found to co-elute with authentic 
MC80.  
 
Table 9.3 Metabolic profile of [11C]-MC80 
                 Retention time on RP-HPLC          
Treatment group Tissue Time 2.5 min 10 min  [11C]-MC80 
Controla Brain 10 min 2 ± 2 % 98 ± 2 % 
  30 min 9 ± 1 % 91 ± 1 % 
     
 Plasma 10 min 37 ± 6 % 63 ± 6 % 
  30 min 42 ± 6 % 58 ± 6 % 
     
CsA pretreatmentb Brain 10 min 1 % 99 % 
  30 min 7 ± 1 % 93 ± 1 % 
     
 Plasma 10 min 35 ± 9 % 65 ± 9 % 
  30 min 78 ± 3 % 22 ± 3 % 
     
mdr1a(-/-) micec Brain 10 min 2 ± 1 % 98 ± 1 % 
  30 min 8 ± 2 % 92 ± 2 % 
     
 Plasma 10 min 23 ± 7 % 77 ± 7 % 
  30 min 40 ± 3 % 60 ± 3 % 
a pretreatment with saline in FVB mice (n=3), b pretreatment with CsA (50 mg/kg) in 
FVB mice (n=3), c pretreatment with saline in mdr1a (-/-) mice (n=3) 
 
The metabolic profile of [11C]-MC80 in the three different treatment regiments is 
summarized in Table 9.3. 
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9.4.4.1. Metabolism study in FVB mice 
 
In brain, [11C]-MC80 remained very stable with over 98 % and 91 % intact 
product at 10 min and 30 min p.i., respectively. The tracer underwent a more 
extensive metabolism in plasma. Plasma metabolite analysis showed 63 ± 6 % 
and 58 ± 6 % intact [11C]-MC80 at 10 and 30 min, respectively. Only one polar 
metabolite was found, that eluted at the void volume of the column. When [11C]-
MC80 is demethylated, it is anticipated that [11C]methyl is removed and 
metabolized to [11C]CH3OH, [11C]CH2O, [11C]CO2H or [11C]CO2. These 
compounds are very polar and are believed to correspond with the radioactive 
peak of the solvent front.  
 
9.4.4.2. Metabolism study after CsA pretreatment 
 
In both tissues, the same radioactive products were found as without CsA 
injection (Table 9.3). Administration of CsA did not affect the metabolic profile 
of [11C]-MC80 in brain. The percentage intact [11C]-MC80 was 99 % and 93 % at 
10 min and 30 min, respectively. Those values are similar to the values found in 
the mice pretreated with saline. Blood metabolite studies indicated that [11C]-
MC80 underwent an elevated metabolism when CsA was given; at 30 min p.i., the 
percentage unchanged [11C]-MC80 was 58 ± 6 % without and 22 ± 3 % with CsA 
pretreatment.  
 
9.4.4.3. Metabolism study in mdr1a (-/-) mice 
 
Similar to the previous reported treatment regiments, two radioactive products 
are detected (Table 9.3). The use of mdr1a (-/-) mice did not affect the amount 
of unchanged [11C]-MC80 present in brain. At 10 min p.i., 98 ± 1 % of parent 
compound remained in the brain and at 30 min p.i. 92 ± 2 %  was still present as 
unchanged [11C]-MC80. The fraction of radioactivity in plasma that represented 
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[11C]-MC80 was 77 ± 7 % at 10 min p.i. and 60 ± 3 % at 30 min p.i. representing 
the same metabolic profile as in FVB mice.  
 
9.5. Conclusion 
 
MC80 was evaluated in vitro using three biological assays. The [3H]vinblastine 
transport inhibition assay defined MC80 as a potent inhibitor of [3H]vinblastine 
transport. The second assay showed that MC80 did not activate ATPase within 
the monolayer. The ratio of drug transport through Caco-2 monolayers in the 
basolateral-apical and apical-basolateral directions was 3.6, indicating that MC80 
is effluxed by P-gp (Colabufo et al., 2008).  
[11C]-MC80 was readily prepared (radiochemical yield of 25 %) for intravenous 
injection by methylation of MC90 with [11C]methyl iodide, itself prepared from 
cyclotron-produced [11C]methane. Purification by RP-HPLC and Sep-pak 
provided [11C]-MC80 in high radiochemical purity (> 98 %) and very high 
specific activity (> 0.3 TBq/µmol).  
Biodistribution studies in wild-type mice demonstrated brain uptake which 
quickly maximized and then washed out. Compared to [11C]N-desmethyl-
loperamide and the clinical used [11C]verapamil (Hendrikse et al., 1998; Lee et al., 
2006), [11C]-MC80 has a high initial brain uptake. CsA administration, as well as 
genetic disruption of the mdr1a gene, resulted in significant changes in tissue 
distribution, confirming that [11C]-MC80 is modulated by P-gp not only in vitro 
but also in vivo. However, the increase in brain radioactivity is not as high as for 
[11C]N-desmethyl-loperamide and [11C]verapamil (Hendrikse et al., 1998; Lee et 
al., 2006). This is probably caused by a difference in pumping efficiency. Blocking 
studies indicated that radioactivity uptake in intestines and pancreas is highly 
specific. In brain, the specific binding is not so apparent indicating non-specific 
binding. Since the blocking study with cold MC80 caused a reduced brain uptake 
of [11C]-MC80 it was hypothesized that [11C]-MC80 is an inhibitor of P-gp. CsA 
pretreatment as well as the genetic disruption of mdr1a on the other hand caused 
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an increased brain uptake, indicating that [11C]-MC80 is a substrate for P-gp. 
Taken together, it was assumed that [11C]-MC80 is a mixed substrate/inhibitor 
for P-gp. 
Summarizing, [11C]-MC80 is modulated by P-gp and shows specific binding to P-
gp. In brain however a high degree of non-specific binding is observed. In 
contrast, intestinal [11C]-MC80 radioactivity uptake is highly specific and sensitive 
towards P-gp indicating [11C]-MC80 has the potential for imaging intestinal P-gp 
function or expression. 
HPLC measurements demonstrated that [11C]-MC80 has an outstanding 
metabolic profile compared to [11C]N-desmethyl-loperamide and [11C]verapamil 
(Hendrikse et al., 1998; Lee et al., 2006). At 30 min p.i. over 90 % of the 
measured radioactivity in brain was related to unchanged [11C]-MC80. Structural 
analogues possessing the same metabolic stability in vivo, but with a higher affinity 
and specificity for P-gp may be extremely useful for imaging of P-gp expression 
at the BBB. 
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SUMMARY 
 
The human brain is a complex organ, consisting of millions of inter-
communicating neurons. Due to the complexity of the brain our knowledge 
about CNS disorders is still limited. SPECT and PET imaging of the living brain 
are unique tools for clinical researchers to elucidate the causes and consequences 
of brain disorders. In vivo brain mapping with PET or SPECT is of great 
importance in drug development as well as in the effective diagnosis, treatment 
and management of neurological and psychiatric illness.  
In this thesis, new SPECT or PET radioligands directed towards two different 
brain systems, were developed and evaluated in vivo.  
Chapter 1 gave a short overview of the medical imaging techniques and 
described the requirements of a valuable radiopharmaceutical for SPECT and 
PET imaging. The first part of Chapter 2 described the blood-brain barrier and 
the transport of compounds across this barrier. One of the most important 
transport mechanisms limiting brain uptake of drugs, P-gp, was detailed in the 
second part of this chapter. After a brief description of the discovery, structure, 
expression and physiological role, the potential modulation agents of P-gp were 
reviewed. The second brain system, the catecholamine system, was addressed in 
Chapter 3. The dopamine and norepinephrine system were discussed briefly, 
followed by a more detailed description of the mechanisms responsible for 
terminating the neurotransmission. After the history, structure and function of 
the catecholamine transporters in general were discussed, the physiological role of 
NET and DAT in health and disease was illustrated. The last part of chapter 3 is 
dedicated to MAO, one of the main enzymes causing degradation of 
catecholamines. In Chapter 4 the general material and methods were described.  
Chapter 5 reported the synthesis, radiosynthesis and preliminary evaluation of 
[123I]-(S,S)-IPBM, an iodinated reboxetine analogue. [123I]-(S,S)-IPBM aimed at 
imaging the norepinephrine transporter. The precursor was prepared in an overall 
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chemical yield of 8 % with an enantiomeric excess of 95 %. Radiosynthesis 
afforded [123I]-(S,S)-IPBM with an excellent radiochemical purity. Biodistribution 
studies demonstrated a high brain uptake of [123I]-(S,S)-IPBM followed by 
efficient wash-out. Since [123I]-(S,S)-IPBM was reported by others at the moment 
we performed our biodistribution studies, we did not conduct additional in vivo 
studies. Regarding their results (Tamagnan et al., 2007; Kanigawara et al., 2006), 
the choice to develop [123I]-(S,S)-IPBM as radiotracer for NET was an excellent 
suggestion. 
In Chapter 6 the radiolabelling as well as the in vivo characterization of two [11C]-
labelled pyrrole-2-carboxamide derivatives, [11C]-RS 2315 and [11C]-RS 2360, were 
described. In vitro, RS 2315 and RS 2360 are potent inhibitors of MAO-A. Both 
tracers were obtained with a good radiochemical yield, excellent radiochemical 
purity and high specific activity. Both radiotracers displayed high brain uptake 
followed by rapid brain clearance. Blocking studies in mice could not 
demonstrate specificity of [11C]-RS 2315 towards MAO-A or B. The blocking 
study with [11C]-RS 2360 on the other hand indicated specific binding at MAO-A 
at the earliest time point. In the imaging study with [11C]-RS 2360, administration 
of clorgyline caused an overall significant reduced brain uptake indicating specific 
binding at MAO-A. These results indicated that [11C]-RS 2315 is not suitable for 
mapping MAO-A in vivo and that further research is necessary to investigate the 
potential of [11C]-RS 2360 in MAO-A imaging.  
The (radio)synthesis and in vivo evaluation of [123I]-FMIP as a selective radiotracer 
for DAT was reported in Chapter 7. FMIP has nanomolar affinity for DAT and 
better selectivity over the other monoamine transporters compared to the already 
existing ligands for DAT imaging with SPECT. The tributylstannyl precursor was 
synthesized using a five-step synthetic procedure. [123I]-FMIP was synthesized 
with a high radiochemical yield and purity. The specific activity of the compound 
was at least 667 GBq/µmol. Biodistribution studies showed low brain uptake and 
high blood activity. Blocking studies indicated no selectivity of [123I]-FMIP 
towards DAT. A metabolite study demonstrated that in brain, over 80 % was 
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present as intact [123I]-FMIP upon 60 min p.i. In rats, regional brain distribution 
of [123I]-FMIP was not in agreement with DAT distribution. These results 
indicated that [123I]-FMIP is not suitable for mapping DAT in vivo.  
The contribution of P-gp to the low brain uptake of [123I]-FMIP along with its 
potential as P-gp imaging agent was investigated in Chapter 8. To date, no 
iodinated SPECT ligands for P-gp imaging have been published. Brain uptake of 
[123I]-FMIP was very low in wild-type mice with saline pretreatment, consistent 
with the rapid action and high capacity of P-gp. Modulation of P-gp with CsA as 
well as mdr1a gene depletion resulted in a significant increase in cerebral uptake 
of [123I]-FMIP with only minor effect on blood activity. A dose-dependent 
sigmoidal increase in brain uptake of [123I]-FMIP with increasing doses of CsA 
was observed. In vivo ROI-based SPECT measurements confirmed the 
observations of the biodistribution studies. These findings indicated that [123I]-
FMIP is a very promising radiotracer to visualize P-gp at the BBB.  
Chapter 9 described the radiolabelling of an in vitro characterized substrate 
(MC80) of the P-gp pump with 11C and the evaluation of this tracer in vivo for its 
potential to image P-gp function and expression. [11C]-MC80 was synthesized 
with high radiochemical purity and high specific activity. Cerebral uptake was 
increased in mdr1a knock-out mice as well as after CsA pretreatment. 
Administration of non-radioactive MC80 caused a reduced uptake in brain, heart, 
lungs, testes, pancreas and intestines. In brain, [11C]-MC80 displayed an excellent 
metabolic profile (> 90 % intact). Since [11C]-MC80 showed specific binding to 
target organs, this compound can be a lead compound for the development of 
novel radioligands for measuring the expression of P-gp in the brain. 
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SAMENVATTING 
 
De menselijke hersenen zijn een complex orgaan die bestaan uit miljoenen 
communicerende neuronen. Door de complexiteit van de hersenen is onze kennis 
over aandoeningen van het central zenuwstelsel nog steeds beperkt. 
Beeldvorming van de hersenen met SPECT en PET zijn unieke hulpmiddelen 
voor klinische onderzoekers om de oorzaken en de gevolgen van 
hersenaandoeningen op te helderen. In vivo beeldvorming van de hersenen met 
PET of SPECT is van groot belang in zowel geneesmiddelenontwikkeling als in 
het stellen van de juiste diagnose, behandeling en controle van neurologische en 
psychiatrische ziektes. In deze thesis werden nieuwe SPECT en PET 
radioliganden gericht naar twee verschillende hersensystemen ontwikkeld en in 
vivo geëvalueerd.  
Hoofdstuk 1 gaf een overzicht van de medische beeldvormingstechnieken en 
beschreef de voorwaarden van een waardevol radiofarmacon voor SPECT en 
PET beeldvorming. Het eerste deel van Hoofdstuk 2 beschreef de bloed-hersen 
barrière en het transport van bestanddelen doorheen deze barrière. Een van de 
belangrijkste transport mechanismen die de hersenopname van geneesmiddelen 
beperkt, P-gp, werd gespecificeerd in het tweede deel van dit hoofdstuk. Na een 
korte beschrijving van de ontdekking, structuur, expressie en fysiologische rol 
werden de mogelijke modulerende agentia van P-gp besproken. Het tweede 
hersensysteem, het catecholamine systeem, werd behandeld in Hoofdstuk 3. Het 
dopamine en norepinephrine systeem werden kort besproken, gevolgd door een 
meer gedetailleerde beschrijving van de mechanismen die verantwoordelijk zijn 
voor het beëindigen van de neurotransmissie. Nadat de geschiedenis, structuur en 
functie van de catecholamine transporters in het algemeen besproken waren, 
werd de fysiologische rol van de norepinephrine transporter en dopamine 
transporter in ziekte en gezondheid toegelicht. Het laatste deel van hoofdstuk 3 
was toegewijd aan monoamine oxidase, één van de belangrijke enzymes die de 
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afbraak van catecholamines veroorzaken. In Hoofdstuk 4 werden de algemene 
materialen en methoden beschreven.  
Hoofdstuk 5 rapporteerde de synthese, radiosynthese en preliminaire evaluatie 
van [123I]-(S,S)-IPBM, een geiodeerd reboxetine analoog. [123I]-(S,S)-IPBM had als 
doel de beeldvorming van de norepinephrine transporter. De precursor werd 
aangemaakt met een chemisch rendement van 8 % met een enantiomere 
overmaat van meer dan 95 %. Radiosynthese leverde [123I]-(S,S)-IPBM op met 
een uitstekende radiochemische zuiverheid. Biodistributie studies toonden een 
hoge hersenopname van [123I]-(S,S)-IPBM gevolgd door een efficiënte klaring. 
Doordat [123I]-(S,S)-IPBM gerapporteerd werd door anderen op het moment dat 
wij onze biodistributies deden, voerden we geen bijkomende in vivo studies uit. 
Hun resultaten in beschouwing nemend (Tamagnan et al., 2007; Kanigawara et 
al., 2006), was de keuze om [123I]-(S,S)-IPBM als radiotracer voor de 
norepinephrine transporter te ontwikkelen een uitstekend voorstel. In 
Hoofdstuk 6 werd zowel de merking met radioactiviteit als de in vivo 
karakterisatie van twee [11C]-gemerkte pyrrool-2-carboxamide derivaten, [11C]-RS 
2315 and [11C]-RS 2360, beschreven. In vitro, zijn RS 2315 en RS 2360 sterke 
inibitoren van MAO-A. Beide tracers werden bekomen met een goed 
radiochemisch rendement, uitstekende radiochemische zuiverheid en hoge 
specifieke activiteit. Beide radiotracers vertoonden hoge hersenopname gevolgd 
door snelle klaring uit de hersenen. Blokkeringstudies in muizen konden geen 
selectiviteit aantonen van [11C]-RS 2315 voor MAO-A of MAO-B. De 
blokkeringstudie met [11C]-RS 2360 toonde specifieke binding aan MAO-A op 
het eerste tijdstip. In de beeldvorming studie met [11C]-RS 2360 veroorzaakte 
toedoening van clorgyline een algemeen significante gedaalde hersenopname wat 
een specifieke binding aan MAO-A indiceerde. Deze resultaten wezen aan dat 
[11C]-RS 2315 niet bruikbaar is voor het in kaart brengen van MAO-A in vivo en 
dat verdere onderzoek nodig is om de mogelijkheid van [11C]-RS 2360 in 
beeldvorming van MAO-A te analyseren. 
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De radiosynthese en in vivo evaluatie van [123I]-FMIP als een selectieve radiotracer 
voor DAT werd gerapporteerd in Hoofdstuk 7. FMIP heeft nanomolaire 
affiniteit voor DAT en een betere selectiviteit vergeleken met de reeds bestaande 
liganden voor DAT beeldvorming met SPECT. De tributyltin precursor werd 
gesynthetiseerd gebruik makend van een vijf-staps synthese. [123I]-FMIP werd 
aangemaakt met hoog radiochemisch rendement en zuiverheid. De specifieke 
activiteit van de component was minstens 667 GBq/µmol. Biodistributie studies 
toonden een lage hersenopname en hoge bloedactiviteit. Blokkeringstudies wezen 
geen selectiviteit van [123I]-FMIP voor DAT aan. Een metabolietanalyse 
demonstreerde dat in de hersenen meer dan 80 % aanwezig was als intact [123I]-
FMIP tot 60 min na injectie. In ratten, bleek de regionale hersendistributie van 
[123I]-FMIP niet in overeenkomst met de DAT verdeling. Deze resultaten 
toonden aan dat [123I]-FMIP niet bruikbaar is voor het in beeld brengen van DAT 
in vivo. 
De deelname van P-gp aan de lage hersenopname van [123I]-FMIP samen met zijn 
potentieel als agens voor beeldvorming van P-gp werd onderzocht in Hoofdstuk 
8. Tot op heden werden nog geen geiodeerde SPECT liganden voor 
beeldvorming van P-gp gepubliceerd. Hersenopname van [123I]-FMIP was zeer 
laag in wildtype muizen voorbehandeld met zoutoplossing, in overeenstemming 
met de snelle actie en hoge capaciteit van P-gp. Zowel modulatie van P-gp met 
CsA als verwijderen van het mdr1a gen resulteerde in een significantie stijging van 
de hersenopname van [123I]-FMIP met slechts een klein effect op de 
bloedactiviteit. Een dosisafhankelijke sigmoidale stijging in hersenopname van 
[123I]-FMIP met stijgende concentraties CsA werd waargenomen. In vivo ROI-
gebaseerde SPECT metingen bevestigden de observatie van de biodistributie 
studies. Deze bevindingen wezen erop dat [123I]-FMIP een veelbelovende 
radiotracer is voor de visualisatie van P-gp ter hoogte van de bloed-hersen 
barrière. 
Hoofdstuk 9 beschreef de radioactieve merking van een in vitro gekarakteriseerd 
substraat (MC80) van de P-gp pomp met 11C en de evaluatie van deze tracer in 
Samenvatting 
 228 
vivo voor zijn potentieel om P-gp functie en expressie in beeld te brengen. [11C]-
MC80 werd zeer snel gesynthetiseerd met hoge radiochemische zuiverheid en 
hoge specifieke activiteit. De hersenopname werd verhoogd zowel in mdr1a 
knock-out muizen als na voorbehandeling met CsA in gewone muizen. 
Toediening van niet radioactief MC80 veroorzaakte een gereduceerde opname in 
de hersenen, hart, longen, testes, pancreas en darmen. In de hersenen vertoonde 
[11C]-MC80 een uitstekend metabolisch profiel (> 90 % intact). Omdat [11C]-
MC80 specifieke binding vertoont aan de doelorganen kan deze component een 
goede basismolecule zijn voor de ontwikkeling van nieuwe radioliganden voor  
het meten van P-gp expressie in de hersenen.  
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